Anteriormente	O	-
informamos	O	-
de	O	-
que	O	-
el	O	-
tratamiento	O	-
de	O	-
pacientes	O	-
con	O	-
cáncer	O	-
de	O	-
pulmón	O	-
de	O	-
células	O	-
no	O	-
pequeñas	O	-
avanzado	O	-
sintomático	O	-
con	O	-
el	O	-
agente	O	-
único	O	-
Gemcitabina	O	-
(	O	-
GEM	O	-
)	O	-
dio	O	-
lugar	O	-
a	O	-
una	O	-
tasa	O	-
de	O	-
respuesta	O	-
de	O	-
beneficio	O	-
clínico	O	-
(	O	-
RR	O	-
)	O	-
superior	O	-
en	O	-
comparación	O	-
con	O	-
la	O	-
quimioterapia	O	-
combinada	O	-
basada	O	-
en	O	-
cisplatino	O	-
.	O	-

Ahora	O	-
informamos	O	-
del	O	-
análisis	O	-
detallado	O	-
del	O	-
control	O	-
de	O	-
los	O	-
síntomas	O	-
individuales	O	-
,	O	-
y	O	-
la	O	-
influencia	O	-
del	O	-
uso	O	-
de	O	-
cisplatino	O	-
,	O	-
la	O	-
edad	O	-
,	O	-
el	O	-
estado	O	-
de	O	-
rendimiento	O	-
(	O	-
PS	O	-
)	O	-
y	O	-
la	O	-
duración	O	-
del	O	-
tratamiento	O	-
.	O	-

Los	O	-
pacientes	O	-
recibieron	O	-
GEM	O	-
(	O	-
1000	O	-
mg/m	O	-
(	O	-
2	O	-
)	O	-
,	O	-
días	O	-
1	O	-
,	O	-
8	O	-
y	O	-
15	O	-
)	O	-
o	O	-
cisplatino	O	-
(	O	-
100	O	-
mg/m	O	-
(	O	-
2	O	-
)	O	-
,	O	-
día	O	-
1	O	-
)	O	-
más	O	-
Vindesina	O	-
(	O	-
3	O	-
mg/m	O	-
(	O	-
2	O	-
)	O	-
,	O	-
días	O	-
1	O	-
y	O	-
15	O	-
)	O	-
(	O	-
PV	O	-
)	O	-
,	O	-
ambos	O	-
cada	O	-
4	O	-
semanas	O	-
.	O	-

Las	O	-
puntuaciones	O	-
de	O	-
9	O	-
síntomas	O	-
fueron	O	-
enumeradas	O	-
semanalmente	O	-
por	O	-
el	O	-
paciente	O	-
en	O	-
escalas	O	-
analógicas	O	-
visuales	O	-
.	O	-

La	O	-
mejora	O	-
de	O	-
un	O	-
síntoma	O	-
se	O	-
definió	O	-
como	O	-
2	O	-
ciclos	O	-
consecutivos	O	-
de	O	-
mejora	O	-
respecto	O	-
a	O	-
la	O	-
línea	O	-
de	O	-
base	O	-
.	O	-

Los	O	-
síntomas	O	-
iniciales	O	-
de	O	-
los	O	-
169	O	-
pacientes	O	-
estaban	O	-
bien	O	-
equilibrados	O	-
entre	O	-
los	O	-
dos	O	-
brazos	O	-
(	O	-
84	O	-
GEM	O	-
,	O	-
85	O	-
PV	O	-
)	O	-
.	O	-

Tanto	B-Premise	HighQuality
los	I-Premise	HighQuality
pacientes	I-Premise	HighQuality
con	I-Premise	HighQuality
respuesta	I-Premise	HighQuality
objetiva	I-Premise	HighQuality
como	I-Premise	HighQuality
con	I-Premise	HighQuality
estabilización	I-Premise	HighQuality
de	I-Premise	HighQuality
la	I-Premise	HighQuality
enfermedad	I-Premise	HighQuality
tenían	I-Premise	HighQuality
un	I-Premise	HighQuality
control	I-Premise	HighQuality
de	I-Premise	HighQuality
los	I-Premise	HighQuality
síntomas	I-Premise	HighQuality
claramente	I-Premise	HighQuality
mejor	I-Premise	HighQuality
que	I-Premise	HighQuality
los	I-Premise	HighQuality
que	I-Premise	HighQuality
presentaban	I-Premise	HighQuality
progresión	I-Premise	HighQuality
de	I-Premise	HighQuality
la	I-Premise	HighQuality
enfermedad	I-Premise	HighQuality
.	I-Premise	HighQuality

El	B-Premise	HighQuality
control	I-Premise	HighQuality
de	I-Premise	HighQuality
los	I-Premise	HighQuality
síntomas	I-Premise	HighQuality
en	I-Premise	HighQuality
ambos	I-Premise	HighQuality
brazos	I-Premise	HighQuality
fue	I-Premise	HighQuality
similar	I-Premise	HighQuality
para	I-Premise	HighQuality
los	I-Premise	HighQuality
síntomas	I-Premise	HighQuality
"específicos	I-Premise	HighQuality
de	I-Premise	HighQuality
la	I-Premise	HighQuality
enfermedad",	I-Premise	HighQuality
como	I-Premise	HighQuality
la	I-Premise	HighQuality
tos,	I-Premise	HighQuality
la	I-Premise	HighQuality
disnea,	I-Premise	HighQuality
el	I-Premise	HighQuality
dolor	I-Premise	HighQuality
o	I-Premise	HighQuality
la	I-Premise	HighQuality
hemoptisis.	I-Premise	HighQuality

En	B-Premise	HighQuality
comparación	I-Premise	HighQuality
con	I-Premise	HighQuality
los	I-Premise	HighQuality
PV,	I-Premise	HighQuality
un	I-Premise	HighQuality
número	I-Premise	HighQuality
significativamente	I-Premise	HighQuality
mayor	I-Premise	HighQuality
de	I-Premise	HighQuality
pacientes	I-Premise	HighQuality
con	I-Premise	HighQuality
GEM	I-Premise	HighQuality
obtuvieron	I-Premise	HighQuality
mejores	I-Premise	HighQuality
puntuaciones	I-Premise	HighQuality
en	I-Premise	HighQuality
los	I-Premise	HighQuality
ítems	I-Premise	HighQuality
"constitucionales",	I-Premise	HighQuality
como	I-Premise	HighQuality
la	I-Premise	HighQuality
anorexia	I-Premise	HighQuality
(	I-Premise	HighQuality
P=0,007	I-Premise	HighQuality
)	I-Premise	HighQuality
,	I-Premise	HighQuality
la	I-Premise	HighQuality
capacidad	I-Premise	HighQuality
de	I-Premise	HighQuality
seguir	I-Premise	HighQuality
con	I-Premise	HighQuality
las	I-Premise	HighQuality
actividades	I-Premise	HighQuality
diarias	I-Premise	HighQuality
(	I-Premise	HighQuality
P=0,04	I-Premise	HighQuality
)	I-Premise	HighQuality
y	I-Premise	HighQuality
la	I-Premise	HighQuality
impresión	I-Premise	HighQuality
general	I-Premise	HighQuality
de	I-Premise	HighQuality
calidad	I-Premise	HighQuality
de	I-Premise	HighQuality
vida	I-Premise	HighQuality
(	I-Premise	HighQuality
P=0,008	I-Premise	HighQuality
)	I-Premise	HighQuality
.	I-Premise	HighQuality

El	B-Premise	HighQuality
control	I-Premise	HighQuality
de	I-Premise	HighQuality
los	I-Premise	HighQuality
síntomas	I-Premise	HighQuality
fue	I-Premise	HighQuality
muy	I-Premise	HighQuality
similar	I-Premise	HighQuality
en	I-Premise	HighQuality
los	I-Premise	HighQuality
pacientes	I-Premise	HighQuality
más	I-Premise	HighQuality
jóvenes	I-Premise	HighQuality
(	I-Premise	HighQuality
<	I-Premise	HighQuality
65	I-Premise	HighQuality
años	I-Premise	HighQuality
)	I-Premise	HighQuality
frente	I-Premise	HighQuality
a	I-Premise	HighQuality
los	I-Premise	HighQuality
de	I-Premise	HighQuality
mayor	I-Premise	HighQuality
edad	I-Premise	HighQuality
(	I-Premise	HighQuality
>	I-Premise	HighQuality
/=65	I-Premise	HighQuality
años	I-Premise	HighQuality
)	I-Premise	HighQuality
,	I-Premise	HighQuality
y	I-Premise	HighQuality
sólo	I-Premise	HighQuality
ligeramente	I-Premise	HighQuality
mejor	I-Premise	HighQuality
en	I-Premise	HighQuality
los	I-Premise	HighQuality
que	I-Premise	HighQuality
tenían	I-Premise	HighQuality
un	I-Premise	HighQuality
PS	I-Premise	HighQuality
de	I-Premise	HighQuality
Karnofsky	I-Premise	HighQuality
>	I-Premise	HighQuality
/=80	I-Premise	HighQuality
%	I-Premise	HighQuality
en	I-Premise	HighQuality
comparación	I-Premise	HighQuality
con	I-Premise	HighQuality
los	I-Premise	HighQuality
de	I-Premise	HighQuality
<	I-Premise	HighQuality
80	I-Premise	HighQuality
%	I-Premise	HighQuality
.	I-Premise	HighQuality

La	B-Premise	HighQuality
mayor	I-Premise	HighQuality
parte	I-Premise	HighQuality
de	I-Premise	HighQuality
la	I-Premise	HighQuality
mejora	I-Premise	HighQuality
de	I-Premise	HighQuality
los	I-Premise	HighQuality
síntomas	I-Premise	HighQuality
se	I-Premise	HighQuality
produjo	I-Premise	HighQuality
en	I-Premise	HighQuality
los	I-Premise	HighQuality
3	I-Premise	HighQuality
primeros	I-Premise	HighQuality
ciclos,	I-Premise	HighQuality
con	I-Premise	HighQuality
alguna	I-Premise	HighQuality
mejora	I-Premise	HighQuality
adicional	I-Premise	HighQuality
de	I-Premise	HighQuality
los	I-Premise	HighQuality
síntomas	I-Premise	HighQuality
en	I-Premise	HighQuality
los	I-Premise	HighQuality
siguientes	I-Premise	HighQuality
ciclos	I-Premise	HighQuality
sólo	I-Premise	HighQuality
en	I-Premise	HighQuality
el	I-Premise	HighQuality
brazo	I-Premise	HighQuality
GEM.	I-Premise	HighQuality

Tanto	B-Claim	HighQuality
la	I-Claim	HighQuality
GEM	I-Claim	HighQuality
como	I-Claim	HighQuality
la	I-Claim	HighQuality
PV	I-Claim	HighQuality
arrojan	I-Claim	HighQuality
una	I-Claim	HighQuality
tasa	I-Claim	HighQuality
de	I-Claim	HighQuality
control	I-Claim	HighQuality
de	I-Claim	HighQuality
los	I-Claim	HighQuality
síntomas	I-Claim	HighQuality
muy	I-Claim	HighQuality
superior	I-Claim	HighQuality
a	I-Claim	HighQuality
la	I-Claim	HighQuality
esperada	I-Claim	HighQuality
por	I-Claim	HighQuality
el	I-Claim	HighQuality
RR	I-Claim	HighQuality
tumoral	I-Claim	HighQuality
objetivo.	I-Claim	HighQuality

GEM	B-Claim	HighQuality
es	I-Claim	HighQuality
igualmente	I-Claim	HighQuality
eficaz	I-Claim	HighQuality
en	I-Claim	HighQuality
el	I-Claim	HighQuality
control	I-Claim	HighQuality
de	I-Claim	HighQuality
los	I-Claim	HighQuality
síntomas	I-Claim	HighQuality
"específicos	I-Claim	HighQuality
de	I-Claim	HighQuality
la	I-Claim	HighQuality
enfermedad",	I-Claim	HighQuality
pero	I-Claim	HighQuality
es	I-Claim	HighQuality
superior	I-Claim	HighQuality
en	I-Claim	HighQuality
el	I-Claim	HighQuality
control	I-Claim	HighQuality
de	I-Claim	HighQuality
los	I-Claim	HighQuality
síntomas	I-Claim	HighQuality
"constitucionales".	I-Claim	HighQuality

La	B-Premise	HighQuality
mayor	I-Premise	HighQuality
parte	I-Premise	HighQuality
del	I-Premise	HighQuality
control	I-Premise	HighQuality
de	I-Premise	HighQuality
los	I-Premise	HighQuality
síntomas	I-Premise	HighQuality
se	I-Premise	HighQuality
consiguió	I-Premise	HighQuality
durante	I-Premise	HighQuality
los	I-Premise	HighQuality
3	I-Premise	HighQuality
primeros	I-Premise	HighQuality
ciclos	I-Premise	HighQuality
de	I-Premise	HighQuality
tratamiento,	I-Premise	HighQuality
con	I-Premise	HighQuality
alguna	I-Premise	HighQuality
mejora	I-Premise	HighQuality
posterior	I-Premise	HighQuality
sólo	I-Premise	HighQuality
en	I-Premise	HighQuality
el	I-Premise	HighQuality
brazo	I-Premise	HighQuality
GEM.	I-Premise	HighQuality

Comparar	O	-
los	O	-
resultados	O	-
a	O	-
un	O	-
año	O	-
de	O	-
la	O	-
trabeculotomía	O	-
circunferencial	O	-
asistida	O	-
por	O	-
microcatéter	O	-
iluminado	O	-
(	O	-
IMCT	O	-
)	O	-
frente	O	-
a	O	-
la	O	-
trabeculotomía	O	-
parcial	O	-
convencional	O	-
(	O	-
CPT	O	-
)	O	-
para	O	-
el	O	-
glaucoma	O	-
congénito	O	-
primario	O	-
(	O	-
PCG	O	-
)	O	-
.	O	-

Cuarenta	O	-
ojos	O	-
de	O	-
31	O	-
pacientes	O	-
con	O	-
glaucoma	O	-
congénito	O	-
primario	O	-
unilateral	O	-
o	O	-
bilateral	O	-
de	O	-
menos	O	-
de	O	-
2	O	-
años	O	-
de	O	-
edad	O	-
fueron	O	-
aleatorizados	O	-
para	O	-
someterse	O	-
a	O	-
una	O	-
TCMI	O	-
(	O	-
20	O	-
ojos	O	-
)	O	-
o	O	-
a	O	-
una	O	-
TPC	O	-
(	O	-
20	O	-
ojos	O	-
)	O	-
.	O	-

La	O	-
medida	O	-
de	O	-
resultado	O	-
primaria	O	-
fue	O	-
la	O	-
reducción	O	-
de	O	-
la	O	-
presión	O	-
intraocular	O	-
(PIO).	O	-

El	O	-
criterio	O	-
de	O	-
éxito	O	-
se	O	-
definió	O	-
como	O	-
PIO	O	-
≤	O	-
12	O	-
mm	O	-
Hg	O	-
sin	O	-
y	O	-
con	O	-
medicamentos	O	-
antiglaucoma	O	-
(	O	-
éxito	O	-
absoluto	O	-
y	O	-
éxito	O	-
cualificado	O	-
,	O	-
respectivamente	O	-
)	O	-
.	O	-

La	O	-
edad	O	-
media	O	-
de	O	-
nuestra	O	-
población	O	-
de	O	-
estudio	O	-
fue	O	-
de	O	-
8,35	O	-
±	O	-
1,2	O	-
meses.	O	-

La	O	-
media	O	-
de	O	-
la	O	-
PIO	O	-
preoperatoria	O	-
fue	O	-
de	O	-
24,70	O	-
±	O	-
3,90	O	-
mm	O	-
Hg	O	-
en	O	-
el	O	-
grupo	O	-
IMCT	O	-
y	O	-
de	O	-
24,60	O	-
±	O	-
3,31	O	-
mm	O	-
Hg	O	-
en	O	-
el	O	-
grupo	O	-
CPT	O	-
.	O	-

Ambos	O	-
grupos	O	-
eran	O	-
comparables	O	-
con	O	-
respecto	O	-
a	O	-
la	O	-
PIO	O	-
preoperatoria,	O	-
la	O	-
claridad	O	-
de	O	-
la	O	-
córnea,	O	-
el	O	-
diámetro	O	-
de	O	-
la	O	-
córnea,	O	-
la	O	-
relación	O	-
copa-disco	O	-
vertical	O	-
y	O	-
el	O	-
error	O	-
refractivo.	O	-

En	B-Premise	HighQuality
el	I-Premise	HighQuality
grupo	I-Premise	HighQuality
de	I-Premise	HighQuality
TMI,	I-Premise	HighQuality
se	I-Premise	HighQuality
consiguió	I-Premise	HighQuality
una	I-Premise	HighQuality
canulación	I-Premise	HighQuality
de	I-Premise	HighQuality
360	I-Premise	HighQuality
grados	I-Premise	HighQuality
en	I-Premise	HighQuality
el	I-Premise	HighQuality
80%	I-Premise	HighQuality
(	I-Premise	HighQuality
16/20	I-Premise	HighQuality
)	I-Premise	HighQuality
de	I-Premise	HighQuality
los	I-Premise	HighQuality
ojos.	I-Premise	HighQuality

Para	B-Premise	HighQuality
los	I-Premise	HighQuality
grupos	I-Premise	HighQuality
de	I-Premise	HighQuality
IMCT	I-Premise	HighQuality
y	I-Premise	HighQuality
CPT	I-Premise	HighQuality
,	I-Premise	HighQuality
respectivamente,	I-Premise	HighQuality
las	I-Premise	HighQuality
tasas	I-Premise	HighQuality
de	I-Premise	HighQuality
éxito	I-Premise	HighQuality
absolutas	I-Premise	HighQuality
fueron	I-Premise	HighQuality
del	I-Premise	HighQuality
80%	I-Premise	HighQuality
(	I-Premise	HighQuality
16/20	I-Premise	HighQuality
)	I-Premise	HighQuality
y	I-Premise	HighQuality
del	I-Premise	HighQuality
60%	I-Premise	HighQuality
(	I-Premise	HighQuality
12/20	I-Premise	HighQuality
)	I-Premise	HighQuality
(	I-Premise	HighQuality
P	I-Premise	HighQuality
<	I-Premise	HighQuality
0,001	I-Premise	HighQuality
)	I-Premise	HighQuality
y	I-Premise	HighQuality
las	I-Premise	HighQuality
tasas	I-Premise	HighQuality
de	I-Premise	HighQuality
éxito	I-Premise	HighQuality
calificadas	I-Premise	HighQuality
fueron	I-Premise	HighQuality
del	I-Premise	HighQuality
90%	I-Premise	HighQuality
(	I-Premise	HighQuality
18/20	I-Premise	HighQuality
)	I-Premise	HighQuality
y	I-Premise	HighQuality
del	I-Premise	HighQuality
70%	I-Premise	HighQuality
(	I-Premise	HighQuality
14/20	I-Premise	HighQuality
)	I-Premise	HighQuality
(	I-Premise	HighQuality
P	I-Premise	HighQuality
<	I-Premise	HighQuality
0,001	I-Premise	HighQuality
)	I-Premise	HighQuality
.	I-Premise	HighQuality

Ambos	B-Claim	HighQuality
procedimientos	I-Claim	HighQuality
produjeron	I-Claim	HighQuality
una	I-Claim	HighQuality
reducción	I-Claim	HighQuality
estadísticamente	I-Claim	HighQuality
significativa	I-Claim	HighQuality
de	I-Claim	HighQuality
la	I-Claim	HighQuality
PIO	I-Claim	HighQuality
,	O	-
y	O	-
los	B-Premise	HighQuality
ojos	I-Premise	HighQuality
sometidos	I-Premise	HighQuality
a	I-Premise	HighQuality
la	I-Premise	HighQuality
IMCT	I-Premise	HighQuality
alcanzaron	I-Premise	HighQuality
una	I-Premise	HighQuality
PIO	I-Premise	HighQuality
más	I-Premise	HighQuality
baja	I-Premise	HighQuality
que	I-Premise	HighQuality
los	I-Premise	HighQuality
ojos	I-Premise	HighQuality
del	I-Premise	HighQuality
grupo	I-Premise	HighQuality
CPT	I-Premise	HighQuality
a	I-Premise	HighQuality
los	I-Premise	HighQuality
12	I-Premise	HighQuality
meses	I-Premise	HighQuality
de	I-Premise	HighQuality
seguimiento	I-Premise	HighQuality
(	I-Premise	HighQuality
9,5	I-Premise	HighQuality
±	I-Premise	HighQuality
2,4	I-Premise	HighQuality
mm	I-Premise	HighQuality
Hg	I-Premise	HighQuality
y	I-Premise	HighQuality
11,7	I-Premise	HighQuality
±	I-Premise	HighQuality
2,1	I-Premise	HighQuality
mm	I-Premise	HighQuality
Hg	I-Premise	HighQuality
,	I-Premise	HighQuality
respectivamente	I-Premise	HighQuality
,	I-Premise	HighQuality
P	I-Premise	HighQuality
<	I-Premise	HighQuality
0,001	I-Premise	HighQuality
)	I-Premise	HighQuality
.	I-Premise	HighQuality

En	B-Claim	HighQuality
el	I-Claim	HighQuality
glaucoma	I-Claim	HighQuality
congénito	I-Claim	HighQuality
primario,	I-Claim	HighQuality
la	I-Claim	HighQuality
trabeculotomía	I-Claim	HighQuality
circunferencial	I-Claim	HighQuality
de	I-Claim	HighQuality
360	I-Claim	HighQuality
grados	I-Claim	HighQuality
asistida	I-Claim	HighQuality
por	I-Claim	HighQuality
microcatéteres	I-Claim	HighQuality
iluminados	I-Claim	HighQuality
tuvo	I-Claim	HighQuality
mejores	I-Claim	HighQuality
resultados	I-Claim	HighQuality
que	I-Claim	HighQuality
la	I-Claim	HighQuality
trabeculotomía	I-Claim	HighQuality
parcial	I-Claim	HighQuality
convencional	I-Claim	HighQuality
en	I-Claim	HighQuality
el	I-Claim	HighQuality
seguimiento	I-Claim	HighQuality
de	I-Claim	HighQuality
1	I-Claim	HighQuality
año	I-Claim	HighQuality
y	I-Claim	HighQuality
dio	I-Claim	HighQuality
lugar	I-Claim	HighQuality
a	I-Claim	HighQuality
mediciones	I-Claim	HighQuality
de	I-Claim	HighQuality
la	I-Claim	HighQuality
PIO	I-Claim	HighQuality
significativamente	I-Claim	HighQuality
menores.	I-Claim	HighQuality

El	O	-
agonista	O	-
oral	O	-
del	O	-
receptor	O	-
tipo	O	-
Toll	O	-
(	O	-
TLR	O	-
)	O	-
7	O	-
GS-9620	O	-
tiene	O	-
efectos	O	-
antivirales	O	-
en	O	-
modelos	O	-
de	O	-
marmota	O	-
y	O	-
chimpancé	O	-
de	O	-
infección	O	-
crónica	O	-
por	O	-
el	O	-
virus	O	-
de	O	-
la	O	-
hepatitis	O	-
B	O	-
(	O	-
HBV	O	-
)	O	-
.	O	-

Hemos	O	-
investigado,	O	-
en	O	-
un	O	-
ensayo	O	-
clínico,	O	-
la	O	-
capacidad	O	-
de	O	-
este	O	-
agente	O	-
para	O	-
reconstituir	O	-
la	O	-
inmunidad	O	-
protectora	O	-
en	O	-
pacientes	O	-
con	O	-
infección	O	-
crónica	O	-
por	O	-
el	O	-
VHB.	O	-

Realizamos	O	-
un	O	-
estudio	O	-
prospectivo	O	-
de	O	-
28	O	-
pacientes	O	-
con	O	-
supresión	O	-
de	O	-
la	O	-
infección	O	-
por	O	-
VHB	O	-
mediante	O	-
terapia	O	-
con	O	-
análogos	O	-
de	O	-
nucleos	O	-
(	O	-
t	O	-
)	O	-
y	O	-
que	O	-
dieron	O	-
negativo	O	-
para	O	-
el	O	-
antígeno	O	-
de	O	-
la	O	-
hepatitis	O	-
B	O	-
e	O	-
en	O	-
4	O	-
centros	O	-
médicos	O	-
de	O	-
Italia	O	-
.	O	-

Los	O	-
pacientes	O	-
fueron	O	-
asignados	O	-
aleatoriamente	O	-
(	O	-
1:3:3:3	O	-
)	O	-
a	O	-
grupos	O	-
que	O	-
recibieron	O	-
placebo	O	-
o	O	-
diferentes	O	-
dosis	O	-
de	O	-
GS-9620	O	-
(	O	-
1	O	-
,	O	-
2	O	-
y	O	-
4	O	-
mg	O	-
,	O	-
semanalmente	O	-
durante	O	-
12	O	-
semanas	O	-
)	O	-
.	O	-

Se	O	-
añadieron	O	-
los	O	-
datos	O	-
de	O	-
8	O	-
pacientes	O	-
que	O	-
recibían	O	-
terapia	O	-
con	O	-
análogos	O	-
de	O	-
nucleos	O	-
(	O	-
t	O	-
)	O	-
ide	O	-
al	O	-
grupo	O	-
de	O	-
placebo	O	-
(	O	-
controles	O	-
)	O	-
;	O	-
13	O	-
pacientes	O	-
sin	O	-
tratamiento	O	-
con	O	-
infección	O	-
crónica	O	-
por	O	-
VHB	O	-
y	O	-
15	O	-
sujetos	O	-
que	O	-
se	O	-
recuperaron	O	-
espontáneamente	O	-
de	O	-
una	O	-
infección	O	-
aguda	O	-
por	O	-
VHB	O	-
sirvieron	O	-
como	O	-
controles	O	-
adicionales	O	-
.	O	-

Se	O	-
recogieron	O	-
células	O	-
mononucleares	O	-
de	O	-
sangre	O	-
periférica	O	-
al	O	-
inicio,	O	-
durante	O	-
la	O	-
administración	O	-
de	O	-
GS-9620	O	-
o	O	-
placebo	O	-
y	O	-
12	O	-
semanas	O	-
después.	O	-

El	O	-
fenotipo	O	-
y	O	-
la	O	-
función	O	-
de	O	-
las	O	-
células	O	-
asesinas	O	-
naturales	O	-
(	O	-
NK	O	-
)	O	-
y	O	-
de	O	-
las	O	-
células	O	-
T	O	-
específicas	O	-
del	O	-
VHB	O	-
se	O	-
analizaron	O	-
mediante	O	-
citometría	O	-
de	O	-
flujo	O	-
.	O	-

Las	O	-
células	O	-
T	O	-
se	O	-
expandieron	O	-
mediante	O	-
la	O	-
incubación	O	-
con	O	-
péptidos	O	-
de	O	-
todo	O	-
el	O	-
proteoma	O	-
del	O	-
VHB	O	-
y	O	-
se	O	-
estudiaron	O	-
tras	O	-
una	O	-
noche	O	-
o	O	-
10	O	-
días	O	-
de	O	-
cultivo.	O	-

La	O	-
inhibición	O	-
de	O	-
la	O	-
respuesta	O	-
de	O	-
las	O	-
células	O	-
T	O	-
por	O	-
parte	O	-
de	O	-
las	O	-
células	O	-
NK	O	-
se	O	-
midió	O	-
evaluando	O	-
la	O	-
producción	O	-
de	O	-
citoquinas	O	-
por	O	-
parte	O	-
de	O	-
las	O	-
células	O	-
T	O	-
estimuladas	O	-
con	O	-
péptidos	O	-
en	O	-
presencia	O	-
o	O	-
ausencia	O	-
de	O	-
células	O	-
NK.	O	-

Las	B-Premise	HighQuality
células	I-Premise	HighQuality
T	I-Premise	HighQuality
recogidas	I-Premise	HighQuality
en	I-Premise	HighQuality
la	I-Premise	HighQuality
línea	I-Premise	HighQuality
de	I-Premise	HighQuality
base	I-Premise	HighQuality
antes	I-Premise	HighQuality
de	I-Premise	HighQuality
la	I-Premise	HighQuality
adición	I-Premise	HighQuality
de	I-Premise	HighQuality
GS-9620	I-Premise	HighQuality
,	I-Premise	HighQuality
cuando	I-Premise	HighQuality
los	I-Premise	HighQuality
pacientes	I-Premise	HighQuality
estaban	I-Premise	HighQuality
recibiendo	I-Premise	HighQuality
sólo	I-Premise	HighQuality
la	I-Premise	HighQuality
terapia	I-Premise	HighQuality
de	I-Premise	HighQuality
nucleos	I-Premise	HighQuality
(	I-Premise	HighQuality
t	I-Premise	HighQuality
)	I-Premise	HighQuality
ide	I-Premise	HighQuality
,	I-Premise	HighQuality
tenían	I-Premise	HighQuality
mayores	I-Premise	HighQuality
respuestas	I-Premise	HighQuality
al	I-Premise	HighQuality
VHB	I-Premise	HighQuality
que	I-Premise	HighQuality
las	I-Premise	HighQuality
células	I-Premise	HighQuality
T	I-Premise	HighQuality
de	I-Premise	HighQuality
los	I-Premise	HighQuality
pacientes	I-Premise	HighQuality
sin	I-Premise	HighQuality
tratamiento	I-Premise	HighQuality
,	I-Premise	HighQuality
sobre	I-Premise	HighQuality
la	I-Premise	HighQuality
base	I-Premise	HighQuality
de	I-Premise	HighQuality
la	I-Premise	HighQuality
producción	I-Premise	HighQuality
de	I-Premise	HighQuality
citoquinas	I-Premise	HighQuality
en	I-Premise	HighQuality
respuesta	I-Premise	HighQuality
a	I-Premise	HighQuality
los	I-Premise	HighQuality
péptidos	I-Premise	HighQuality
del	I-Premise	HighQuality
VHB	I-Premise	HighQuality
.	I-Premise	HighQuality

Sin	B-Premise	HighQuality
embargo	I-Premise	HighQuality
,	I-Premise	HighQuality
durante	I-Premise	HighQuality
o	I-Premise	HighQuality
después	I-Premise	HighQuality
de	I-Premise	HighQuality
la	I-Premise	HighQuality
administración	I-Premise	HighQuality
de	I-Premise	HighQuality
GS-9620	I-Premise	HighQuality
,	I-Premise	HighQuality
las	I-Premise	HighQuality
células	I-Premise	HighQuality
T	I-Premise	HighQuality
produjeron	I-Premise	HighQuality
niveles	I-Premise	HighQuality
más	I-Premise	HighQuality
altos	I-Premise	HighQuality
de	I-Premise	HighQuality
citoquinas	I-Premise	HighQuality
en	I-Premise	HighQuality
comparación	I-Premise	HighQuality
con	I-Premise	HighQuality
la	I-Premise	HighQuality
línea	I-Premise	HighQuality
de	I-Premise	HighQuality
base	I-Premise	HighQuality
.	I-Premise	HighQuality

La	B-Premise	HighQuality
activación	I-Premise	HighQuality
y	I-Premise	HighQuality
la	I-Premise	HighQuality
función	I-Premise	HighQuality
de	I-Premise	HighQuality
las	I-Premise	HighQuality
células	I-Premise	HighQuality
NK	I-Premise	HighQuality
aumentó	I-Premise	HighQuality
después	I-Premise	HighQuality
de	I-Premise	HighQuality
que	I-Premise	HighQuality
los	I-Premise	HighQuality
pacientes	I-Premise	HighQuality
recibieran	I-Premise	HighQuality
GS-9620	I-Premise	HighQuality
,	I-Premise	HighQuality
pero	I-Premise	HighQuality
la	I-Premise	HighQuality
capacidad	I-Premise	HighQuality
de	I-Premise	HighQuality
las	I-Premise	HighQuality
células	I-Premise	HighQuality
NK	I-Premise	HighQuality
para	I-Premise	HighQuality
suprimir	I-Premise	HighQuality
las	I-Premise	HighQuality
respuestas	I-Premise	HighQuality
de	I-Premise	HighQuality
las	I-Premise	HighQuality
células	I-Premise	HighQuality
T	I-Premise	HighQuality
fue	I-Premise	HighQuality
menor	I-Premise	HighQuality
durante	I-Premise	HighQuality
el	I-Premise	HighQuality
tratamiento	I-Premise	HighQuality
con	I-Premise	HighQuality
GS-9620	I-Premise	HighQuality
que	I-Premise	HighQuality
antes.	I-Premise	HighQuality

Los	B-Premise	HighQuality
cambios	I-Premise	HighQuality
en	I-Premise	HighQuality
la	I-Premise	HighQuality
función	I-Premise	HighQuality
de	I-Premise	HighQuality
las	I-Premise	HighQuality
células	I-Premise	HighQuality
T	I-Premise	HighQuality
o	I-Premise	HighQuality
NK	I-Premise	HighQuality
no	I-Premise	HighQuality
se	I-Premise	HighQuality
correlacionaron	I-Premise	HighQuality
con	I-Premise	HighQuality
los	I-Premise	HighQuality
niveles	I-Premise	HighQuality
del	I-Premise	HighQuality
antígeno	I-Premise	HighQuality
de	I-Premise	HighQuality
superficie	I-Premise	HighQuality
de	I-Premise	HighQuality
la	I-Premise	HighQuality
hepatitis	I-Premise	HighQuality
B	I-Premise	HighQuality
.	I-Premise	HighQuality

Los	B-Premise	HighQuality
niveles	I-Premise	HighQuality
séricos	I-Premise	HighQuality
del	I-Premise	HighQuality
antígeno	I-Premise	HighQuality
de	I-Premise	HighQuality
superficie	I-Premise	HighQuality
de	I-Premise	HighQuality
la	I-Premise	HighQuality
hepatitis	I-Premise	HighQuality
B	I-Premise	HighQuality
no	I-Premise	HighQuality
disminuyeron	I-Premise	HighQuality
significativamente	I-Premise	HighQuality
en	I-Premise	HighQuality
comparación	I-Premise	HighQuality
con	I-Premise	HighQuality
los	I-Premise	HighQuality
valores	I-Premise	HighQuality
iniciales	I-Premise	HighQuality
en	I-Premise	HighQuality
los	I-Premise	HighQuality
pacientes	I-Premise	HighQuality
a	I-Premise	HighQuality
los	I-Premise	HighQuality
que	I-Premise	HighQuality
se	I-Premise	HighQuality
les	I-Premise	HighQuality
administró	I-Premise	HighQuality
cualquier	I-Premise	HighQuality
dosis	I-Premise	HighQuality
de	I-Premise	HighQuality
GS-9620.	I-Premise	HighQuality

La	B-Claim	HighQuality
administración	I-Claim	HighQuality
de	I-Claim	HighQuality
GS-9620	I-Claim	HighQuality
durante	I-Claim	HighQuality
doce	I-Claim	HighQuality
semanas	I-Claim	HighQuality
no	I-Claim	HighQuality
tuvo	I-Claim	HighQuality
un	I-Claim	HighQuality
efecto	I-Claim	HighQuality
significativo	I-Claim	HighQuality
sobre	I-Claim	HighQuality
los	I-Claim	HighQuality
niveles	I-Claim	HighQuality
de	I-Claim	HighQuality
antígeno	I-Claim	HighQuality
de	I-Claim	HighQuality
superficie	I-Claim	HighQuality
de	I-Claim	HighQuality
la	I-Claim	HighQuality
hepatitis	I-Claim	HighQuality
B	I-Claim	HighQuality
en	I-Claim	HighQuality
suero,	I-Claim	HighQuality
pero	I-Claim	HighQuality
sí	I-Claim	HighQuality
pareció	I-Claim	HighQuality
aumentar	I-Claim	HighQuality
las	I-Claim	HighQuality
respuestas	I-Claim	HighQuality
de	I-Claim	HighQuality
las	I-Claim	HighQuality
células	I-Claim	HighQuality
T	I-Claim	HighQuality
y	I-Claim	HighQuality
NK	I-Claim	HighQuality
y	I-Claim	HighQuality
reducir	I-Claim	HighQuality
la	I-Claim	HighQuality
capacidad	I-Claim	HighQuality
de	I-Claim	HighQuality
las	I-Claim	HighQuality
NK	I-Claim	HighQuality
para	I-Claim	HighQuality
suprimir	I-Claim	HighQuality
las	I-Claim	HighQuality
células	I-Claim	HighQuality
T.	I-Claim	HighQuality

Por	B-Claim	HighQuality
lo	I-Claim	HighQuality
tanto,	I-Claim	HighQuality
GS-9620	I-Claim	HighQuality
podría	I-Claim	HighQuality
incluirse	I-Claim	HighQuality
en	I-Claim	HighQuality
las	I-Claim	HighQuality
terapias	I-Claim	HighQuality
para	I-Claim	HighQuality
aumentar	I-Claim	HighQuality
la	I-Claim	HighQuality
respuesta	I-Claim	HighQuality
inmunitaria	I-Claim	HighQuality
al	I-Claim	HighQuality
VHB.	I-Claim	HighQuality

El	O	-
cumplimiento	O	-
de	O	-
una	O	-
nutrición	O	-
y	O	-
una	O	-
ingesta	O	-
de	O	-
líquidos	O	-
adecuadas	O	-
es	O	-
una	O	-
de	O	-
las	O	-
partes	O	-
esenciales	O	-
del	O	-
tratamiento	O	-
de	O	-
la	O	-
insuficiencia	O	-
renal	O	-
crónica	O	-
para	O	-
lograr	O	-
los	O	-
resultados	O	-
deseados	O	-
entre	O	-
los	O	-
pacientes	O	-
en	O	-
hemodiálisis.	O	-

Entre	O	-
los	O	-
diversos	O	-
métodos	O	-
de	O	-
formación,	O	-
el	O	-
"método	O	-
de	O	-
los	O	-
pequeños	O	-
grupos",	O	-
como	O	-
método	O	-
avanzado,	O	-
puede	O	-
ser	O	-
realizado	O	-
por	O	-
las	O	-
enfermeras	O	-
para	O	-
conseguir	O	-
los	O	-
resultados	O	-
terapéuticos	O	-
deseados.	O	-

El	O	-
presente	O	-
estudio	O	-
tenía	O	-
como	O	-
objetivo	O	-
investigar	O	-
el	O	-
efecto	O	-
de	O	-
una	O	-
formación	O	-
nutricional	O	-
adecuada	O	-
en	O	-
grupos	O	-
pequeños	O	-
sobre	O	-
los	O	-
parámetros	O	-
de	O	-
laboratorio	O	-
en	O	-
pacientes	O	-
en	O	-
hemodiálisis.	O	-

En	O	-
este	O	-
ensayo	O	-
clínico,	O	-
se	O	-
seleccionaron	O	-
aleatoriamente	O	-
64	O	-
pacientes	O	-
que	O	-
cumplían	O	-
los	O	-
criterios	O	-
de	O	-
inclusión	O	-
y	O	-
se	O	-
dividieron	O	-
en	O	-
un	O	-
grupo	O	-
de	O	-
intervención	O	-
y	O	-
un	O	-
grupo	O	-
de	O	-
control.	O	-

Posteriormente,	O	-
se	O	-
llevó	O	-
a	O	-
cabo	O	-
un	O	-
programa	O	-
de	O	-
formación	O	-
nutricional	O	-
adecuado,	O	-
que	O	-
incluía	O	-
conferencias	O	-
junto	O	-
con	O	-
folletos	O	-
de	O	-
nutrición	O	-
adecuados	O	-
en	O	-
tres	O	-
sesiones	O	-
de	O	-
preguntas	O	-
y	O	-
respuestas	O	-
de	O	-
una	O	-
hora	O	-
de	O	-
duración.	O	-

Treinta	O	-
y	O	-
dos	O	-
pacientes	O	-
de	O	-
cada	O	-
grupo	O	-
fueron	O	-
asignados	O	-
a	O	-
grupos	O	-
de	O	-
intervención	O	-
de	O	-
cinco	O	-
.	O	-

A	O	-
continuación,	O	-
se	O	-
midieron	O	-
los	O	-
indicadores	O	-
de	O	-
laboratorio	O	-
de	O	-
cada	O	-
paciente	O	-
en	O	-
cada	O	-
grupo	O	-
un	O	-
mes	O	-
después	O	-
del	O	-
entrenamiento.	O	-

A	O	-
continuación,	O	-
se	O	-
realizó	O	-
el	O	-
análisis	O	-
de	O	-
los	O	-
datos	O	-
mediante	O	-
estadísticas	O	-
descriptivas	O	-
y	O	-
analíticas	O	-
(pruebas	O	-
estadísticas	O	-
como	O	-
la	O	-
prueba	O	-
t	O	-
independiente,	O	-
la	O	-
prueba	O	-
t	O	-
emparejada,	O	-
las	O	-
medidas	O	-
repetidas	O	-
y	O	-
el	O	-
ANOVA)	O	-
en	O	-
el	O	-
software	O	-
SPSS	O	-
V.16.	O	-

La	O	-
edad	O	-
media	O	-
de	O	-
los	O	-
pacientes	O	-
era	O	-
de	O	-
50,1	O	-
±	O	-
13,1	O	-
años;	O	-
el	O	-
47,5%	O	-
de	O	-
ellos	O	-
se	O	-
había	O	-
sometido	O	-
a	O	-
diálisis	O	-
por	O	-
hipertensión	O	-
y	O	-
el	O	-
55,7%	O	-
tenía	O	-
un	O	-
historial	O	-
de	O	-
1	O	-
a	O	-
5	O	-
años	O	-
de	O	-
hemodiálisis	O	-
.	O	-

Hubo	B-Premise	HighQuality
una	I-Premise	HighQuality
diferencia	I-Premise	HighQuality
significativa	I-Premise	HighQuality
en	I-Premise	HighQuality
los	I-Premise	HighQuality
niveles	I-Premise	HighQuality
de	I-Premise	HighQuality
urea,	I-Premise	HighQuality
creatinina,	I-Premise	HighQuality
sodio,	I-Premise	HighQuality
potasio,	I-Premise	HighQuality
calcio	I-Premise	HighQuality
y	I-Premise	HighQuality
fósforo	I-Premise	HighQuality
después	I-Premise	HighQuality
de	I-Premise	HighQuality
la	I-Premise	HighQuality
intervención	I-Premise	HighQuality
entre	I-Premise	HighQuality
los	I-Premise	HighQuality
dos	I-Premise	HighQuality
grupos.	I-Premise	HighQuality

Una	B-Claim	HighQuality
formación	I-Claim	HighQuality
nutricional	I-Claim	HighQuality
adecuada	I-Claim	HighQuality
mediante	I-Claim	HighQuality
el	I-Claim	HighQuality
método	I-Claim	HighQuality
de	I-Claim	HighQuality
grupos	I-Claim	HighQuality
reducidos	I-Claim	HighQuality
para	I-Claim	HighQuality
pacientes	I-Claim	HighQuality
en	I-Claim	HighQuality
hemodiálisis	I-Claim	HighQuality
puede	I-Claim	HighQuality
imponer	I-Claim	HighQuality
efectos	I-Claim	HighQuality
positivos	I-Claim	HighQuality
en	I-Claim	HighQuality
los	I-Claim	HighQuality
parámetros	I-Claim	HighQuality
de	I-Claim	HighQuality
laboratorio	I-Claim	HighQuality
.	I-Claim	HighQuality

En	B-Claim	HighQuality
pacientes	I-Claim	HighQuality
con	I-Claim	HighQuality
hepatitis	I-Claim	HighQuality
B	I-Claim	HighQuality
crónica,	I-Claim	HighQuality
el	I-Claim	HighQuality
fumarato	I-Claim	HighQuality
de	I-Claim	HighQuality
disoproxilo	I-Claim	HighQuality
de	I-Claim	HighQuality
tenofovir	I-Claim	HighQuality
(	I-Claim	HighQuality
TDF	I-Claim	HighQuality
)	I-Claim	HighQuality
más	I-Claim	HighQuality
interferón	I-Claim	HighQuality
pegilado	I-Claim	HighQuality
(	I-Claim	HighQuality
PEG-IFN	I-Claim	HighQuality
)	I-Claim	HighQuality
durante	I-Claim	HighQuality
48	I-Claim	HighQuality
semanas	I-Claim	HighQuality
da	I-Claim	HighQuality
lugar	I-Claim	HighQuality
a	I-Claim	HighQuality
tasas	I-Claim	HighQuality
más	I-Claim	HighQuality
altas	I-Claim	HighQuality
de	I-Claim	HighQuality
pérdida	I-Claim	HighQuality
del	I-Claim	HighQuality
antígeno	I-Claim	HighQuality
de	I-Claim	HighQuality
superficie	I-Claim	HighQuality
de	I-Claim	HighQuality
la	I-Claim	HighQuality
hepatitis	I-Claim	HighQuality
B	I-Claim	HighQuality
(	I-Claim	HighQuality
HBsAg	I-Claim	HighQuality
)	I-Claim	HighQuality
que	I-Claim	HighQuality
cualquiera	I-Claim	HighQuality
de	I-Claim	HighQuality
las	I-Claim	HighQuality
dos	I-Claim	HighQuality
monoterapias	I-Claim	HighQuality
.	I-Claim	HighQuality

Identificar	O	-
los	O	-
factores	O	-
basales	O	-
y	O	-
durante	O	-
el	O	-
tratamiento	O	-
asociados	O	-
a	O	-
la	O	-
pérdida	O	-
de	O	-
HBsAg	O	-
en	O	-
la	O	-
semana	O	-
72	O	-
y	O	-
proporcionar	O	-
un	O	-
modelo	O	-
para	O	-
predecir	O	-
la	O	-
pérdida	O	-
de	O	-
HBsAg	O	-
en	O	-
pacientes	O	-
que	O	-
reciben	O	-
un	O	-
tratamiento	O	-
combinado	O	-
durante	O	-
48	O	-
semanas	O	-
.	O	-

Un	O	-
análisis	O	-
secundario	O	-
de	O	-
los	O	-
datos	O	-
de	O	-
un	O	-
estudio	O	-
abierto	O	-
en	O	-
el	O	-
que	O	-
los	O	-
pacientes	O	-
fueron	O	-
aleatorizados	O	-
a	O	-
TDF	O	-
(	O	-
300	O	-
mg/día	O	-
,	O	-
oral	O	-
)	O	-
más	O	-
PEG-IFN	O	-
(	O	-
PI	O	-
,	O	-
180	O	-
μg/semana	O	-
,	O	-
subcutáneo	O	-
)	O	-
durante	O	-
48	O	-
semanas	O	-
(	O	-
TDF/PI-48w	O	-
)	O	-
;	O	-
TDF	O	-
más	O	-
PEG-IFN	O	-
durante	O	-
16	O	-
semanas	O	-
,	O	-
TDF	O	-
durante	O	-
32	O	-
semanas	O	-
(	O	-
TDF/PI-16w+TDF-32w	O	-
)	O	-
;	O	-
TDF	O	-
durante	O	-
120	O	-
semanas	O	-
(	O	-
TDF-120w	O	-
)	O	-
o	O	-
PEG-IFN	O	-
durante	O	-
48	O	-
semanas	O	-
(	O	-
PI-48w	O	-
)	O	-
.	O	-

Se	O	-
utilizaron	O	-
métodos	O	-
de	O	-
regresión	O	-
logística	O	-
para	O	-
identificar	O	-
los	O	-
modelos	O	-
que	O	-
mejor	O	-
predecían	O	-
la	O	-
pérdida	O	-
de	O	-
HBsAg	O	-
en	O	-
la	O	-
semana	O	-
72	O	-
.	O	-

Las	B-Premise	HighQuality
tasas	I-Premise	HighQuality
de	I-Premise	HighQuality
pérdida	I-Premise	HighQuality
de	I-Premise	HighQuality
HBsAg	I-Premise	HighQuality
en	I-Premise	HighQuality
la	I-Premise	HighQuality
semana	I-Premise	HighQuality
72	I-Premise	HighQuality
fueron	I-Premise	HighQuality
significativamente	I-Premise	HighQuality
mayores	I-Premise	HighQuality
en	I-Premise	HighQuality
el	I-Premise	HighQuality
grupo	I-Premise	HighQuality
de	I-Premise	HighQuality
TDF/PI-48w	I-Premise	HighQuality
(	I-Premise	HighQuality
6,5	I-Premise	HighQuality
%	I-Premise	HighQuality
)	I-Premise	HighQuality
que	I-Premise	HighQuality
en	I-Premise	HighQuality
los	I-Premise	HighQuality
grupos	I-Premise	HighQuality
de	I-Premise	HighQuality
TDF/PI-16w+TDF-32w	I-Premise	HighQuality
(	I-Premise	HighQuality
0,5	I-Premise	HighQuality
%	I-Premise	HighQuality
)	I-Premise	HighQuality
,	I-Premise	HighQuality
TDF-120w	I-Premise	HighQuality
(	I-Premise	HighQuality
0	I-Premise	HighQuality
%	I-Premise	HighQuality
)	I-Premise	HighQuality
y	I-Premise	HighQuality
PI-48w	I-Premise	HighQuality
(	I-Premise	HighQuality
2,2	I-Premise	HighQuality
%	I-Premise	HighQuality
)	I-Premise	HighQuality
(	I-Premise	HighQuality
P	I-Premise	HighQuality
=	I-Premise	HighQuality
0,09	I-Premise	HighQuality
)	I-Premise	HighQuality
.	I-Premise	HighQuality

El	O	-
único	O	-
factor	O	-
basal	O	-
asociado	O	-
a	O	-
la	O	-
respuesta	O	-
fue	O	-
el	O	-
genotipo	O	-
A.	O	-
El	O	-
descenso	B-Premise	HighQuality
del	I-Premise	HighQuality
HBsAg	I-Premise	HighQuality
en	I-Premise	HighQuality
la	I-Premise	HighQuality
semana	I-Premise	HighQuality
12	I-Premise	HighQuality
o	I-Premise	HighQuality
24	I-Premise	HighQuality
de	I-Premise	HighQuality
tratamiento	I-Premise	HighQuality
se	I-Premise	HighQuality
asoció	I-Premise	HighQuality
a	I-Premise	HighQuality
la	I-Premise	HighQuality
pérdida	I-Premise	HighQuality
de	I-Premise	HighQuality
HBsAg	I-Premise	HighQuality
en	I-Premise	HighQuality
la	I-Premise	HighQuality
semana	I-Premise	HighQuality
72	I-Premise	HighQuality
(	I-Premise	HighQuality
P	I-Premise	HighQuality
<	I-Premise	HighQuality
0,001	I-Premise	HighQuality
)	I-Premise	HighQuality
.	I-Premise	HighQuality

El	B-Premise	HighQuality
descenso	I-Premise	HighQuality
del	I-Premise	HighQuality
HBsAg	I-Premise	HighQuality
>	I-Premise	HighQuality
3,5	I-Premise	HighQuality
log10	I-Premise	HighQuality
UI/mL	I-Premise	HighQuality
en	I-Premise	HighQuality
la	I-Premise	HighQuality
semana	I-Premise	HighQuality
24	I-Premise	HighQuality
en	I-Premise	HighQuality
el	I-Premise	HighQuality
grupo	I-Premise	HighQuality
de	I-Premise	HighQuality
TDF/PI-48w	I-Premise	HighQuality
dio	I-Premise	HighQuality
lugar	I-Premise	HighQuality
a	I-Premise	HighQuality
un	I-Premise	HighQuality
valor	I-Premise	HighQuality
predictivo	I-Premise	HighQuality
positivo	I-Premise	HighQuality
del	I-Premise	HighQuality
85	I-Premise	HighQuality
%	I-Premise	HighQuality
y	I-Premise	HighQuality
a	I-Premise	HighQuality
un	I-Premise	HighQuality
valor	I-Premise	HighQuality
predictivo	I-Premise	HighQuality
negativo	I-Premise	HighQuality
del	I-Premise	HighQuality
99	I-Premise	HighQuality
%	I-Premise	HighQuality
para	I-Premise	HighQuality
la	I-Premise	HighQuality
pérdida	I-Premise	HighQuality
de	I-Premise	HighQuality
HBsAg	I-Premise	HighQuality
en	I-Premise	HighQuality
la	I-Premise	HighQuality
semana	I-Premise	HighQuality
72	I-Premise	HighQuality
.	I-Premise	HighQuality

El	B-Claim	HighQuality
descenso	I-Claim	HighQuality
del	I-Claim	HighQuality
HBsAg	I-Claim	HighQuality
en	I-Claim	HighQuality
la	I-Claim	HighQuality
semana	I-Claim	HighQuality
24	I-Claim	HighQuality
del	I-Claim	HighQuality
tratamiento	I-Claim	HighQuality
combinado	I-Claim	HighQuality
de	I-Claim	HighQuality
TDF	I-Claim	HighQuality
más	I-Claim	HighQuality
PEG-IFN	I-Claim	HighQuality
puede	I-Claim	HighQuality
identificar	I-Claim	HighQuality
a	I-Claim	HighQuality
los	I-Claim	HighQuality
pacientes	I-Claim	HighQuality
que,	I-Claim	HighQuality
tras	I-Claim	HighQuality
completar	I-Claim	HighQuality
48	I-Claim	HighQuality
semanas	I-Claim	HighQuality
de	I-Claim	HighQuality
tratamiento,	I-Claim	HighQuality
tienen	I-Claim	HighQuality
más	I-Claim	HighQuality
posibilidades	I-Claim	HighQuality
de	I-Claim	HighQuality
lograr	I-Claim	HighQuality
la	I-Claim	HighQuality
pérdida	I-Claim	HighQuality
del	I-Claim	HighQuality
HBsAg	I-Claim	HighQuality
en	I-Claim	HighQuality
la	I-Claim	HighQuality
semana	I-Claim	HighQuality
72.	I-Claim	HighQuality

El	O	-
objetivo	O	-
de	O	-
este	O	-
trabajo	O	-
es	O	-
evaluar	O	-
la	O	-
eficacia	O	-
y	O	-
la	O	-
tolerabilidad	O	-
de	O	-
tafluprost	O	-
con	O	-
conservante	O	-
al	O	-
0,0015	O	-
%	O	-
y	O	-
de	O	-
tafluprost	O	-
sin	O	-
conservante	O	-
al	O	-
0,0015	O	-
%	O	-
mediante	O	-
un	O	-
estudio	O	-
cruzado	O	-
prospectivo.	O	-

Se	O	-
incluyeron	O	-
aleatoriamente	O	-
pacientes	O	-
con	O	-
glaucoma	O	-
primario	O	-
de	O	-
ángulo	O	-
abierto	O	-
(GPAA)	O	-
y	O	-
glaucoma	O	-
normotensivo	O	-
(GNT).	O	-

Los	O	-
pacientes	O	-
del	O	-
grupo	O	-
1	O	-
("NPT	O	-
a	O	-
PT")	O	-
utilizaron	O	-
tafluprost	O	-
sin	O	-
conservante	O	-
al	O	-
0,0015	O	-
%	O	-
(	O	-
NPT	O	-
)	O	-
durante	O	-
6	O	-
meses	O	-
y	O	-
luego	O	-
cambiaron	O	-
a	O	-
tafluprost	O	-
con	O	-
conservante	O	-
al	O	-
0,0015	O	-
%	O	-
(	O	-
PT	O	-
)	O	-
durante	O	-
6	O	-
meses	O	-
.	O	-

Los	O	-
pacientes	O	-
del	O	-
grupo	O	-
2	O	-
("PT	O	-
a	O	-
NPT")	O	-
utilizaron	O	-
tafluprost	O	-
con	O	-
conservante	O	-
al	O	-
0,0015%	O	-
durante	O	-
6	O	-
meses	O	-
y	O	-
cambiaron	O	-
a	O	-
tafluprost	O	-
sin	O	-
conservante	O	-
al	O	-
0,0015%	O	-
durante	O	-
6	O	-
meses.	O	-

A	O	-
los	O	-
1	O	-
,	O	-
3	O	-
,	O	-
6	O	-
,	O	-
7	O	-
,	O	-
9	O	-
,	O	-
y	O	-
12	O	-
meses	O	-
,	O	-
se	O	-
midió	O	-
la	O	-
presión	O	-
intraocular	O	-
para	O	-
la	O	-
eficacia	O	-
y	O	-
se	O	-
calificó	O	-
la	O	-
erosión	O	-
corneal	O	-
,	O	-
el	O	-
tiempo	O	-
de	O	-
ruptura	O	-
de	O	-
la	O	-
lágrima	O	-
(	O	-
TBUT	O	-
)	O	-
,	O	-
y	O	-
el	O	-
malestar	O	-
subjetivo	O	-
.	O	-

Se	O	-
inscribieron	O	-
un	O	-
total	O	-
de	O	-
20	O	-
pacientes	O	-
y	O	-
20	O	-
ojos.	O	-

En	B-Premise	HighQuality
los	I-Premise	HighQuality
grupos	I-Premise	HighQuality
1	I-Premise	HighQuality
y	I-Premise	HighQuality
2	I-Premise	HighQuality
,	I-Premise	HighQuality
la	I-Premise	HighQuality
presión	I-Premise	HighQuality
intraocular	I-Premise	HighQuality
se	I-Premise	HighQuality
controló	I-Premise	HighQuality
bien	I-Premise	HighQuality
hasta	I-Premise	HighQuality
aproximadamente	I-Premise	HighQuality
14	I-Premise	HighQuality
mmHg	I-Premise	HighQuality
(	I-Premise	HighQuality
9,38-18,46	I-Premise	HighQuality
%	I-Premise	HighQuality
de	I-Premise	HighQuality
disminución	I-Premise	HighQuality
)	I-Premise	HighQuality
.	I-Premise	HighQuality

En	B-Premise	HighQuality
general,	I-Premise	HighQuality
la	I-Premise	HighQuality
satisfacción	I-Premise	HighQuality
subjetiva	I-Premise	HighQuality
mejoró	I-Premise	HighQuality
tras	I-Premise	HighQuality
el	I-Premise	HighQuality
cambio	I-Premise	HighQuality
de	I-Premise	HighQuality
PT	I-Premise	HighQuality
a	I-Premise	HighQuality
NPT	I-Premise	HighQuality
(	I-Premise	HighQuality
p	I-Premise	HighQuality
=	I-Premise	HighQuality
0,03	I-Premise	HighQuality
)	I-Premise	HighQuality
y	I-Premise	HighQuality
el	I-Premise	HighQuality
TBUT	I-Premise	HighQuality
con	I-Premise	HighQuality
PT	I-Premise	HighQuality
fue	I-Premise	HighQuality
numéricamente	I-Premise	HighQuality
inferior	I-Premise	HighQuality
al	I-Premise	HighQuality
de	I-Premise	HighQuality
NPT	I-Premise	HighQuality
(	I-Premise	HighQuality
p	I-Premise	HighQuality
=	I-Premise	HighQuality
0,06	I-Premise	HighQuality
),	I-Premise	HighQuality
pero	I-Premise	HighQuality
no	I-Premise	HighQuality
al	I-Premise	HighQuality
cambiar	I-Premise	HighQuality
de	I-Premise	HighQuality
NPT	I-Premise	HighQuality
a	I-Premise	HighQuality
PT	I-Premise	HighQuality
.	I-Premise	HighQuality

Tanto	B-Claim	HighQuality
el	I-Claim	HighQuality
tafluprost	I-Claim	HighQuality
que	I-Claim	HighQuality
contiene	I-Claim	HighQuality
conservantes	I-Claim	HighQuality
como	I-Claim	HighQuality
el	I-Claim	HighQuality
que	I-Claim	HighQuality
no	I-Claim	HighQuality
los	I-Claim	HighQuality
tiene,	I-Claim	HighQuality
redujeron	I-Claim	HighQuality
significativamente	I-Claim	HighQuality
la	I-Claim	HighQuality
presión	I-Claim	HighQuality
intraocular.	I-Claim	HighQuality

Además	O	-
,	O	-
el	B-Claim	HighQuality
cambio	I-Claim	HighQuality
de	I-Claim	HighQuality
medicación	I-Claim	HighQuality
de	I-Claim	HighQuality
PT	I-Claim	HighQuality
a	I-Claim	HighQuality
NPT	I-Claim	HighQuality
podría	I-Claim	HighQuality
mejorar	I-Claim	HighQuality
la	I-Claim	HighQuality
satisfacción	I-Claim	HighQuality
subjetiva	I-Claim	HighQuality
y	I-Claim	HighQuality
el	I-Claim	HighQuality
tiempo	I-Claim	HighQuality
de	I-Claim	HighQuality
ruptura	I-Claim	HighQuality
de	I-Claim	HighQuality
lágrimas	I-Claim	HighQuality
.	I-Claim	HighQuality

Comparar	O	-
la	O	-
facoemulsificación	O	-
frente	O	-
a	O	-
la	O	-
trabeculectomía	O	-
con	O	-
mitomicina	O	-
C	O	-
adyuvante	O	-
en	O	-
el	O	-
glaucoma	O	-
crónico	O	-
de	O	-
ángulo	O	-
cerrado	O	-
(	O	-
CACG	O	-
)	O	-
no	O	-
controlado	O	-
médicamente	O	-
y	O	-
sin	O	-
cataratas	O	-
.	O	-

Ensayo	O	-
clínico	O	-
prospectivo	O	-
y	O	-
aleatorizado.	O	-

Cincuenta	O	-
ojos	O	-
CACG	O	-
no	O	-
controlados	O	-
médicamente	O	-
sin	O	-
cataratas	O	-
de	O	-
50	O	-
pacientes	O	-
.	O	-

Los	O	-
pacientes	O	-
fueron	O	-
asignados	O	-
aleatoriamente	O	-
para	O	-
someterse	O	-
a	O	-
una	O	-
facoemulsificación	O	-
o	O	-
a	O	-
una	O	-
trabeculectomía	O	-
con	O	-
mitomicina	O	-
C	O	-
adjunta.	O	-

Presión	O	-
intraocular	O	-
(	O	-
PIO	O	-
)	O	-
y	O	-
necesidad	O	-
de	O	-
medicamentos	O	-
para	O	-
el	O	-
glaucoma	O	-
.	O	-

Veintiséis	O	-
ojos	O	-
con	O	-
CACG	O	-
fueron	O	-
asignados	O	-
al	O	-
azar	O	-
para	O	-
recibir	O	-
facoemulsificación,	O	-
y	O	-
24	O	-
ojos	O	-
fueron	O	-
sometidos	O	-
a	O	-
trabeculectomía	O	-
con	O	-
mitomicina	O	-
C.	O	-
La	B-Premise	HighQuality
facoemulsificación	I-Premise	HighQuality
y	I-Premise	HighQuality
la	I-Premise	HighQuality
trabeculectomía	I-Premise	HighQuality
dieron	I-Premise	HighQuality
lugar	I-Premise	HighQuality
a	I-Premise	HighQuality
una	I-Premise	HighQuality
reducción	I-Premise	HighQuality
significativa	I-Premise	HighQuality
y	I-Premise	HighQuality
comparable	I-Premise	HighQuality
de	I-Premise	HighQuality
la	I-Premise	HighQuality
PIO	I-Premise	HighQuality
a	I-Premise	HighQuality
los	I-Premise	HighQuality
24	I-Premise	HighQuality
meses	I-Premise	HighQuality
de	I-Premise	HighQuality
la	I-Premise	HighQuality
cirugía	I-Premise	HighQuality
(	I-Premise	HighQuality
reducción	I-Premise	HighQuality
de	I-Premise	HighQuality
8,4	I-Premise	HighQuality
mmHg	I-Premise	HighQuality
o	I-Premise	HighQuality
34%	I-Premise	HighQuality
para	I-Premise	HighQuality
la	I-Premise	HighQuality
facoemulsificación	I-Premise	HighQuality
frente	I-Premise	HighQuality
a	I-Premise	HighQuality
8,9	I-Premise	HighQuality
mmHg	I-Premise	HighQuality
o	I-Premise	HighQuality
36%	I-Premise	HighQuality
para	I-Premise	HighQuality
la	I-Premise	HighQuality
trabeculectomía	I-Premise	HighQuality
;	I-Premise	HighQuality
P=0,76	I-Premise	HighQuality
)	I-Premise	HighQuality
.	O	-

Durante	B-Premise	HighQuality
los	I-Premise	HighQuality
primeros	I-Premise	HighQuality
24	I-Premise	HighQuality
meses,	I-Premise	HighQuality
los	I-Premise	HighQuality
ojos	I-Premise	HighQuality
tratados	I-Premise	HighQuality
con	I-Premise	HighQuality
trabeculectomía	I-Premise	HighQuality
necesitaron	I-Premise	HighQuality
una	I-Premise	HighQuality
media	I-Premise	HighQuality
de	I-Premise	HighQuality
1,1	I-Premise	HighQuality
fármacos	I-Premise	HighQuality
menos	I-Premise	HighQuality
que	I-Premise	HighQuality
los	I-Premise	HighQuality
tratados	I-Premise	HighQuality
con	I-Premise	HighQuality
facoemulsificación	I-Premise	HighQuality
(	I-Premise	HighQuality
P	I-Premise	HighQuality
<	I-Premise	HighQuality
0,001	I-Premise	HighQuality
)	I-Premise	HighQuality
.	I-Premise	HighQuality

Sin	O	-
embargo,	O	-
la	B-Premise	HighQuality
trabeculectomía	I-Premise	HighQuality
se	I-Premise	HighQuality
asoció	I-Premise	HighQuality
con	I-Premise	HighQuality
un	I-Premise	HighQuality
número	I-Premise	HighQuality
significativamente	I-Premise	HighQuality
mayor	I-Premise	HighQuality
de	I-Premise	HighQuality
complicaciones	I-Premise	HighQuality
quirúrgicas	I-Premise	HighQuality
que	I-Premise	HighQuality
la	I-Premise	HighQuality
facoemulsificación	I-Premise	HighQuality
(	I-Premise	HighQuality
46	I-Premise	HighQuality
%	I-Premise	HighQuality
frente	I-Premise	HighQuality
a	I-Premise	HighQuality
4	I-Premise	HighQuality
%	I-Premise	HighQuality
;	I-Premise	HighQuality
P=0,001	I-Premise	HighQuality
)	I-Premise	HighQuality
.	I-Premise	HighQuality

Ocho	B-Premise	HighQuality
(	I-Premise	HighQuality
33	I-Premise	HighQuality
%	I-Premise	HighQuality
)	I-Premise	HighQuality
de	I-Premise	HighQuality
los	I-Premise	HighQuality
24	I-Premise	HighQuality
ojos	I-Premise	HighQuality
sometidos	I-Premise	HighQuality
a	I-Premise	HighQuality
trabeculectomía	I-Premise	HighQuality
presentaron	I-Premise	HighQuality
cataratas	I-Premise	HighQuality
durante	I-Premise	HighQuality
el	I-Premise	HighQuality
seguimiento	I-Premise	HighQuality
.	I-Premise	HighQuality

Tanto	B-Claim	HighQuality
la	I-Claim	HighQuality
facoemulsificación	I-Claim	HighQuality
como	I-Claim	HighQuality
la	I-Claim	HighQuality
trabeculectomía	I-Claim	HighQuality
son	I-Claim	HighQuality
eficaces	I-Claim	HighQuality
para	I-Claim	HighQuality
reducir	I-Claim	HighQuality
la	I-Claim	HighQuality
PIO	I-Claim	HighQuality
en	I-Claim	HighQuality
ojos	I-Claim	HighQuality
con	I-Claim	HighQuality
CACG	I-Claim	HighQuality
no	I-Claim	HighQuality
controlados	I-Claim	HighQuality
médicamente	I-Claim	HighQuality
y	I-Claim	HighQuality
sin	I-Claim	HighQuality
cataratas.	I-Claim	HighQuality

La	B-Claim	HighQuality
trabeculectomía	I-Claim	HighQuality
es	I-Claim	HighQuality
más	I-Claim	HighQuality
eficaz	I-Claim	HighQuality
que	I-Claim	HighQuality
la	I-Claim	HighQuality
facoemulsificación	I-Claim	HighQuality
para	I-Claim	HighQuality
reducir	I-Claim	HighQuality
la	I-Claim	HighQuality
dependencia	I-Claim	HighQuality
de	I-Claim	HighQuality
los	I-Claim	HighQuality
fármacos	I-Claim	HighQuality
para	I-Claim	HighQuality
el	I-Claim	HighQuality
glaucoma,	I-Claim	HighQuality
pero	I-Claim	HighQuality
se	I-Claim	HighQuality
asocia	I-Claim	HighQuality
a	I-Claim	HighQuality
más	I-Claim	HighQuality
complicaciones.	I-Claim	HighQuality

La	O	-
hipertensión	O	-
no	O	-
controlada	O	-
es	O	-
un	O	-
problema	O	-
importante	O	-
entre	O	-
los	O	-
hombres	O	-
negros	O	-
no	O	-
hispanos	O	-
,	O	-
que	O	-
están	O	-
infrarrepresentados	O	-
en	O	-
los	O	-
ensayos	O	-
de	O	-
intervención	O	-
farmacéutica	O	-
en	O	-
los	O	-
entornos	O	-
sanitarios	O	-
tradicionales	O	-
.	O	-

Se	O	-
inscribió	O	-
una	O	-
cohorte	O	-
de	O	-
319	O	-
clientes	O	-
masculinos	O	-
de	O	-
raza	O	-
negra	O	-
con	O	-
una	O	-
presión	O	-
arterial	O	-
sistólica	O	-
de	O	-
140	O	-
mm	O	-
Hg	O	-
o	O	-
más	O	-
de	O	-
52	O	-
peluquerías	O	-
de	O	-
propietarios	O	-
de	O	-
raza	O	-
negra	O	-
(un	O	-
entorno	O	-
de	O	-
atención	O	-
sanitaria	O	-
no	O	-
tradicional)	O	-
en	O	-
un	O	-
ensayo	O	-
aleatorio	O	-
por	O	-
grupos	O	-
en	O	-
el	O	-
que	O	-
las	O	-
peluquerías	O	-
se	O	-
asignaron	O	-
a	O	-
una	O	-
intervención	O	-
dirigida	O	-
por	O	-
farmacéuticos	O	-
(en	O	-
la	O	-
que	O	-
los	O	-
peluqueros	O	-
fomentaron	O	-
las	O	-
reuniones	O	-
en	O	-
las	O	-
peluquerías	O	-
con	O	-
farmacéuticos	O	-
formados	O	-
en	O	-
la	O	-
especialidad	O	-
que	O	-
prescribieron	O	-
el	O	-
tratamiento	O	-
farmacológico	O	-
en	O	-
virtud	O	-
de	O	-
un	O	-
acuerdo	O	-
de	O	-
práctica	O	-
colaborativa	O	-
con	O	-
los	O	-
médicos	O	-
de	O	-
los	O	-
participantes)	O	-
o	O	-
a	O	-
un	O	-
enfoque	O	-
de	O	-
control	O	-
activo	O	-
(en	O	-
el	O	-
que	O	-
los	O	-
peluqueros	O	-
fomentaron	O	-
la	O	-
modificación	O	-
del	O	-
estilo	O	-
de	O	-
vida	O	-
y	O	-
las	O	-
citas	O	-
con	O	-
el	O	-
médico).	O	-

El	O	-
resultado	O	-
primario	O	-
fue	O	-
la	O	-
reducción	O	-
de	O	-
la	O	-
presión	O	-
arterial	O	-
sistólica	O	-
a	O	-
los	O	-
6	O	-
meses.	O	-

Al	O	-
inicio,	O	-
la	O	-
presión	O	-
arterial	O	-
sistólica	O	-
media	O	-
era	O	-
de	O	-
152,8	O	-
mm	O	-
Hg	O	-
en	O	-
el	O	-
grupo	O	-
de	O	-
intervención	O	-
y	O	-
de	O	-
154,6	O	-
mm	O	-
Hg	O	-
en	O	-
el	O	-
grupo	O	-
de	O	-
control.	O	-

A	B-Premise	HighQuality
los	I-Premise	HighQuality
6	I-Premise	HighQuality
meses,	I-Premise	HighQuality
la	I-Premise	HighQuality
presión	I-Premise	HighQuality
arterial	I-Premise	HighQuality
sistólica	I-Premise	HighQuality
media	I-Premise	HighQuality
descendió	I-Premise	HighQuality
27,0	I-Premise	HighQuality
mm	I-Premise	HighQuality
Hg	I-Premise	HighQuality
(	I-Premise	HighQuality
a	I-Premise	HighQuality
125,8	I-Premise	HighQuality
mm	I-Premise	HighQuality
Hg	I-Premise	HighQuality
)	I-Premise	HighQuality
en	I-Premise	HighQuality
el	I-Premise	HighQuality
grupo	I-Premise	HighQuality
de	I-Premise	HighQuality
intervención	I-Premise	HighQuality
y	I-Premise	HighQuality
9,3	I-Premise	HighQuality
mm	I-Premise	HighQuality
Hg	I-Premise	HighQuality
(	I-Premise	HighQuality
a	I-Premise	HighQuality
145,4	I-Premise	HighQuality
mm	I-Premise	HighQuality
Hg	I-Premise	HighQuality
)	I-Premise	HighQuality
en	I-Premise	HighQuality
el	I-Premise	HighQuality
grupo	I-Premise	HighQuality
de	I-Premise	HighQuality
control;	I-Premise	HighQuality
la	I-Premise	HighQuality
reducción	I-Premise	HighQuality
media	I-Premise	HighQuality
fue	I-Premise	HighQuality
21,6	I-Premise	HighQuality
mm	I-Premise	HighQuality
Hg	I-Premise	HighQuality
mayor	I-Premise	HighQuality
con	I-Premise	HighQuality
la	I-Premise	HighQuality
intervención	I-Premise	HighQuality
(	I-Premise	HighQuality
intervalo	I-Premise	HighQuality
de	I-Premise	HighQuality
confianza	I-Premise	HighQuality
del	I-Premise	HighQuality
95	I-Premise	HighQuality
%	I-Premise	HighQuality
,	I-Premise	HighQuality
14,7	I-Premise	HighQuality
a	I-Premise	HighQuality
28,4	I-Premise	HighQuality
;	I-Premise	HighQuality
P	I-Premise	HighQuality
<	I-Premise	HighQuality
0,001	I-Premise	HighQuality
)	I-Premise	HighQuality
.	I-Premise	HighQuality

El	B-Premise	HighQuality
63,6%	I-Premise	HighQuality
de	I-Premise	HighQuality
los	I-Premise	HighQuality
participantes	I-Premise	HighQuality
del	I-Premise	HighQuality
grupo	I-Premise	HighQuality
de	I-Premise	HighQuality
intervención	I-Premise	HighQuality
alcanzaron	I-Premise	HighQuality
un	I-Premise	HighQuality
nivel	I-Premise	HighQuality
de	I-Premise	HighQuality
presión	I-Premise	HighQuality
arterial	I-Premise	HighQuality
inferior	I-Premise	HighQuality
a	I-Premise	HighQuality
130/80	I-Premise	HighQuality
mm	I-Premise	HighQuality
Hg,	I-Premise	HighQuality
frente	I-Premise	HighQuality
al	I-Premise	HighQuality
11,7%	I-Premise	HighQuality
de	I-Premise	HighQuality
los	I-Premise	HighQuality
participantes	I-Premise	HighQuality
del	I-Premise	HighQuality
grupo	I-Premise	HighQuality
de	I-Premise	HighQuality
control	I-Premise	HighQuality
(	I-Premise	HighQuality
P	I-Premise	HighQuality
<	I-Premise	HighQuality
0,001	I-Premise	HighQuality
)	I-Premise	HighQuality
.	I-Premise	HighQuality

En	B-Premise	HighQuality
el	I-Premise	HighQuality
grupo	I-Premise	HighQuality
de	I-Premise	HighQuality
intervención,	I-Premise	HighQuality
la	I-Premise	HighQuality
tasa	I-Premise	HighQuality
de	I-Premise	HighQuality
retención	I-Premise	HighQuality
de	I-Premise	HighQuality
la	I-Premise	HighQuality
cohorte	I-Premise	HighQuality
fue	I-Premise	HighQuality
del	I-Premise	HighQuality
95	I-Premise	HighQuality
%,	I-Premise	HighQuality
y	I-Premise	HighQuality
hubo	I-Premise	HighQuality
pocos	I-Premise	HighQuality
acontecimientos	I-Premise	HighQuality
adversos	I-Premise	HighQuality
(	I-Premise	HighQuality
tres	I-Premise	HighQuality
casos	I-Premise	HighQuality
de	I-Premise	HighQuality
lesión	I-Premise	HighQuality
renal	I-Premise	HighQuality
aguda	I-Premise	HighQuality
)	I-Premise	HighQuality
.	I-Premise	HighQuality

Entre	B-Claim	HighQuality
los	I-Claim	HighQuality
clientes	I-Claim	HighQuality
masculinos	I-Claim	HighQuality
negros	I-Claim	HighQuality
de	I-Claim	HighQuality
las	I-Claim	HighQuality
barberías	I-Claim	HighQuality
con	I-Claim	HighQuality
hipertensión	I-Claim	HighQuality
no	I-Claim	HighQuality
controlada,	I-Claim	HighQuality
la	I-Claim	HighQuality
promoción	I-Claim	HighQuality
de	I-Claim	HighQuality
la	I-Claim	HighQuality
salud	I-Claim	HighQuality
por	I-Claim	HighQuality
parte	I-Claim	HighQuality
de	I-Claim	HighQuality
los	I-Claim	HighQuality
barberos	I-Claim	HighQuality
dio	I-Claim	HighQuality
lugar	I-Claim	HighQuality
a	I-Claim	HighQuality
una	I-Claim	HighQuality
mayor	I-Claim	HighQuality
reducción	I-Claim	HighQuality
de	I-Claim	HighQuality
la	I-Claim	HighQuality
presión	I-Claim	HighQuality
arterial	I-Claim	HighQuality
cuando	I-Claim	HighQuality
se	I-Claim	HighQuality
combinó	I-Claim	HighQuality
con	I-Claim	HighQuality
la	I-Claim	HighQuality
gestión	I-Claim	HighQuality
de	I-Claim	HighQuality
la	I-Claim	HighQuality
medicación	I-Claim	HighQuality
en	I-Claim	HighQuality
las	I-Claim	HighQuality
barberías	I-Claim	HighQuality
por	I-Claim	HighQuality
parte	I-Claim	HighQuality
de	I-Claim	HighQuality
farmacéuticos	I-Claim	HighQuality
especializados.	I-Claim	HighQuality

La	B-Claim	HighQuality
calidad	I-Claim	HighQuality
de	I-Claim	HighQuality
vida	I-Claim	HighQuality
relacionada	I-Claim	HighQuality
con	I-Claim	HighQuality
el	I-Claim	HighQuality
tratamiento	I-Claim	HighQuality
(	I-Claim	HighQuality
QOL	I-Claim	HighQuality
)	I-Claim	HighQuality
es	I-Claim	HighQuality
un	I-Claim	HighQuality
aspecto	I-Claim	HighQuality
importante	I-Claim	HighQuality
del	I-Claim	HighQuality
control	I-Claim	HighQuality
de	I-Claim	HighQuality
la	I-Claim	HighQuality
diabetes	I-Claim	HighQuality
.	I-Claim	HighQuality

Sin	O	-
embargo,	O	-
ningún	O	-
estudio	O	-
ha	O	-
comparado	O	-
la	O	-
influencia	O	-
de	O	-
los	O	-
inhibidores	O	-
de	O	-
la	O	-
dipeptidil	O	-
peptidasa-4	O	-
frente	O	-
a	O	-
los	O	-
inhibidores	O	-
de	O	-
la	O	-
alfa-glucosidasa	O	-
en	O	-
la	O	-
CdV	O	-
relacionada	O	-
con	O	-
el	O	-
tratamiento.	O	-

Este	O	-
subanálisis	O	-
preespecificado	O	-
del	O	-
Estudio	O	-
de	O	-
Linagliptina	O	-
sobre	O	-
los	O	-
Efectos	O	-
en	O	-
la	O	-
Glucemia	O	-
Postprandial	O	-
(	O	-
L-STEP	O	-
)	O	-
comparó	O	-
los	O	-
efectos	O	-
de	O	-
la	O	-
linagliptina	O	-
(	O	-
5	O	-
mg	O	-
una	O	-
vez	O	-
al	O	-
día	O	-
)	O	-
y	O	-
la	O	-
voglibosa	O	-
(	O	-
0,2	O	-
mg/comida	O	-
tres	O	-
veces	O	-
al	O	-
día	O	-
)	O	-
sobre	O	-
la	O	-
CdV	O	-
relacionada	O	-
con	O	-
el	O	-
tratamiento	O	-
en	O	-
pacientes	O	-
japoneses	O	-
con	O	-
diabetes	O	-
tipo	O	-
2	O	-
(	O	-
T2DM	O	-
)	O	-
inadecuadamente	O	-
controlada	O	-
con	O	-
dieta	O	-
y	O	-
terapia	O	-
de	O	-
ejercicio	O	-
.	O	-

De	O	-
los	O	-
366	O	-
sujetos	O	-
del	O	-
estudio	O	-
original,	O	-
182	O	-
del	O	-
grupo	O	-
de	O	-
linagliptina	O	-
y	O	-
173	O	-
del	O	-
grupo	O	-
de	O	-
voglibosa	O	-
fueron	O	-
incluidos	O	-
en	O	-
este	O	-
análisis.	O	-

El	O	-
resultado	O	-
de	O	-
este	O	-
estudio	O	-
fue	O	-
el	O	-
cambio	O	-
en	O	-
la	O	-
calidad	O	-
de	O	-
vida	O	-
evaluada	O	-
por	O	-
el	O	-
cuestionario	O	-
Diabetes	O	-
Therapy-Related	O	-
Quality	O	-
of	O	-
Life	O	-
17	O	-
(	O	-
DTR-QOL17	O	-
)	O	-
desde	O	-
el	O	-
inicio	O	-
hasta	O	-
la	O	-
semana	O	-
12.	O	-

En	B-Premise	HighQuality
comparación	I-Premise	HighQuality
con	I-Premise	HighQuality
los	I-Premise	HighQuality
datos	I-Premise	HighQuality
iniciales,	I-Premise	HighQuality
las	I-Premise	HighQuality
puntuaciones	I-Premise	HighQuality
totales	I-Premise	HighQuality
de	I-Premise	HighQuality
DTR-QOL17	I-Premise	HighQuality
fueron	I-Premise	HighQuality
significativamente	I-Premise	HighQuality
mayores	I-Premise	HighQuality
tras	I-Premise	HighQuality
12	I-Premise	HighQuality
semanas	I-Premise	HighQuality
de	I-Premise	HighQuality
tratamiento	I-Premise	HighQuality
con	I-Premise	HighQuality
linagliptina	I-Premise	HighQuality
y	I-Premise	HighQuality
voglibosa.	I-Premise	HighQuality

El	B-Premise	HighQuality
cambio	I-Premise	HighQuality
en	I-Premise	HighQuality
la	I-Premise	HighQuality
puntuación	I-Premise	HighQuality
total	I-Premise	HighQuality
del	I-Premise	HighQuality
DTR-QOL17	I-Premise	HighQuality
y	I-Premise	HighQuality
la	I-Premise	HighQuality
puntuación	I-Premise	HighQuality
de	I-Premise	HighQuality
un	I-Premise	HighQuality
dominio,	I-Premise	HighQuality
la	I-Premise	HighQuality
carga	I-Premise	HighQuality
en	I-Premise	HighQuality
las	I-Premise	HighQuality
actividades	I-Premise	HighQuality
sociales	I-Premise	HighQuality
y	I-Premise	HighQuality
las	I-Premise	HighQuality
actividades	I-Premise	HighQuality
diarias,	I-Premise	HighQuality
fue	I-Premise	HighQuality
significativamente	I-Premise	HighQuality
mayor	I-Premise	HighQuality
en	I-Premise	HighQuality
el	I-Premise	HighQuality
grupo	I-Premise	HighQuality
de	I-Premise	HighQuality
linagliptina	I-Premise	HighQuality
que	I-Premise	HighQuality
en	I-Premise	HighQuality
el	I-Premise	HighQuality
grupo	I-Premise	HighQuality
de	I-Premise	HighQuality
voglibosa.	I-Premise	HighQuality

Además,	B-Premise	HighQuality
sólo	I-Premise	HighQuality
el	I-Premise	HighQuality
tratamiento	I-Premise	HighQuality
con	I-Premise	HighQuality
linagliptina	I-Premise	HighQuality
se	I-Premise	HighQuality
identificó	I-Premise	HighQuality
como	I-Premise	HighQuality
un	I-Premise	HighQuality
factor	I-Premise	HighQuality
asociado	I-Premise	HighQuality
a	I-Premise	HighQuality
una	I-Premise	HighQuality
mayor	I-Premise	HighQuality
puntuación	I-Premise	HighQuality
total	I-Premise	HighQuality
de	I-Premise	HighQuality
DTR-QOL17	I-Premise	HighQuality
.	I-Premise	HighQuality

La	B-Claim	HighQuality
linagliptina	I-Claim	HighQuality
es	I-Claim	HighQuality
superior	I-Claim	HighQuality
a	I-Claim	HighQuality
la	I-Claim	HighQuality
voglibosa	I-Claim	HighQuality
en	I-Claim	HighQuality
cuanto	I-Claim	HighQuality
a	I-Claim	HighQuality
la	I-Claim	HighQuality
mejora	I-Claim	HighQuality
de	I-Claim	HighQuality
la	I-Claim	HighQuality
calidad	I-Claim	HighQuality
de	I-Claim	HighQuality
vida	I-Claim	HighQuality
relacionada	I-Claim	HighQuality
con	I-Claim	HighQuality
el	I-Claim	HighQuality
tratamiento	I-Claim	HighQuality
en	I-Claim	HighQuality
pacientes	I-Claim	HighQuality
japoneses	I-Claim	HighQuality
con	I-Claim	HighQuality
DMT2.	I-Claim	HighQuality

El	O	-
tratamiento	O	-
a	O	-
largo	O	-
plazo	O	-
con	O	-
tenofovir	O	-
disoproxil	O	-
fumarato	O	-
(	O	-
TDF	O	-
)	O	-
solo	O	-
o	O	-
en	O	-
combinación	O	-
con	O	-
emtricitabina	O	-
(	O	-
FTC	O	-
)	O	-
se	O	-
asocia	O	-
con	O	-
una	O	-
supresión	O	-
viral	O	-
sostenida	O	-
en	O	-
pacientes	O	-
con	O	-
hepatitis	O	-
B	O	-
crónica	O	-
(	O	-
CHB	O	-
)	O	-
resistentes	O	-
a	O	-
la	O	-
lamivudina	O	-
(	O	-
LAM-R	O	-
)	O	-
.	O	-

Los	O	-
pacientes	O	-
con	O	-
LAM-R	O	-
CHB	O	-
fueron	O	-
aleatorizados	O	-
1:1	O	-
para	O	-
recibir	O	-
TDF	O	-
300mg	O	-
o	O	-
FTC	O	-
200mg	O	-
y	O	-
TDF	O	-
300mg	O	-
una	O	-
vez	O	-
al	O	-
día	O	-
en	O	-
un	O	-
estudio	O	-
prospectivo,	O	-
doble	O	-
ciego.	O	-

La	O	-
proporción	O	-
de	O	-
pacientes	O	-
con	O	-
ADN	O	-
plasmático	O	-
del	O	-
virus	O	-
de	O	-
la	O	-
hepatitis	O	-
B	O	-
(	O	-
VHB	O	-
)	O	-
<	O	-
69	O	-
UI/ml	O	-
(	O	-
<	O	-
400	O	-
copias/ml	O	-
)	O	-
en	O	-
la	O	-
semana	O	-
96	O	-
(	O	-
criterio	O	-
de	O	-
valoración	O	-
primario	O	-
de	O	-
la	O	-
eficacia	O	-
)	O	-
se	O	-
comunicó	O	-
anteriormente.	O	-

Aquí	O	-
presentamos	O	-
los	O	-
datos	O	-
de	O	-
seguimiento	O	-
de	O	-
la	O	-
semana	O	-
240	O	-
.	O	-

En	O	-
total,	O	-
280	O	-
pacientes	O	-
fueron	O	-
asignados	O	-
al	O	-
azar	O	-
para	O	-
recibir	O	-
TDF	O	-
(	O	-
n=141	O	-
)	O	-
o	O	-
FTC/TDF	O	-
(	O	-
n=139	O	-
)	O	-
,	O	-
y	O	-
el	O	-
85,4%	O	-
completó	O	-
240	O	-
semanas	O	-
de	O	-
tratamiento	O	-
.	O	-

En	B-Premise	HighQuality
la	I-Premise	HighQuality
semana	I-Premise	HighQuality
240,	I-Premise	HighQuality
el	I-Premise	HighQuality
83,0%	I-Premise	HighQuality
de	I-Premise	HighQuality
los	I-Premise	HighQuality
pacientes	I-Premise	HighQuality
del	I-Premise	HighQuality
brazo	I-Premise	HighQuality
de	I-Premise	HighQuality
TDF	I-Premise	HighQuality
y	I-Premise	HighQuality
el	I-Premise	HighQuality
82,7%	I-Premise	HighQuality
de	I-Premise	HighQuality
los	I-Premise	HighQuality
pacientes	I-Premise	HighQuality
del	I-Premise	HighQuality
brazo	I-Premise	HighQuality
de	I-Premise	HighQuality
tratamiento	I-Premise	HighQuality
con	I-Premise	HighQuality
FTC/TDF	I-Premise	HighQuality
tenían	I-Premise	HighQuality
un	I-Premise	HighQuality
ADN	I-Premise	HighQuality
del	I-Premise	HighQuality
VHB	I-Premise	HighQuality
<	I-Premise	HighQuality
69	I-Premise	HighQuality
UI/ml	I-Premise	HighQuality
(	I-Premise	HighQuality
p=0,96	I-Premise	HighQuality
)	I-Premise	HighQuality
.	I-Premise	HighQuality

Las	B-Premise	HighQuality
tasas	I-Premise	HighQuality
de	I-Premise	HighQuality
alanina	I-Premise	HighQuality
aminotransferasa	I-Premise	HighQuality
(	I-Premise	HighQuality
ALT	I-Premise	HighQuality
)	I-Premise	HighQuality
normalizada	I-Premise	HighQuality
y	I-Premise	HighQuality
de	I-Premise	HighQuality
ALT	I-Premise	HighQuality
normalizada	I-Premise	HighQuality
fueron	I-Premise	HighQuality
similares	I-Premise	HighQuality
entre	I-Premise	HighQuality
los	I-Premise	HighQuality
grupos	I-Premise	HighQuality
(	I-Premise	HighQuality
p=0,41	I-Premise	HighQuality
y	I-Premise	HighQuality
p=0,97	I-Premise	HighQuality
respectivamente	I-Premise	HighQuality
)	I-Premise	HighQuality
.	I-Premise	HighQuality

La	B-Premise	HighQuality
pérdida	I-Premise	HighQuality
del	I-Premise	HighQuality
antígeno	I-Premise	HighQuality
de	I-Premise	HighQuality
la	I-Premise	HighQuality
hepatitis	I-Premise	HighQuality
B	I-Premise	HighQuality
y	I-Premise	HighQuality
la	I-Premise	HighQuality
seroconversión	I-Premise	HighQuality
en	I-Premise	HighQuality
la	I-Premise	HighQuality
semana	I-Premise	HighQuality
240	I-Premise	HighQuality
fueron	I-Premise	HighQuality
similares	I-Premise	HighQuality
entre	I-Premise	HighQuality
los	I-Premise	HighQuality
grupos,	I-Premise	HighQuality
(	I-Premise	HighQuality
p=0,41	I-Premise	HighQuality
y	I-Premise	HighQuality
p=0,67	I-Premise	HighQuality
respectivamente	I-Premise	HighQuality
)	I-Premise	HighQuality
.	I-Premise	HighQuality

En	B-Premise	HighQuality
general,	I-Premise	HighQuality
seis	I-Premise	HighQuality
pacientes	I-Premise	HighQuality
lograron	I-Premise	HighQuality
la	I-Premise	HighQuality
pérdida	I-Premise	HighQuality
del	I-Premise	HighQuality
antígeno	I-Premise	HighQuality
de	I-Premise	HighQuality
superficie	I-Premise	HighQuality
de	I-Premise	HighQuality
la	I-Premise	HighQuality
hepatitis	I-Premise	HighQuality
B	I-Premise	HighQuality
(	I-Premise	HighQuality
HBsAg	I-Premise	HighQuality
)	I-Premise	HighQuality
y	I-Premise	HighQuality
un	I-Premise	HighQuality
paciente	I-Premise	HighQuality
(	I-Premise	HighQuality
brazo	I-Premise	HighQuality
FTC/TDF	I-Premise	HighQuality
)	I-Premise	HighQuality
tuvo	I-Premise	HighQuality
la	I-Premise	HighQuality
seroconversión	I-Premise	HighQuality
del	I-Premise	HighQuality
HBsAg	I-Premise	HighQuality
en	I-Premise	HighQuality
la	I-Premise	HighQuality
semana	I-Premise	HighQuality
240	I-Premise	HighQuality
.	I-Premise	HighQuality

No	B-Premise	HighQuality
se	I-Premise	HighQuality
observó	I-Premise	HighQuality
resistencia	I-Premise	HighQuality
a	I-Premise	HighQuality
la	I-Premise	HighQuality
TDF	I-Premise	HighQuality
hasta	I-Premise	HighQuality
la	I-Premise	HighQuality
semana	I-Premise	HighQuality
240	I-Premise	HighQuality
.	I-Premise	HighQuality

El	B-Premise	HighQuality
tratamiento	I-Premise	HighQuality
fue	I-Premise	HighQuality
generalmente	I-Premise	HighQuality
bien	I-Premise	HighQuality
tolerado	I-Premise	HighQuality
,	I-Premise	HighQuality
y	I-Premise	HighQuality
los	I-Premise	HighQuality
eventos	I-Premise	HighQuality
renales	I-Premise	HighQuality
fueron	I-Premise	HighQuality
leves	I-Premise	HighQuality
y	I-Premise	HighQuality
poco	I-Premise	HighQuality
frecuentes	I-Premise	HighQuality
(	I-Premise	HighQuality
∼8,6	I-Premise	HighQuality
%	I-Premise	HighQuality
)	I-Premise	HighQuality
.	I-Premise	HighQuality

El	B-Premise	HighQuality
cambio	I-Premise	HighQuality
medio	I-Premise	HighQuality
en	I-Premise	HighQuality
la	I-Premise	HighQuality
densidad	I-Premise	HighQuality
mineral	I-Premise	HighQuality
ósea	I-Premise	HighQuality
en	I-Premise	HighQuality
la	I-Premise	HighQuality
semana	I-Premise	HighQuality
240	I-Premise	HighQuality
fue	I-Premise	HighQuality
de	I-Premise	HighQuality
-0,98	I-Premise	HighQuality
%	I-Premise	HighQuality
y	I-Premise	HighQuality
-2,54	I-Premise	HighQuality
%	I-Premise	HighQuality
en	I-Premise	HighQuality
la	I-Premise	HighQuality
columna	I-Premise	HighQuality
vertebral	I-Premise	HighQuality
y	I-Premise	HighQuality
la	I-Premise	HighQuality
cadera,	I-Premise	HighQuality
respectivamente.	I-Premise	HighQuality

La	B-Claim	HighQuality
monoterapia	I-Claim	HighQuality
con	I-Claim	HighQuality
TDF	I-Claim	HighQuality
fue	I-Claim	HighQuality
eficaz	I-Claim	HighQuality
y	I-Claim	HighQuality
bien	I-Claim	HighQuality
tolerada	I-Claim	HighQuality
en	I-Claim	HighQuality
pacientes	I-Claim	HighQuality
con	I-Claim	HighQuality
LAM-R	I-Claim	HighQuality
CHB	I-Claim	HighQuality
durante	I-Claim	HighQuality
hasta	I-Claim	HighQuality
240	I-Claim	HighQuality
semanas.	I-Claim	HighQuality

El	O	-
objetivo	O	-
del	O	-
tratamiento	O	-
antiviral	O	-
oral	O	-
para	O	-
la	O	-
hepatitis	O	-
B	O	-
crónica	O	-
(	O	-
CHB	O	-
)	O	-
es	O	-
lograr	O	-
y	O	-
mantener	O	-
niveles	O	-
indetectables	O	-
de	O	-
ADN	O	-
del	O	-
VHB	O	-
.	O	-

Se	O	-
necesitan	O	-
opciones	O	-
de	O	-
tratamiento	O	-
con	O	-
mayor	O	-
potencia	O	-
y	O	-
bajo	O	-
riesgo	O	-
de	O	-
desarrollo	O	-
de	O	-
resistencia	O	-
para	O	-
los	O	-
pacientes	O	-
infectados	O	-
por	O	-
el	O	-
VHB	O	-
resistente	O	-
a	O	-
la	O	-
lamivudina	O	-
(	O	-
LAM-R	O	-
).	O	-

La	B-Claim	HighQuality
monoterapia	I-Claim	HighQuality
con	I-Claim	HighQuality
tenofovir	I-Claim	HighQuality
disoproxil	I-Claim	HighQuality
fumarato	I-Claim	HighQuality
(	I-Claim	HighQuality
TDF	I-Claim	HighQuality
)	I-Claim	HighQuality
fue	I-Claim	HighQuality
eficaz	I-Claim	HighQuality
y	I-Claim	HighQuality
bien	I-Claim	HighQuality
tolerada	I-Claim	HighQuality
sin	I-Claim	HighQuality
que	I-Claim	HighQuality
se	I-Claim	HighQuality
desarrollara	I-Claim	HighQuality
resistencia	I-Claim	HighQuality
al	I-Claim	HighQuality
TDF	I-Claim	HighQuality
en	I-Claim	HighQuality
pacientes	I-Claim	HighQuality
con	I-Claim	HighQuality
CHB	I-Claim	HighQuality
y	I-Claim	HighQuality
LAM-R	I-Claim	HighQuality
,	I-Claim	HighQuality
hasta	I-Claim	HighQuality
240	I-Claim	HighQuality
semanas	I-Claim	HighQuality
.	I-Claim	HighQuality

Comparar	O	-
el	O	-
resultado	O	-
de	O	-
la	O	-
trabeculectomía	O	-
utilizando	O	-
bevacizumab	O	-
intracameral	O	-
adjunto	O	-
frente	O	-
a	O	-
la	O	-
mitomicina	O	-
C	O	-
(	O	-
MMC	O	-
)	O	-
intraoperatoria.	O	-

En	O	-
este	O	-
ensayo	O	-
clínico	O	-
doble	O	-
ciego	O	-
y	O	-
aleatorizado	O	-
se	O	-
asignaron	O	-
87	O	-
ojos	O	-
de	O	-
87	O	-
pacientes	O	-
con	O	-
glaucoma	O	-
primario	O	-
de	O	-
ángulo	O	-
abierto	O	-
o	O	-
pseudoexfoliación	O	-
a	O	-
cada	O	-
grupo	O	-
de	O	-
tratamiento	O	-
(	O	-
44	O	-
casos	O	-
recibieron	O	-
1,25	O	-
mg	O	-
de	O	-
bevacizumab	O	-
intracameral	O	-
al	O	-
final	O	-
de	O	-
la	O	-
operación	O	-
y	O	-
en	O	-
43	O	-
casos	O	-
se	O	-
aplicó	O	-
MMC	O	-
durante	O	-
la	O	-
cirugía	O	-
)	O	-
.	O	-

El	O	-
éxito	O	-
se	O	-
definió	O	-
como	O	-
una	O	-
presión	O	-
intraocular	O	-
(	O	-
PIO	O	-
)	O	-
entre	O	-
6	O	-
y	O	-
21	O	-
mm	O	-
Hg	O	-
y	O	-
un	O	-
descenso	O	-
de	O	-
la	O	-
PIO	O	-
de	O	-
al	O	-
menos	O	-
un	O	-
30	O	-
%	O	-
con	O	-
(	O	-
calificada	O	-
)	O	-
o	O	-
sin	O	-
(	O	-
completa	O	-
)	O	-
medicación	O	-
para	O	-
el	O	-
glaucoma	O	-
sin	O	-
cirugía	O	-
adicional	O	-
para	O	-
el	O	-
glaucoma	O	-
.	O	-

El	O	-
tiempo	O	-
de	O	-
seguimiento	O	-
fue	O	-
de	O	-
17,12±2,58	O	-
meses	O	-
en	O	-
el	O	-
grupo	O	-
de	O	-
bevacizumab	O	-
y	O	-
de	O	-
17,23±2,42	O	-
meses	O	-
en	O	-
el	O	-
grupo	O	-
de	O	-
MMC	O	-
(	O	-
P=0,845	O	-
)	O	-
.	O	-

La	B-Premise	HighQuality
PIO	I-Premise	HighQuality
preoperatoria	I-Premise	HighQuality
fue	I-Premise	HighQuality
de	I-Premise	HighQuality
29,17±3,94	I-Premise	HighQuality
y	I-Premise	HighQuality
28,8±4,08	I-Premise	HighQuality
mm	I-Premise	HighQuality
Hg	I-Premise	HighQuality
en	I-Premise	HighQuality
los	I-Premise	HighQuality
grupos	I-Premise	HighQuality
de	I-Premise	HighQuality
bevacizumab	I-Premise	HighQuality
y	I-Premise	HighQuality
MMC	I-Premise	HighQuality
,	I-Premise	HighQuality
respectivamente	I-Premise	HighQuality
(	I-Premise	HighQuality
P=0,689	I-Premise	HighQuality
)	I-Premise	HighQuality
.	I-Premise	HighQuality

La	B-Premise	HighQuality
PIO	I-Premise	HighQuality
en	I-Premise	HighQuality
la	I-Premise	HighQuality
última	I-Premise	HighQuality
visita	I-Premise	HighQuality
fue	I-Premise	HighQuality
de	I-Premise	HighQuality
17,41±3,11	I-Premise	HighQuality
mm	I-Premise	HighQuality
Hg	I-Premise	HighQuality
en	I-Premise	HighQuality
el	I-Premise	HighQuality
grupo	I-Premise	HighQuality
de	I-Premise	HighQuality
bevacizumab	I-Premise	HighQuality
y	I-Premise	HighQuality
de	I-Premise	HighQuality
15,34±3,62	I-Premise	HighQuality
mm	I-Premise	HighQuality
Hg	I-Premise	HighQuality
en	I-Premise	HighQuality
el	I-Premise	HighQuality
grupo	I-Premise	HighQuality
de	I-Premise	HighQuality
MMC	I-Premise	HighQuality
(	I-Premise	HighQuality
P	I-Premise	HighQuality
<	I-Premise	HighQuality
0,009	I-Premise	HighQuality
)	I-Premise	HighQuality
.	I-Premise	HighQuality

En	B-Premise	HighQuality
comparación	I-Premise	HighQuality
con	I-Premise	HighQuality
el	I-Premise	HighQuality
valor	I-Premise	HighQuality
inicial,	I-Premise	HighQuality
el	I-Premise	HighQuality
descenso	I-Premise	HighQuality
de	I-Premise	HighQuality
la	I-Premise	HighQuality
PIO	I-Premise	HighQuality
en	I-Premise	HighQuality
la	I-Premise	HighQuality
última	I-Premise	HighQuality
visita	I-Premise	HighQuality
fue	I-Premise	HighQuality
de	I-Premise	HighQuality
11,76±5,51	I-Premise	HighQuality
y	I-Premise	HighQuality
13,43±5,92	I-Premise	HighQuality
en	I-Premise	HighQuality
los	I-Premise	HighQuality
grupos	I-Premise	HighQuality
de	I-Premise	HighQuality
bevacizumab	I-Premise	HighQuality
y	I-Premise	HighQuality
MMC,	I-Premise	HighQuality
respectivamente	I-Premise	HighQuality
(	I-Premise	HighQuality
P=0,207	I-Premise	HighQuality
)	I-Premise	HighQuality
.	I-Premise	HighQuality

En	B-Premise	HighQuality
la	I-Premise	HighQuality
última	I-Premise	HighQuality
visita,	I-Premise	HighQuality
se	I-Premise	HighQuality
logró	I-Premise	HighQuality
el	I-Premise	HighQuality
éxito	I-Premise	HighQuality
completo	I-Premise	HighQuality
en	I-Premise	HighQuality
25	I-Premise	HighQuality
casos	I-Premise	HighQuality
(	I-Premise	HighQuality
61%	I-Premise	HighQuality
)	I-Premise	HighQuality
del	I-Premise	HighQuality
grupo	I-Premise	HighQuality
de	I-Premise	HighQuality
bevacizumab	I-Premise	HighQuality
y	I-Premise	HighQuality
23	I-Premise	HighQuality
casos	I-Premise	HighQuality
(	I-Premise	HighQuality
66%	I-Premise	HighQuality
)	I-Premise	HighQuality
del	I-Premise	HighQuality
grupo	I-Premise	HighQuality
de	I-Premise	HighQuality
MMC	I-Premise	HighQuality
(	I-Premise	HighQuality
P=0,669	I-Premise	HighQuality
)	I-Premise	HighQuality
.	I-Premise	HighQuality

La	B-Premise	HighQuality
fuga	I-Premise	HighQuality
de	I-Premise	HighQuality
la	I-Premise	HighQuality
ampolla	I-Premise	HighQuality
filtrante	I-Premise	HighQuality
temprana	I-Premise	HighQuality
fue	I-Premise	HighQuality
más	I-Premise	HighQuality
frecuente	I-Premise	HighQuality
en	I-Premise	HighQuality
el	I-Premise	HighQuality
grupo	I-Premise	HighQuality
de	I-Premise	HighQuality
bevacizumab	I-Premise	HighQuality
(	I-Premise	HighQuality
29	I-Premise	HighQuality
%	I-Premise	HighQuality
frente	I-Premise	HighQuality
al	I-Premise	HighQuality
11	I-Premise	HighQuality
%	I-Premise	HighQuality
)	I-Premise	HighQuality
.	I-Premise	HighQuality

Una	B-Claim	HighQuality
dosis	I-Claim	HighQuality
única	I-Claim	HighQuality
de	I-Claim	HighQuality
1,25	I-Claim	HighQuality
mg	I-Claim	HighQuality
de	I-Claim	HighQuality
bevacizumab	I-Claim	HighQuality
intracameral	I-Claim	HighQuality
mejora	I-Claim	HighQuality
el	I-Claim	HighQuality
éxito	I-Claim	HighQuality
de	I-Claim	HighQuality
la	I-Claim	HighQuality
trabeculectomía	I-Claim	HighQuality
en	I-Claim	HighQuality
comparación	I-Claim	HighQuality
con	I-Claim	HighQuality
la	I-Claim	HighQuality
MMC;	I-Claim	HighQuality
sin	B-Claim	HighQuality
embargo,	I-Claim	HighQuality
aumenta	I-Claim	HighQuality
el	I-Claim	HighQuality
riesgo	I-Claim	HighQuality
de	I-Claim	HighQuality
fuga	I-Claim	HighQuality
temprana	I-Claim	HighQuality
de	I-Claim	HighQuality
la	I-Claim	HighQuality
ampolla	I-Claim	HighQuality
filtrante.	I-Claim	HighQuality

Evaluar	O	-
la	O	-
eficacia	O	-
y	O	-
la	O	-
tolerabilidad	O	-
de	O	-
dos	O	-
dosis	O	-
de	O	-
gefitinib	O	-
(	O	-
Iressa	O	-
[	O	-
ZD1839	O	-
]	O	-
;	O	-
AstraZeneca	O	-
,	O	-
Wilmington	O	-
,	O	-
DE	O	-
)	O	-
,	O	-
un	O	-
nuevo	O	-
inhibidor	O	-
de	O	-
la	O	-
tirosina	O	-
quinasa	O	-
del	O	-
receptor	O	-
del	O	-
factor	O	-
de	O	-
crecimiento	O	-
epidérmico	O	-
,	O	-
en	O	-
pacientes	O	-
con	O	-
cáncer	O	-
de	O	-
pulmón	O	-
no	O	-
microcítico	O	-
avanzado	O	-
(	O	-
CPNM	O	-
)	O	-
pretratado	O	-
.	O	-

Se	O	-
trata	O	-
de	O	-
un	O	-
ensayo	O	-
de	O	-
fase	O	-
II	O	-
aleatorizado,	O	-
doble	O	-
ciego,	O	-
de	O	-
grupos	O	-
paralelos	O	-
y	O	-
multicéntrico.	O	-

Doscientos	O	-
diez	O	-
pacientes	O	-
con	O	-
CPNM	O	-
avanzado	O	-
que	O	-
fueron	O	-
tratados	O	-
previamente	O	-
con	O	-
uno	O	-
o	O	-
dos	O	-
regímenes	O	-
de	O	-
quimioterapia	O	-
(	O	-
al	O	-
menos	O	-
uno	O	-
que	O	-
contenía	O	-
platino	O	-
)	O	-
fueron	O	-
asignados	O	-
aleatoriamente	O	-
para	O	-
recibir	O	-
dosis	O	-
orales	O	-
de	O	-
250	O	-
mg	O	-
o	O	-
500	O	-
mg	O	-
de	O	-
gefitinib	O	-
una	O	-
vez	O	-
al	O	-
día	O	-
.	O	-

La	B-Premise	HighQuality
eficacia	I-Premise	HighQuality
fue	I-Premise	HighQuality
similar	I-Premise	HighQuality
en	I-Premise	HighQuality
los	I-Premise	HighQuality
grupos	I-Premise	HighQuality
de	I-Premise	HighQuality
250	I-Premise	HighQuality
y	I-Premise	HighQuality
500	I-Premise	HighQuality
mg/día.	I-Premise	HighQuality

Las	B-Premise	HighQuality
tasas	I-Premise	HighQuality
de	I-Premise	HighQuality
respuesta	I-Premise	HighQuality
tumoral	I-Premise	HighQuality
objetiva	I-Premise	HighQuality
fueron	I-Premise	HighQuality
del	I-Premise	HighQuality
18,4	I-Premise	HighQuality
%	I-Premise	HighQuality
(intervalo	I-Premise	HighQuality
de	I-Premise	HighQuality
confianza	I-Premise	HighQuality
del	I-Premise	HighQuality
95	I-Premise	HighQuality
%,	I-Premise	HighQuality
11,5	I-Premise	HighQuality
a	I-Premise	HighQuality
27,3)	I-Premise	HighQuality
y	I-Premise	HighQuality
del	I-Premise	HighQuality
19,0	I-Premise	HighQuality
%	I-Premise	HighQuality
(intervalo	I-Premise	HighQuality
de	I-Premise	HighQuality
confianza	I-Premise	HighQuality
del	I-Premise	HighQuality
95	I-Premise	HighQuality
%,	I-Premise	HighQuality
12,1	I-Premise	HighQuality
a	I-Premise	HighQuality
27,9);	I-Premise	HighQuality
entre	I-Premise	HighQuality
los	I-Premise	HighQuality
pacientes	I-Premise	HighQuality
evaluables,	I-Premise	HighQuality
las	I-Premise	HighQuality
tasas	I-Premise	HighQuality
de	I-Premise	HighQuality
mejora	I-Premise	HighQuality
de	I-Premise	HighQuality
los	I-Premise	HighQuality
síntomas	I-Premise	HighQuality
fueron	I-Premise	HighQuality
del	I-Premise	HighQuality
40,3	I-Premise	HighQuality
%	I-Premise	HighQuality
(intervalo	I-Premise	HighQuality
de	I-Premise	HighQuality
confianza	I-Premise	HighQuality
del	I-Premise	HighQuality
95	I-Premise	HighQuality
%,	I-Premise	HighQuality
28,5	I-Premise	HighQuality
a	I-Premise	HighQuality
53,0)	I-Premise	HighQuality
y	I-Premise	HighQuality
del	I-Premise	HighQuality
37,0	I-Premise	HighQuality
%	I-Premise	HighQuality
(intervalo	I-Premise	HighQuality
de	I-Premise	HighQuality
confianza	I-Premise	HighQuality
del	I-Premise	HighQuality
95	I-Premise	HighQuality
%,	I-Premise	HighQuality
26,0	I-Premise	HighQuality
a	I-Premise	HighQuality
49,1);	I-Premise	HighQuality
la	I-Premise	HighQuality
mediana	I-Premise	HighQuality
de	I-Premise	HighQuality
la	I-Premise	HighQuality
supervivencia	I-Premise	HighQuality
sin	I-Premise	HighQuality
progresión	I-Premise	HighQuality
fue	I-Premise	HighQuality
de	I-Premise	HighQuality
2,7	I-Premise	HighQuality
y	I-Premise	HighQuality
2,8	I-Premise	HighQuality
meses;	I-Premise	HighQuality
y	I-Premise	HighQuality
la	I-Premise	HighQuality
mediana	I-Premise	HighQuality
de	I-Premise	HighQuality
la	I-Premise	HighQuality
supervivencia	I-Premise	HighQuality
global	I-Premise	HighQuality
fue	I-Premise	HighQuality
de	I-Premise	HighQuality
7,6	I-Premise	HighQuality
y	I-Premise	HighQuality
8,0	I-Premise	HighQuality
meses,	I-Premise	HighQuality
respectivamente.	I-Premise	HighQuality

Se	B-Premise	HighQuality
registraron	I-Premise	HighQuality
mejoras	I-Premise	HighQuality
de	I-Premise	HighQuality
los	I-Premise	HighQuality
síntomas	I-Premise	HighQuality
en	I-Premise	HighQuality
el	I-Premise	HighQuality
69,2%	I-Premise	HighQuality
(	I-Premise	HighQuality
250	I-Premise	HighQuality
mg/d	I-Premise	HighQuality
)	I-Premise	HighQuality
y	I-Premise	HighQuality
el	I-Premise	HighQuality
85,7%	I-Premise	HighQuality
(	I-Premise	HighQuality
500	I-Premise	HighQuality
mg/d	I-Premise	HighQuality
)	I-Premise	HighQuality
de	I-Premise	HighQuality
los	I-Premise	HighQuality
pacientes	I-Premise	HighQuality
con	I-Premise	HighQuality
respuesta	I-Premise	HighQuality
tumoral	I-Premise	HighQuality
.	I-Premise	HighQuality

Los	B-Premise	HighQuality
efectos	I-Premise	HighQuality
adversos	I-Premise	HighQuality
(EA)	I-Premise	HighQuality
en	I-Premise	HighQuality
ambos	I-Premise	HighQuality
niveles	I-Premise	HighQuality
de	I-Premise	HighQuality
dosis	I-Premise	HighQuality
fueron	I-Premise	HighQuality
generalmente	I-Premise	HighQuality
leves	I-Premise	HighQuality
(grado	I-Premise	HighQuality
1	I-Premise	HighQuality
o	I-Premise	HighQuality
2)	I-Premise	HighQuality
y	I-Premise	HighQuality
consistieron	I-Premise	HighQuality
principalmente	I-Premise	HighQuality
en	I-Premise	HighQuality
reacciones	I-Premise	HighQuality
cutáneas	I-Premise	HighQuality
y	I-Premise	HighQuality
diarrea.	I-Premise	HighQuality

Las	B-Premise	HighQuality
toxicidades	I-Premise	HighQuality
relacionadas	I-Premise	HighQuality
con	I-Premise	HighQuality
el	I-Premise	HighQuality
fármaco	I-Premise	HighQuality
fueron	I-Premise	HighQuality
más	I-Premise	HighQuality
frecuentes	I-Premise	HighQuality
en	I-Premise	HighQuality
el	I-Premise	HighQuality
grupo	I-Premise	HighQuality
de	I-Premise	HighQuality
dosis	I-Premise	HighQuality
más	I-Premise	HighQuality
altas.	I-Premise	HighQuality

La	B-Premise	HighQuality
retirada	I-Premise	HighQuality
debida	I-Premise	HighQuality
a	I-Premise	HighQuality
los	I-Premise	HighQuality
EA	I-Premise	HighQuality
relacionados	I-Premise	HighQuality
con	I-Premise	HighQuality
el	I-Premise	HighQuality
fármaco	I-Premise	HighQuality
fue	I-Premise	HighQuality
del	I-Premise	HighQuality
1,9	I-Premise	HighQuality
%	I-Premise	HighQuality
y	I-Premise	HighQuality
del	I-Premise	HighQuality
9,4	I-Premise	HighQuality
%	I-Premise	HighQuality
para	I-Premise	HighQuality
los	I-Premise	HighQuality
pacientes	I-Premise	HighQuality
que	I-Premise	HighQuality
recibieron	I-Premise	HighQuality
gefitinib	I-Premise	HighQuality
250	I-Premise	HighQuality
y	I-Premise	HighQuality
500	I-Premise	HighQuality
mg/día	I-Premise	HighQuality
,	I-Premise	HighQuality
respectivamente.	I-Premise	HighQuality

Gefitinib	B-Claim	HighQuality
mostró	I-Claim	HighQuality
una	I-Claim	HighQuality
actividad	I-Claim	HighQuality
antitumoral	I-Claim	HighQuality
clínicamente	I-Claim	HighQuality
significativa	I-Claim	HighQuality
y	I-Claim	HighQuality
proporcionó	I-Claim	HighQuality
alivio	I-Claim	HighQuality
de	I-Claim	HighQuality
los	I-Claim	HighQuality
síntomas	I-Claim	HighQuality
como	I-Claim	HighQuality
tratamiento	I-Claim	HighQuality
de	I-Claim	HighQuality
segunda	I-Claim	HighQuality
y	I-Claim	HighQuality
tercera	I-Claim	HighQuality
línea	I-Claim	HighQuality
en	I-Claim	HighQuality
estos	I-Claim	HighQuality
pacientes	I-Claim	HighQuality
.	I-Claim	HighQuality

A	B-Claim	HighQuality
250	I-Claim	HighQuality
mg/día,	I-Claim	HighQuality
gefitinib	I-Claim	HighQuality
tuvo	I-Claim	HighQuality
un	I-Claim	HighQuality
perfil	I-Claim	HighQuality
de	I-Claim	HighQuality
EA	I-Claim	HighQuality
favorable.	I-Claim	HighQuality

Gefitinib	B-Claim	HighQuality
250	I-Claim	HighQuality
mg/d	I-Claim	HighQuality
es	I-Claim	HighQuality
una	I-Claim	HighQuality
importante	I-Claim	HighQuality
y	I-Claim	HighQuality
novedosa	I-Claim	HighQuality
opción	I-Claim	HighQuality
de	I-Claim	HighQuality
tratamiento	I-Claim	HighQuality
para	I-Claim	HighQuality
los	I-Claim	HighQuality
pacientes	I-Claim	HighQuality
con	I-Claim	HighQuality
CPNM	I-Claim	HighQuality
avanzado	I-Claim	HighQuality
pretratado.	I-Claim	HighQuality

Múltiples	B-Claim	HighQuality
estudios	I-Claim	HighQuality
han	I-Claim	HighQuality
evaluado	I-Claim	HighQuality
el	I-Claim	HighQuality
efecto	I-Claim	HighQuality
hipoglucemiante	I-Claim	HighQuality
de	I-Claim	HighQuality
la	I-Claim	HighQuality
canela	I-Claim	HighQuality
en	I-Claim	HighQuality
pacientes	I-Claim	HighQuality
con	I-Claim	HighQuality
diabetes	I-Claim	HighQuality
mellitus	I-Claim	HighQuality
(	I-Claim	HighQuality
DM	I-Claim	HighQuality
)	I-Claim	HighQuality
tipo	I-Claim	HighQuality
II	I-Claim	HighQuality
,	I-Claim	HighQuality
con	I-Claim	HighQuality
resultados	I-Claim	HighQuality
contradictorios	I-Claim	HighQuality
.	I-Claim	HighQuality

Las	O	-
diferencias	O	-
en	O	-
el	O	-
Índice	O	-
de	O	-
Masa	O	-
Corporal	O	-
(	O	-
IMC	O	-
)	O	-
de	O	-
partida	O	-
de	O	-
los	O	-
pacientes	O	-
pueden	O	-
explicar	O	-
las	O	-
diferencias	O	-
observadas	O	-
en	O	-
los	O	-
resultados	O	-
.	O	-

Este	O	-
estudio	O	-
se	O	-
diseñó	O	-
para	O	-
evaluar	O	-
el	O	-
efecto	O	-
de	O	-
la	O	-
suplementación	O	-
con	O	-
canela	O	-
en	O	-
los	O	-
resultados	O	-
antropométricos,	O	-
glucémicos	O	-
y	O	-
lipídicos	O	-
de	O	-
los	O	-
pacientes	O	-
con	O	-
DM	O	-
tipo	O	-
II	O	-
en	O	-
función	O	-
de	O	-
su	O	-
IMC	O	-
basal.	O	-

El	O	-
estudio	O	-
se	O	-
diseñó	O	-
como	O	-
un	O	-
ensayo	O	-
clínico	O	-
aleatorio	O	-
triple	O	-
ciego	O	-
controlado	O	-
con	O	-
placebo	O	-
,	O	-
utilizando	O	-
un	O	-
diseño	O	-
paralelo	O	-
.	O	-

Ciento	O	-
cuarenta	O	-
pacientes	O	-
remitidos	O	-
a	O	-
la	O	-
Clínica	O	-
de	O	-
Diabetes	O	-
de	O	-
la	O	-
Universidad	O	-
de	O	-
Ciencias	O	-
Médicas	O	-
de	O	-
Yazd	O	-
con	O	-
diagnóstico	O	-
de	O	-
DM	O	-
tipo	O	-
II	O	-
fueron	O	-
asignados	O	-
aleatoriamente	O	-
en	O	-
cuatro	O	-
grupos	O	-
:	O	-
canela	O	-
(	O	-
IMC	O	-
≥	O	-
27	O	-
,	O	-
IMC	O	-
<	O	-
27	O	-
)	O	-
y	O	-
Placebo	O	-
(	O	-
IMC	O	-
≥	O	-
27	O	-
,	O	-
IMC	O	-
<	O	-
27	O	-
)	O	-
.	O	-

Los	O	-
pacientes	O	-
recibieron	O	-
polvo	O	-
de	O	-
corteza	O	-
de	O	-
canela	O	-
o	O	-
placebo	O	-
en	O	-
cápsulas	O	-
de	O	-
500	O	-
mg	O	-
dos	O	-
veces	O	-
al	O	-
día	O	-
durante	O	-
3	O	-
meses.	O	-

Se	O	-
midieron	O	-
los	O	-
resultados	O	-
antropométricos,	O	-
glucémicos	O	-
y	O	-
lipídicos	O	-
antes	O	-
y	O	-
después	O	-
de	O	-
la	O	-
intervención.	O	-

La	B-Premise	HighQuality
suplementación	I-Premise	HighQuality
con	I-Premise	HighQuality
canela	I-Premise	HighQuality
condujo	I-Premise	HighQuality
a	I-Premise	HighQuality
una	I-Premise	HighQuality
mejora	I-Premise	HighQuality
de	I-Premise	HighQuality
todos	I-Premise	HighQuality
los	I-Premise	HighQuality
resultados	I-Premise	HighQuality
antropométricos	I-Premise	HighQuality
(	I-Premise	HighQuality
IMC	I-Premise	HighQuality
,	I-Premise	HighQuality
grasa	I-Premise	HighQuality
corporal	I-Premise	HighQuality
y	I-Premise	HighQuality
grasa	I-Premise	HighQuality
visceral	I-Premise	HighQuality
)	I-Premise	HighQuality
,	I-Premise	HighQuality
glucémicos	I-Premise	HighQuality
(	I-Premise	HighQuality
FPG	I-Premise	HighQuality
,	I-Premise	HighQuality
2hpp	I-Premise	HighQuality
,	I-Premise	HighQuality
HbA1C	I-Premise	HighQuality
,	I-Premise	HighQuality
insulina	I-Premise	HighQuality
en	I-Premise	HighQuality
ayunas	I-Premise	HighQuality
y	I-Premise	HighQuality
resistencia	I-Premise	HighQuality
a	I-Premise	HighQuality
la	I-Premise	HighQuality
insulina	I-Premise	HighQuality
)	I-Premise	HighQuality
y	I-Premise	HighQuality
lipídicos	I-Premise	HighQuality
(	I-Premise	HighQuality
colesterol	I-Premise	HighQuality
total	I-Premise	HighQuality
,	I-Premise	HighQuality
LDL-c	I-Premise	HighQuality
y	I-Premise	HighQuality
HDL-c	I-Premise	HighQuality
)	I-Premise	HighQuality
(	I-Premise	HighQuality
excepto	I-Premise	HighQuality
el	I-Premise	HighQuality
nivel	I-Premise	HighQuality
de	I-Premise	HighQuality
triglicéridos	I-Premise	HighQuality
)	I-Premise	HighQuality
.	I-Premise	HighQuality

Todos	B-Premise	HighQuality
los	I-Premise	HighQuality
cambios	I-Premise	HighQuality
observados	I-Premise	HighQuality
(	I-Premise	HighQuality
excepto	I-Premise	HighQuality
para	I-Premise	HighQuality
el	I-Premise	HighQuality
colesterol	I-Premise	HighQuality
total	I-Premise	HighQuality
y	I-Premise	HighQuality
el	I-Premise	HighQuality
LDL-c	I-Premise	HighQuality
)	I-Premise	HighQuality
fueron	I-Premise	HighQuality
significativamente	I-Premise	HighQuality
más	I-Premise	HighQuality
prominentes	I-Premise	HighQuality
en	I-Premise	HighQuality
los	I-Premise	HighQuality
pacientes	I-Premise	HighQuality
con	I-Premise	HighQuality
un	I-Premise	HighQuality
IMC	I-Premise	HighQuality
basal	I-Premise	HighQuality
más	I-Premise	HighQuality
alto	I-Premise	HighQuality
(	I-Premise	HighQuality
IMC	I-Premise	HighQuality
≥	I-Premise	HighQuality
27	I-Premise	HighQuality
)	I-Premise	HighQuality
.	I-Premise	HighQuality

Según	B-Claim	HighQuality
los	I-Claim	HighQuality
resultados	I-Claim	HighQuality
del	I-Claim	HighQuality
estudio,	I-Claim	HighQuality
la	I-Claim	HighQuality
canela	I-Claim	HighQuality
puede	I-Claim	HighQuality
mejorar	I-Claim	HighQuality
los	I-Claim	HighQuality
parámetros	I-Claim	HighQuality
antropométricos,	I-Claim	HighQuality
los	I-Claim	HighQuality
índices	I-Claim	HighQuality
glucémicos	I-Claim	HighQuality
y	I-Claim	HighQuality
el	I-Claim	HighQuality
perfil	I-Claim	HighQuality
lipídico	I-Claim	HighQuality
de	I-Claim	HighQuality
los	I-Claim	HighQuality
pacientes	I-Claim	HighQuality
con	I-Claim	HighQuality
diabetes	I-Claim	HighQuality
de	I-Claim	HighQuality
tipo	I-Claim	HighQuality
II.	I-Claim	HighQuality

Estos	B-Claim	HighQuality
beneficios	I-Claim	HighQuality
son	I-Claim	HighQuality
significativamente	I-Claim	HighQuality
más	I-Claim	HighQuality
prominentes	I-Claim	HighQuality
en	I-Claim	HighQuality
los	I-Claim	HighQuality
pacientes	I-Claim	HighQuality
con	I-Claim	HighQuality
mayor	I-Claim	HighQuality
IMC	I-Claim	HighQuality
de	I-Claim	HighQuality
partida	I-Claim	HighQuality
(	I-Claim	HighQuality
IMC	I-Claim	HighQuality
≥	I-Claim	HighQuality
27	I-Claim	HighQuality
)	I-Claim	HighQuality
.	I-Claim	HighQuality

Aunque	O	-
las	B-Claim	HighQuality
antraciclinas	I-Claim	HighQuality
son	I-Claim	HighQuality
agentes	I-Claim	HighQuality
quimioterapéuticos	I-Claim	HighQuality
eficaces	I-Claim	HighQuality
para	I-Claim	HighQuality
el	I-Claim	HighQuality
tratamiento	I-Claim	HighQuality
del	I-Claim	HighQuality
linfoma	I-Claim	HighQuality
de	I-Claim	HighQuality
células	I-Claim	HighQuality
B,	I-Claim	HighQuality
los	I-Claim	HighQuality
efectos	I-Claim	HighQuality
adversos,	I-Claim	HighQuality
como	I-Claim	HighQuality
la	I-Claim	HighQuality
supresión	I-Claim	HighQuality
de	I-Claim	HighQuality
la	I-Claim	HighQuality
médula	I-Claim	HighQuality
ósea	I-Claim	HighQuality
y	I-Claim	HighQuality
la	I-Claim	HighQuality
cardiotoxicidad,	I-Claim	HighQuality
limitan	I-Claim	HighQuality
su	I-Claim	HighQuality
aplicación	I-Claim	HighQuality
clínica.	I-Claim	HighQuality

Se	O	-
evaluó	O	-
si	O	-
el	O	-
tratamiento	O	-
con	O	-
antraciclinas	O	-
también	O	-
aumenta	O	-
el	O	-
riesgo	O	-
de	O	-
diabetes	O	-
mellitus	O	-
en	O	-
pacientes	O	-
con	O	-
linfoma	O	-
de	O	-
células	O	-
B	O	-
.	O	-

Utilizando	O	-
datos	O	-
obtenidos	O	-
de	O	-
la	O	-
Base	O	-
de	O	-
Datos	O	-
de	O	-
Investigación	O	-
del	O	-
Seguro	O	-
Nacional	O	-
de	O	-
Salud	O	-
de	O	-
Taiwán	O	-
de	O	-
2004	O	-
a	O	-
2011	O	-
,	O	-
se	O	-
comparó	O	-
la	O	-
supervivencia	O	-
global	O	-
y	O	-
las	O	-
características	O	-
clínicas	O	-
de	O	-
los	O	-
pacientes	O	-
con	O	-
linfoma	O	-
de	O	-
células	O	-
B	O	-
a	O	-
los	O	-
que	O	-
se	O	-
les	O	-
administró	O	-
antraciclinas	O	-
(	O	-
n	O	-
=	O	-
3147	O	-
)	O	-
y	O	-
los	O	-
que	O	-
no	O	-
se	O	-
les	O	-
administró	O	-
antraciclinas	O	-
(	O	-
n	O	-
=	O	-
837	O	-
)	O	-
.	O	-

El	O	-
impacto	O	-
del	O	-
tratamiento	O	-
con	O	-
antraciclinas	O	-
en	O	-
el	O	-
riesgo	O	-
de	O	-
diabetes	O	-
se	O	-
investigó	O	-
además	O	-
mediante	O	-
una	O	-
prueba	O	-
de	O	-
Gray	O	-
y	O	-
modelos	O	-
de	O	-
regresión	O	-
multivariante	O	-
de	O	-
riesgo	O	-
competitivo	O	-
de	O	-
forma	O	-
dependiente	O	-
de	O	-
la	O	-
dosis.	O	-

La	B-Premise	HighQuality
administración	I-Premise	HighQuality
de	I-Premise	HighQuality
antraciclinas	I-Premise	HighQuality
se	I-Premise	HighQuality
asoció	I-Premise	HighQuality
con	I-Premise	HighQuality
una	I-Premise	HighQuality
mayor	I-Premise	HighQuality
incidencia	I-Premise	HighQuality
de	I-Premise	HighQuality
diabetes	I-Premise	HighQuality
(	I-Premise	HighQuality
HR	I-Premise	HighQuality
:	I-Premise	HighQuality
1,75	I-Premise	HighQuality
;	I-Premise	HighQuality
95	I-Premise	HighQuality
%	I-Premise	HighQuality
CI	I-Premise	HighQuality
1,11-2,75	I-Premise	HighQuality
;	I-Premise	HighQuality
p	I-Premise	HighQuality
=	I-Premise	HighQuality
0,0163	I-Premise	HighQuality
)	I-Premise	HighQuality
después	I-Premise	HighQuality
de	I-Premise	HighQuality
los	I-Premise	HighQuality
ajustes	I-Premise	HighQuality
por	I-Premise	HighQuality
edad	I-Premise	HighQuality
,	I-Premise	HighQuality
sexo	I-Premise	HighQuality
,	I-Premise	HighQuality
dosis	I-Premise	HighQuality
acumulada	I-Premise	HighQuality
de	I-Premise	HighQuality
prednisolona	I-Premise	HighQuality
,	I-Premise	HighQuality
y	I-Premise	HighQuality
comorbilidades	I-Premise	HighQuality
.	I-Premise	HighQuality

Las	B-Premise	HighQuality
dosis	I-Premise	HighQuality
acumuladas	I-Premise	HighQuality
de	I-Premise	HighQuality
antraciclina	I-Premise	HighQuality
de	I-Premise	HighQuality
253-400	I-Premise	HighQuality
mg	I-Premise	HighQuality
(	I-Premise	HighQuality
HR	I-Premise	HighQuality
:	I-Premise	HighQuality
2,35	I-Premise	HighQuality
;	I-Premise	HighQuality
95	I-Premise	HighQuality
%	I-Premise	HighQuality
CI	I-Premise	HighQuality
1,41-3,91	I-Premise	HighQuality
;	I-Premise	HighQuality
p	I-Premise	HighQuality
=	I-Premise	HighQuality
0,0010	I-Premise	HighQuality
)	I-Premise	HighQuality
,	I-Premise	HighQuality
401-504	I-Premise	HighQuality
mg	I-Premise	HighQuality
(	I-Premise	HighQuality
HR	I-Premise	HighQuality
:	I-Premise	HighQuality
2,26	I-Premise	HighQuality
;	I-Premise	HighQuality
95	I-Premise	HighQuality
%	I-Premise	HighQuality
CI	I-Premise	HighQuality
1,26-4,05	I-Premise	HighQuality
;	I-Premise	HighQuality
p	I-Premise	HighQuality
=	I-Premise	HighQuality
0,0063	I-Premise	HighQuality
)	I-Premise	HighQuality
,	I-Premise	HighQuality
y	I-Premise	HighQuality
>	I-Premise	HighQuality
504	I-Premise	HighQuality
mg	I-Premise	HighQuality
(	I-Premise	HighQuality
HR	I-Premise	HighQuality
:	I-Premise	HighQuality
2,29	I-Premise	HighQuality
;	I-Premise	HighQuality
95	I-Premise	HighQuality
%	I-Premise	HighQuality
CI	I-Premise	HighQuality
1,25-4,18	I-Premise	HighQuality
;	I-Premise	HighQuality
p	I-Premise	HighQuality
=	I-Premise	HighQuality
0,0072	I-Premise	HighQuality
)	I-Premise	HighQuality
aumentaron	I-Premise	HighQuality
la	I-Premise	HighQuality
densidad	I-Premise	HighQuality
de	I-Premise	HighQuality
incidencia	I-Premise	HighQuality
de	I-Premise	HighQuality
la	I-Premise	HighQuality
diabetes	I-Premise	HighQuality
de	I-Premise	HighQuality
manera	I-Premise	HighQuality
dependiente	I-Premise	HighQuality
de	I-Premise	HighQuality
la	I-Premise	HighQuality
dosis	I-Premise	HighQuality
(	I-Premise	HighQuality
p	I-Premise	HighQuality
=	I-Premise	HighQuality
0,0006	I-Premise	HighQuality
)	I-Premise	HighQuality
.	I-Premise	HighQuality

La	B-Premise	HighQuality
alteración	I-Premise	HighQuality
anual	I-Premise	HighQuality
de	I-Premise	HighQuality
la	I-Premise	HighQuality
puntuación	I-Premise	HighQuality
del	I-Premise	HighQuality
índice	I-Premise	HighQuality
de	I-Premise	HighQuality
gravedad	I-Premise	HighQuality
de	I-Premise	HighQuality
las	I-Premise	HighQuality
complicaciones	I-Premise	HighQuality
de	I-Premise	HighQuality
la	I-Premise	HighQuality
diabetes	I-Premise	HighQuality
adaptada	I-Premise	HighQuality
no	I-Premise	HighQuality
fue	I-Premise	HighQuality
significativamente	I-Premise	HighQuality
diferente	I-Premise	HighQuality
entre	I-Premise	HighQuality
los	I-Premise	HighQuality
pacientes	I-Premise	HighQuality
con	I-Premise	HighQuality
linfoma	I-Premise	HighQuality
de	I-Premise	HighQuality
células	I-Premise	HighQuality
B	I-Premise	HighQuality
con	I-Premise	HighQuality
o	I-Premise	HighQuality
sin	I-Premise	HighQuality
tratamiento	I-Premise	HighQuality
con	I-Premise	HighQuality
antraciclina	I-Premise	HighQuality
(	I-Premise	HighQuality
p	I-Premise	HighQuality
=	I-Premise	HighQuality
0,4924	I-Premise	HighQuality
)	I-Premise	HighQuality
.	I-Premise	HighQuality

El	B-Claim	HighQuality
tratamiento	I-Claim	HighQuality
con	I-Claim	HighQuality
antraciclinas	I-Claim	HighQuality
aumenta	I-Claim	HighQuality
el	I-Claim	HighQuality
riesgo	I-Claim	HighQuality
de	I-Claim	HighQuality
diabetes	I-Claim	HighQuality
de	I-Claim	HighQuality
forma	I-Claim	HighQuality
dependiente	I-Claim	HighQuality
de	I-Claim	HighQuality
la	I-Claim	HighQuality
dosis	I-Claim	HighQuality
en	I-Claim	HighQuality
pacientes	I-Claim	HighQuality
con	I-Claim	HighQuality
linfoma	I-Claim	HighQuality
de	I-Claim	HighQuality
células	I-Claim	HighQuality
B	I-Claim	HighQuality
.	I-Claim	HighQuality

En	B-Claim	HighQuality
los	I-Claim	HighQuality
pacientes	I-Claim	HighQuality
con	I-Claim	HighQuality
linfoma	I-Claim	HighQuality
de	I-Claim	HighQuality
células	I-Claim	HighQuality
B	I-Claim	HighQuality
que	I-Claim	HighQuality
reciben	I-Claim	HighQuality
tratamiento	I-Claim	HighQuality
con	I-Claim	HighQuality
antraciclinas	I-Claim	HighQuality
se	I-Claim	HighQuality
debe	I-Claim	HighQuality
recomendar	I-Claim	HighQuality
un	I-Claim	HighQuality
seguimiento	I-Claim	HighQuality
y	I-Claim	HighQuality
control	I-Claim	HighQuality
intensivo	I-Claim	HighQuality
de	I-Claim	HighQuality
la	I-Claim	HighQuality
glucemia.	I-Claim	HighQuality

Se	O	-
ha	O	-
recomendado	O	-
la	O	-
terapia	O	-
combinada	O	-
para	O	-
el	O	-
tratamiento	O	-
de	O	-
pacientes	O	-
que	O	-
albergan	O	-
el	O	-
virus	O	-
de	O	-
la	O	-
hepatitis	O	-
B	O	-
(	O	-
VHB	O	-
)	O	-
resistente	O	-
a	O	-
múltiples	O	-
fármacos.	O	-

Sin	O	-
embargo,	O	-
recientemente	O	-
hemos	O	-
demostrado	O	-
que	O	-
la	O	-
monoterapia	O	-
con	O	-
tenofovir	O	-
disoproxil	O	-
fumarato	O	-
(	O	-
TDF	O	-
)	O	-
durante	O	-
48	O	-
semanas	O	-
mostró	O	-
una	O	-
eficacia	O	-
no	O	-
inferior	O	-
a	O	-
la	O	-
terapia	O	-
combinada	O	-
de	O	-
TDF	O	-
más	O	-
entecavir	O	-
(	O	-
ETV	O	-
)	O	-
en	O	-
pacientes	O	-
con	O	-
VHB	O	-
resistente	O	-
a	O	-
múltiples	O	-
fármacos	O	-
,	O	-
incluyendo	O	-
ETV	O	-
y	O	-
adefovir	O	-
.	O	-

Sin	O	-
embargo,	O	-
no	O	-
está	O	-
claro	O	-
si	O	-
la	O	-
monoterapia	O	-
prolongada	O	-
con	O	-
TDF	O	-
sería	O	-
segura	O	-
y	O	-
aumentaría	O	-
la	O	-
tasa	O	-
de	O	-
respuesta	O	-
virológica	O	-
en	O	-
estos	O	-
pacientes.	O	-

De	O	-
los	O	-
192	O	-
pacientes	O	-
con	O	-
mutaciones	O	-
de	O	-
resistencia	O	-
del	O	-
VHB	O	-
a	O	-
ETV	O	-
y/o	O	-
adefovir	O	-
,	O	-
que	O	-
fueron	O	-
aleatorizados	O	-
para	O	-
recibir	O	-
monoterapia	O	-
con	O	-
TDF	O	-
(	O	-
n	O	-
=	O	-
95	O	-
)	O	-
o	O	-
terapia	O	-
combinada	O	-
con	O	-
TDF/ETV	O	-
(	O	-
n	O	-
=	O	-
97	O	-
)	O	-
durante	O	-
48	O	-
semanas	O	-
,	O	-
189	O	-
aceptaron	O	-
continuar	O	-
con	O	-
la	O	-
monoterapia	O	-
con	O	-
TDF	O	-
(	O	-
grupo	O	-
TDF-TDF	O	-
)	O	-
o	O	-
cambiar	O	-
a	O	-
monoterapia	O	-
con	O	-
TDF	O	-
(	O	-
grupo	O	-
TDF/ETV-TDF	O	-
)	O	-
y	O	-
180	O	-
(	O	-
93,8	O	-
%	O	-
)	O	-
completaron	O	-
el	O	-
estudio	O	-
de	O	-
144	O	-
semanas	O	-
.	O	-

El	B-Premise	HighQuality
ADN	I-Premise	HighQuality
sérico	I-Premise	HighQuality
del	I-Premise	HighQuality
VHB	I-Premise	HighQuality
<	I-Premise	HighQuality
15	I-Premise	HighQuality
UI/mL	I-Premise	HighQuality
en	I-Premise	HighQuality
la	I-Premise	HighQuality
semana	I-Premise	HighQuality
48,	I-Premise	HighQuality
el	I-Premise	HighQuality
criterio	I-Premise	HighQuality
de	I-Premise	HighQuality
valoración	I-Premise	HighQuality
primario	I-Premise	HighQuality
de	I-Premise	HighQuality
la	I-Premise	HighQuality
eficacia,	I-Premise	HighQuality
se	I-Premise	HighQuality
alcanzó	I-Premise	HighQuality
en	I-Premise	HighQuality
un	I-Premise	HighQuality
66,3%	I-Premise	HighQuality
en	I-Premise	HighQuality
el	I-Premise	HighQuality
grupo	I-Premise	HighQuality
TDF-TDF	I-Premise	HighQuality
y	I-Premise	HighQuality
en	I-Premise	HighQuality
un	I-Premise	HighQuality
68,0%	I-Premise	HighQuality
en	I-Premise	HighQuality
el	I-Premise	HighQuality
grupo	I-Premise	HighQuality
TDF/ETV-TDF	I-Premise	HighQuality
(	I-Premise	HighQuality
P	I-Premise	HighQuality
=	I-Premise	HighQuality
0,80	I-Premise	HighQuality
)	I-Premise	HighQuality
.	I-Premise	HighQuality

En	B-Premise	HighQuality
la	I-Premise	HighQuality
semana	I-Premise	HighQuality
144	I-Premise	HighQuality
,	I-Premise	HighQuality
la	I-Premise	HighQuality
proporción	I-Premise	HighQuality
con	I-Premise	HighQuality
ADN	I-Premise	HighQuality
del	I-Premise	HighQuality
VHB	I-Premise	HighQuality
<	I-Premise	HighQuality
15	I-Premise	HighQuality
UI/mL	I-Premise	HighQuality
aumentó	I-Premise	HighQuality
hasta	I-Premise	HighQuality
el	I-Premise	HighQuality
74,5%	I-Premise	HighQuality
,	I-Premise	HighQuality
que	I-Premise	HighQuality
fue	I-Premise	HighQuality
significativamente	I-Premise	HighQuality
mayor	I-Premise	HighQuality
en	I-Premise	HighQuality
comparación	I-Premise	HighQuality
con	I-Premise	HighQuality
la	I-Premise	HighQuality
de	I-Premise	HighQuality
la	I-Premise	HighQuality
semana	I-Premise	HighQuality
48	I-Premise	HighQuality
(	I-Premise	HighQuality
P	I-Premise	HighQuality
=	I-Premise	HighQuality
0,03	I-Premise	HighQuality
)	I-Premise	HighQuality
,	I-Premise	HighQuality
sin	I-Premise	HighQuality
una	I-Premise	HighQuality
diferencia	I-Premise	HighQuality
significativa	I-Premise	HighQuality
entre	I-Premise	HighQuality
los	I-Premise	HighQuality
grupos	I-Premise	HighQuality
(	I-Premise	HighQuality
P	I-Premise	HighQuality
=	I-Premise	HighQuality
0,46	I-Premise	HighQuality
)	I-Premise	HighQuality
.	I-Premise	HighQuality

En	B-Premise	HighQuality
el	I-Premise	HighQuality
análisis	I-Premise	HighQuality
del	I-Premise	HighQuality
tratamiento,	I-Premise	HighQuality
un	I-Premise	HighQuality
total	I-Premise	HighQuality
del	I-Premise	HighQuality
79,4%	I-Premise	HighQuality
tenía	I-Premise	HighQuality
un	I-Premise	HighQuality
ADN	I-Premise	HighQuality
del	I-Premise	HighQuality
VHB	I-Premise	HighQuality
<	I-Premise	HighQuality
15	I-Premise	HighQuality
UI/mL	I-Premise	HighQuality
en	I-Premise	HighQuality
la	I-Premise	HighQuality
semana	I-Premise	HighQuality
144.	I-Premise	HighQuality

En	B-Premise	HighQuality
6	I-Premise	HighQuality
pacientes	I-Premise	HighQuality
se	I-Premise	HighQuality
produjo	I-Premise	HighQuality
una	I-Premise	HighQuality
ruptura	I-Premise	HighQuality
virológica	I-Premise	HighQuality
transitoria,	I-Premise	HighQuality
que	I-Premise	HighQuality
se	I-Premise	HighQuality
debió	I-Premise	HighQuality
a	I-Premise	HighQuality
una	I-Premise	HighQuality
mala	I-Premise	HighQuality
adherencia	I-Premise	HighQuality
al	I-Premise	HighQuality
fármaco.	I-Premise	HighQuality

En	B-Premise	HighQuality
la	I-Premise	HighQuality
semana	I-Premise	HighQuality
144	I-Premise	HighQuality
,	I-Premise	HighQuality
19	I-Premise	HighQuality
pacientes	I-Premise	HighQuality
que	I-Premise	HighQuality
tenían	I-Premise	HighQuality
niveles	I-Premise	HighQuality
de	I-Premise	HighQuality
ADN	I-Premise	HighQuality
del	I-Premise	HighQuality
VHB	I-Premise	HighQuality
>	I-Premise	HighQuality
60	I-Premise	HighQuality
UI/mL	I-Premise	HighQuality
cumplían	I-Premise	HighQuality
los	I-Premise	HighQuality
requisitos	I-Premise	HighQuality
para	I-Premise	HighQuality
el	I-Premise	HighQuality
análisis	I-Premise	HighQuality
de	I-Premise	HighQuality
resistencia	I-Premise	HighQuality
genotípica	I-Premise	HighQuality
,	I-Premise	HighQuality
y	I-Premise	HighQuality
6	I-Premise	HighQuality
conservaban	I-Premise	HighQuality
algunas	I-Premise	HighQuality
de	I-Premise	HighQuality
sus	I-Premise	HighQuality
mutaciones	I-Premise	HighQuality
de	I-Premise	HighQuality
resistencia	I-Premise	HighQuality
del	I-Premise	HighQuality
VHB	I-Premise	HighQuality
en	I-Premise	HighQuality
la	I-Premise	HighQuality
línea	I-Premise	HighQuality
de	I-Premise	HighQuality
base	I-Premise	HighQuality
.	I-Premise	HighQuality

Ningún	B-Premise	HighQuality
paciente	I-Premise	HighQuality
desarrolló	I-Premise	HighQuality
mutaciones	I-Premise	HighQuality
de	I-Premise	HighQuality
resistencia	I-Premise	HighQuality
adicionales	I-Premise	HighQuality
a	I-Premise	HighQuality
lo	I-Premise	HighQuality
largo	I-Premise	HighQuality
del	I-Premise	HighQuality
periodo	I-Premise	HighQuality
de	I-Premise	HighQuality
estudio.	I-Premise	HighQuality

La	B-Claim	HighQuality
monoterapia	I-Claim	HighQuality
con	I-Claim	HighQuality
TDF	I-Claim	HighQuality
fue	I-Claim	HighQuality
eficaz	I-Claim	HighQuality
y	I-Claim	HighQuality
segura	I-Claim	HighQuality
durante	I-Claim	HighQuality
hasta	I-Claim	HighQuality
144	I-Claim	HighQuality
semanas,	I-Claim	HighQuality
proporcionando	I-Claim	HighQuality
una	I-Claim	HighQuality
tasa	I-Claim	HighQuality
creciente	I-Claim	HighQuality
de	I-Claim	HighQuality
respuesta	I-Claim	HighQuality
virológica	I-Claim	HighQuality
en	I-Claim	HighQuality
pacientes	I-Claim	HighQuality
muy	I-Claim	HighQuality
pretratados	I-Claim	HighQuality
con	I-Claim	HighQuality
VHB	I-Claim	HighQuality
multirresistente.	I-Claim	HighQuality

Estimar	O	-
los	O	-
efectos	O	-
en	O	-
el	O	-
mundo	O	-
real	O	-
de	O	-
ofrecer	O	-
una	O	-
intervención	O	-
de	O	-
estilo	O	-
de	O	-
vida	O	-
basada	O	-
en	O	-
el	O	-
grupo	O	-
(	O	-
GLI	O	-
)	O	-
a	O	-
los	O	-
adultos	O	-
con	O	-
diabetes	O	-
.	O	-

Este	O	-
ensayo	O	-
aleatorio	O	-
de	O	-
estímulo	O	-
incluyó	O	-
a	O	-
pacientes	O	-
adultos	O	-
de	O	-
atención	O	-
primaria	O	-
del	O	-
área	O	-
metropolitana	O	-
de	O	-
Chicago	O	-
con	O	-
diabetes	O	-
tipo	O	-
2	O	-
e	O	-
índice	O	-
de	O	-
masa	O	-
corporal	O	-
≥24	O	-
kg/m2.	O	-

Los	O	-
participantes	O	-
fueron	O	-
asignados	O	-
aleatoriamente	O	-
a	O	-
la	O	-
atención	O	-
estándar	O	-
(asesoramiento	O	-
breve	O	-
sobre	O	-
la	O	-
dieta	O	-
y	O	-
el	O	-
estilo	O	-
de	O	-
vida)	O	-
o	O	-
a	O	-
la	O	-
atención	O	-
estándar	O	-
y	O	-
se	O	-
les	O	-
animó,	O	-
pero	O	-
no	O	-
se	O	-
les	O	-
exigió,	O	-
a	O	-
participar	O	-
en	O	-
un	O	-
GLI	O	-
gratuito	O	-
ofrecido	O	-
por	O	-
la	O	-
YMCA.	O	-

El	O	-
GLI	O	-
fue	O	-
una	O	-
adaptación	O	-
en	O	-
grupo	O	-
de	O	-
la	O	-
intervención	O	-
sobre	O	-
el	O	-
estilo	O	-
de	O	-
vida	O	-
Look	O	-
AHEAD	O	-
.	O	-

De	O	-
los	O	-
331	O	-
participantes,	O	-
167	O	-
fueron	O	-
asignados	O	-
aleatoriamente	O	-
a	O	-
la	O	-
atención	O	-
estándar	O	-
y	O	-
164	O	-
a	O	-
la	O	-
rama	O	-
de	O	-
fomento	O	-
de	O	-
la	O	-
GLI.	O	-

Aproximadamente	O	-
un	O	-
tercio	O	-
de	O	-
los	O	-
participantes	O	-
eran	O	-
blancos	O	-
no	O	-
hispanos	O	-
(	O	-
34,4%	O	-
)	O	-
.	O	-

En	O	-
el	O	-
brazo	O	-
GLI	O	-
,	O	-
75	O	-
(	O	-
45,7	O	-
%	O	-
)	O	-
asistieron	O	-
a	O	-
≥1	O	-
visitas	O	-
GLI	O	-
.	O	-

En	B-Premise	HighQuality
el	I-Premise	HighQuality
análisis	I-Premise	HighQuality
primario	I-Premise	HighQuality
por	I-Premise	HighQuality
intención	I-Premise	HighQuality
de	I-Premise	HighQuality
tratar,	I-Premise	HighQuality
el	I-Premise	HighQuality
efecto	I-Premise	HighQuality
del	I-Premise	HighQuality
fomento	I-Premise	HighQuality
de	I-Premise	HighQuality
la	I-Premise	HighQuality
GLI	I-Premise	HighQuality
fue	I-Premise	HighQuality
de	I-Premise	HighQuality
un	I-Premise	HighQuality
0,95	I-Premise	HighQuality
%	I-Premise	HighQuality
de	I-Premise	HighQuality
pérdida	I-Premise	HighQuality
de	I-Premise	HighQuality
peso	I-Premise	HighQuality
a	I-Premise	HighQuality
los	I-Premise	HighQuality
seis	I-Premise	HighQuality
meses	I-Premise	HighQuality
(	I-Premise	HighQuality
intervalo	I-Premise	HighQuality
de	I-Premise	HighQuality
confianza	I-Premise	HighQuality
del	I-Premise	HighQuality
95	I-Premise	HighQuality
%	I-Premise	HighQuality
[	I-Premise	HighQuality
IC	I-Premise	HighQuality
]	I-Premise	HighQuality
,	I-Premise	HighQuality
0,13-1,77	I-Premise	HighQuality
%	I-Premise	HighQuality
;	I-Premise	HighQuality
P	I-Premise	HighQuality
=	I-Premise	HighQuality
0,02	I-Premise	HighQuality
)	I-Premise	HighQuality
,	I-Premise	HighQuality
y	I-Premise	HighQuality
de	I-Premise	HighQuality
un	I-Premise	HighQuality
1,20	I-Premise	HighQuality
%	I-Premise	HighQuality
de	I-Premise	HighQuality
pérdida	I-Premise	HighQuality
de	I-Premise	HighQuality
peso	I-Premise	HighQuality
a	I-Premise	HighQuality
los	I-Premise	HighQuality
12	I-Premise	HighQuality
meses	I-Premise	HighQuality
(	I-Premise	HighQuality
IC	I-Premise	HighQuality
del	I-Premise	HighQuality
95	I-Premise	HighQuality
%	I-Premise	HighQuality
,	I-Premise	HighQuality
0,05-2,36	I-Premise	HighQuality
%	I-Premise	HighQuality
;	I-Premise	HighQuality
P	I-Premise	HighQuality
=	I-Premise	HighQuality
0,04	I-Premise	HighQuality
)	I-Premise	HighQuality
.	I-Premise	HighQuality

A	O	-
los	O	-
12	O	-
meses,	O	-
hubo	O	-
una	O	-
reducción	O	-
del	O	-
0,30	O	-
%	O	-
(	O	-
3,3	O	-
mmol/mol	O	-
)	O	-
en	O	-
la	O	-
hemoglobina	O	-
A1c	O	-
,	O	-
pero	O	-
este	O	-
resultado	O	-
no	O	-
alcanzó	O	-
significación	O	-
estadística	O	-
(	O	-
P	O	-
=	O	-
0,054	O	-
)	O	-
.	O	-

En	B-Premise	HighQuality
el	I-Premise	HighQuality
análisis	I-Premise	HighQuality
de	I-Premise	HighQuality
variables	I-Premise	HighQuality
instrumentales	I-Premise	HighQuality
que	I-Premise	HighQuality
estimó	I-Premise	HighQuality
los	I-Premise	HighQuality
efectos	I-Premise	HighQuality
entre	I-Premise	HighQuality
el	I-Premise	HighQuality
subgrupo	I-Premise	HighQuality
de	I-Premise	HighQuality
participantes	I-Premise	HighQuality
que	I-Premise	HighQuality
asistieron	I-Premise	HighQuality
a	I-Premise	HighQuality
alguna	I-Premise	HighQuality
visita	I-Premise	HighQuality
de	I-Premise	HighQuality
GLI	I-Premise	HighQuality
,	I-Premise	HighQuality
el	I-Premise	HighQuality
efecto	I-Premise	HighQuality
de	I-Premise	HighQuality
la	I-Premise	HighQuality
asistencia	I-Premise	HighQuality
a	I-Premise	HighQuality
GLI	I-Premise	HighQuality
fue	I-Premise	HighQuality
de	I-Premise	HighQuality
un	I-Premise	HighQuality
2,30	I-Premise	HighQuality
%	I-Premise	HighQuality
de	I-Premise	HighQuality
pérdida	I-Premise	HighQuality
de	I-Premise	HighQuality
peso	I-Premise	HighQuality
a	I-Premise	HighQuality
los	I-Premise	HighQuality
seis	I-Premise	HighQuality
meses	I-Premise	HighQuality
(	I-Premise	HighQuality
IC	I-Premise	HighQuality
del	I-Premise	HighQuality
95	I-Premise	HighQuality
%	I-Premise	HighQuality
,	I-Premise	HighQuality
0,30-4,30	I-Premise	HighQuality
%	I-Premise	HighQuality
;	I-Premise	HighQuality
P	I-Premise	HighQuality
=	I-Premise	HighQuality
0,02	I-Premise	HighQuality
)	I-Premise	HighQuality
,	I-Premise	HighQuality
y	I-Premise	HighQuality
de	I-Premise	HighQuality
un	I-Premise	HighQuality
2,07	I-Premise	HighQuality
%	I-Premise	HighQuality
de	I-Premise	HighQuality
pérdida	I-Premise	HighQuality
de	I-Premise	HighQuality
peso	I-Premise	HighQuality
a	I-Premise	HighQuality
los	I-Premise	HighQuality
12	I-Premise	HighQuality
meses	I-Premise	HighQuality
(	I-Premise	HighQuality
IC	I-Premise	HighQuality
del	I-Premise	HighQuality
95	I-Premise	HighQuality
%	I-Premise	HighQuality
,	I-Premise	HighQuality
0,25-3,88	I-Premise	HighQuality
%	I-Premise	HighQuality
;	I-Premise	HighQuality
P	I-Premise	HighQuality
=	I-Premise	HighQuality
0,02	I-Premise	HighQuality
)	I-Premise	HighQuality
.	I-Premise	HighQuality

No	O	-
se	O	-
detectaron	O	-
efectos	O	-
significativos	O	-
sobre	O	-
la	O	-
presión	O	-
arterial	O	-
o	O	-
el	O	-
colesterol.	O	-

Entre	B-Claim	HighQuality
los	I-Claim	HighQuality
adultos	I-Claim	HighQuality
con	I-Claim	HighQuality
diabetes	I-Claim	HighQuality
de	I-Claim	HighQuality
tipo	I-Claim	HighQuality
2,	I-Claim	HighQuality
una	I-Claim	HighQuality
intervención	I-Claim	HighQuality
grupal	I-Claim	HighQuality
sobre	I-Claim	HighQuality
el	I-Claim	HighQuality
estilo	I-Claim	HighQuality
de	I-Claim	HighQuality
vida	I-Claim	HighQuality
en	I-Claim	HighQuality
un	I-Claim	HighQuality
entorno	I-Claim	HighQuality
comunitario	I-Claim	HighQuality
logró	I-Claim	HighQuality
una	I-Claim	HighQuality
modesta	I-Claim	HighQuality
pérdida	I-Claim	HighQuality
de	I-Claim	HighQuality
peso	I-Claim	HighQuality
a	I-Claim	HighQuality
los	I-Claim	HighQuality
6	I-Claim	HighQuality
y	I-Claim	HighQuality
12	I-Claim	HighQuality
meses.	I-Claim	HighQuality

Determinar	O	-
la	O	-
seguridad	O	-
y	O	-
eficacia	O	-
del	O	-
bexaroteno	O	-
oral	O	-
(	O	-
Targretin	O	-
capsules	O	-
;	O	-
Ligand	O	-
Pharmaceuticals	O	-
Incorporated	O	-
,	O	-
San	O	-
Diego	O	-
,	O	-
Calif	O	-
)	O	-
.	O	-

Los	O	-
efectos	O	-
de	O	-
2	O	-
dosis	O	-
aleatorias	O	-
de	O	-
6,5	O	-
mg/m	O	-
(	O	-
2	O	-
)	O	-
al	O	-
día	O	-
(	O	-
con	O	-
cruce	O	-
para	O	-
la	O	-
progresión	O	-
)	O	-
frente	O	-
a	O	-
650	O	-
mg/m	O	-
(	O	-
2	O	-
)	O	-
al	O	-
día	O	-
(	O	-
posteriormente	O	-
modificado	O	-
a	O	-
300	O	-
mg/m	O	-
(	O	-
2	O	-
)	O	-
al	O	-
día	O	-
)	O	-
se	O	-
evaluaron	O	-
en	O	-
un	O	-
estudio	O	-
abierto	O	-
,	O	-
multicéntrico	O	-
,	O	-
de	O	-
fase	O	-
2	O	-
y	O	-
3	O	-
realizado	O	-
entre	O	-
febrero	O	-
de	O	-
1997	O	-
y	O	-
noviembre	O	-
de	O	-
1998	O	-
.	O	-

Dieciocho	O	-
clínicas	O	-
internacionales	O	-
de	O	-
linfoma	O	-
cutáneo	O	-
de	O	-
células	O	-
T	O	-
en	O	-
centros	O	-
académicos	O	-
de	O	-
referencia	O	-
.	O	-

Cincuenta	O	-
y	O	-
ocho	O	-
pacientes	O	-
con	O	-
linfoma	O	-
cutáneo	O	-
de	O	-
células	O	-
T	O	-
en	O	-
estadio	O	-
IA	O	-
a	O	-
IIA	O	-
comprobado	O	-
por	O	-
biopsia	O	-
que	O	-
era	O	-
refractario	O	-
al	O	-
tratamiento	O	-
(	O	-
o	O	-
los	O	-
pacientes	O	-
no	O	-
lo	O	-
toleraban	O	-
)	O	-
o	O	-
que	O	-
había	O	-
alcanzado	O	-
al	O	-
menos	O	-
una	O	-
meseta	O	-
de	O	-
respuesta	O	-
de	O	-
6	O	-
meses	O	-
bajo	O	-
al	O	-
menos	O	-
2	O	-
formas	O	-
de	O	-
terapia	O	-
previa	O	-
(	O	-
mediana	O	-
de	O	-
3,5	O	-
terapias	O	-
previas	O	-
)	O	-
.	O	-

Bexaroteno	O	-
(	O	-
Targretin	O	-
cápsulas	O	-
)	O	-
administrado	O	-
una	O	-
vez	O	-
al	O	-
día	O	-
con	O	-
la	O	-
comida	O	-
durante	O	-
16	O	-
semanas	O	-
o	O	-
más	O	-
.	O	-

Clasificación	O	-
del	O	-
punto	O	-
final	O	-
primario	O	-
de	O	-
la	O	-
tasa	O	-
de	O	-
respuesta	O	-
global	O	-
de	O	-
remisiones	O	-
completas	O	-
y	O	-
parciales	O	-
determinada	O	-
por	O	-
la	O	-
Evaluación	O	-
Global	O	-
del	O	-
Estado	O	-
Clínico	O	-
del	O	-
Médico	O	-
o	O	-
la	O	-
Evaluación	O	-
Compuesta	O	-
objetiva	O	-
de	O	-
la	O	-
Severidad	O	-
de	O	-
la	O	-
Lesión	O	-
Índice	O	-
.	O	-

El	O	-
área	O	-
de	O	-
superficie	O	-
corporal,	O	-
el	O	-
tiempo	O	-
de	O	-
respuesta,	O	-
la	O	-
duración	O	-
del	O	-
control	O	-
de	O	-
la	O	-
enfermedad,	O	-
el	O	-
tiempo	O	-
de	O	-
progresión	O	-
de	O	-
la	O	-
enfermedad,	O	-
los	O	-
signos	O	-
y	O	-
síntomas	O	-
individuales	O	-
de	O	-
la	O	-
lesión	O	-
índice	O	-
y	O	-
los	O	-
parámetros	O	-
de	O	-
calidad	O	-
de	O	-
vida	O	-
fueron	O	-
resultados	O	-
secundarios.	O	-

Se	B-Premise	HighQuality
observaron	I-Premise	HighQuality
respuestas	I-Premise	HighQuality
(	I-Premise	HighQuality
>	I-Premise	HighQuality
o	I-Premise	HighQuality
=	I-Premise	HighQuality
50	I-Premise	HighQuality
%	I-Premise	HighQuality
de	I-Premise	HighQuality
mejoría	I-Premise	HighQuality
)	I-Premise	HighQuality
en	I-Premise	HighQuality
3	I-Premise	HighQuality
(	I-Premise	HighQuality
20	I-Premise	HighQuality
%	I-Premise	HighQuality
)	I-Premise	HighQuality
de	I-Premise	HighQuality
15	I-Premise	HighQuality
pacientes	I-Premise	HighQuality
con	I-Premise	HighQuality
una	I-Premise	HighQuality
dosis	I-Premise	HighQuality
inicial	I-Premise	HighQuality
de	I-Premise	HighQuality
6,5	I-Premise	HighQuality
mg/m	I-Premise	HighQuality
(	I-Premise	HighQuality
2	I-Premise	HighQuality
)	I-Premise	HighQuality
al	I-Premise	HighQuality
día	I-Premise	HighQuality
(	I-Premise	HighQuality
intervalo	I-Premise	HighQuality
de	I-Premise	HighQuality
confianza	I-Premise	HighQuality
[	I-Premise	HighQuality
IC	I-Premise	HighQuality
]	I-Premise	HighQuality
del	I-Premise	HighQuality
95	I-Premise	HighQuality
%	I-Premise	HighQuality
,	I-Premise	HighQuality
0	I-Premise	HighQuality
%	I-Premise	HighQuality
-40	I-Premise	HighQuality
%	I-Premise	HighQuality
)	I-Premise	HighQuality
,	I-Premise	HighQuality
15	I-Premise	HighQuality
(	I-Premise	HighQuality
54	I-Premise	HighQuality
%	I-Premise	HighQuality
)	I-Premise	HighQuality
de	I-Premise	HighQuality
28	I-Premise	HighQuality
pacientes	I-Premise	HighQuality
con	I-Premise	HighQuality
300	I-Premise	HighQuality
mg/m	I-Premise	HighQuality
(	I-Premise	HighQuality
2	I-Premise	HighQuality
)	I-Premise	HighQuality
al	I-Premise	HighQuality
día	I-Premise	HighQuality
(	I-Premise	HighQuality
IC	I-Premise	HighQuality
del	I-Premise	HighQuality
95	I-Premise	HighQuality
%	I-Premise	HighQuality
,	I-Premise	HighQuality
35	I-Premise	HighQuality
%	I-Premise	HighQuality
-72	I-Premise	HighQuality
%	I-Premise	HighQuality
)	I-Premise	HighQuality
,	I-Premise	HighQuality
y	I-Premise	HighQuality
10	I-Premise	HighQuality
(	I-Premise	HighQuality
67	I-Premise	HighQuality
%	I-Premise	HighQuality
)	I-Premise	HighQuality
de	I-Premise	HighQuality
15	I-Premise	HighQuality
pacientes	I-Premise	HighQuality
con	I-Premise	HighQuality
más	I-Premise	HighQuality
de	I-Premise	HighQuality
300	I-Premise	HighQuality
mg/m	I-Premise	HighQuality
(	I-Premise	HighQuality
2	I-Premise	HighQuality
)	I-Premise	HighQuality
al	I-Premise	HighQuality
día	I-Premise	HighQuality
(	I-Premise	HighQuality
IC	I-Premise	HighQuality
del	I-Premise	HighQuality
95	I-Premise	HighQuality
%	I-Premise	HighQuality
,	I-Premise	HighQuality
43	I-Premise	HighQuality
%	I-Premise	HighQuality
-91	I-Premise	HighQuality
%	I-Premise	HighQuality
)	I-Premise	HighQuality
.	I-Premise	HighQuality

La	B-Premise	HighQuality
tasa	I-Premise	HighQuality
de	I-Premise	HighQuality
enfermedad	I-Premise	HighQuality
progresiva	I-Premise	HighQuality
fue	I-Premise	HighQuality
del	I-Premise	HighQuality
47	I-Premise	HighQuality
%,	I-Premise	HighQuality
21	I-Premise	HighQuality
%	I-Premise	HighQuality
y	I-Premise	HighQuality
13	I-Premise	HighQuality
%	I-Premise	HighQuality
en	I-Premise	HighQuality
los	I-Premise	HighQuality
mismos	I-Premise	HighQuality
niveles	I-Premise	HighQuality
de	I-Premise	HighQuality
dosis,	I-Premise	HighQuality
respectivamente.	I-Premise	HighQuality

Ocho	B-Premise	HighQuality
(	I-Premise	HighQuality
73	I-Premise	HighQuality
%	I-Premise	HighQuality
)	I-Premise	HighQuality
de	I-Premise	HighQuality
11	I-Premise	HighQuality
pacientes	I-Premise	HighQuality
que	I-Premise	HighQuality
pasaron	I-Premise	HighQuality
de	I-Premise	HighQuality
6,5	I-Premise	HighQuality
mg/m	I-Premise	HighQuality
(	I-Premise	HighQuality
2	I-Premise	HighQuality
)	I-Premise	HighQuality
al	I-Premise	HighQuality
día	I-Premise	HighQuality
a	I-Premise	HighQuality
dosis	I-Premise	HighQuality
más	I-Premise	HighQuality
altas	I-Premise	HighQuality
respondieron	I-Premise	HighQuality
posteriormente	I-Premise	HighQuality
.	I-Premise	HighQuality

La	B-Premise	HighQuality
mediana	I-Premise	HighQuality
de	I-Premise	HighQuality
la	I-Premise	HighQuality
duración	I-Premise	HighQuality
de	I-Premise	HighQuality
la	I-Premise	HighQuality
respuesta	I-Premise	HighQuality
desde	I-Premise	HighQuality
el	I-Premise	HighQuality
inicio	I-Premise	HighQuality
del	I-Premise	HighQuality
tratamiento	I-Premise	HighQuality
no	I-Premise	HighQuality
pudo	I-Premise	HighQuality
estimarse	I-Premise	HighQuality
para	I-Premise	HighQuality
los	I-Premise	HighQuality
15	I-Premise	HighQuality
pacientes	I-Premise	HighQuality
con	I-Premise	HighQuality
300	I-Premise	HighQuality
mg/m	I-Premise	HighQuality
(	I-Premise	HighQuality
2	I-Premise	HighQuality
)	I-Premise	HighQuality
al	I-Premise	HighQuality
día	I-Premise	HighQuality
debido	I-Premise	HighQuality
a	I-Premise	HighQuality
las	I-Premise	HighQuality
bajas	I-Premise	HighQuality
tasas	I-Premise	HighQuality
de	I-Premise	HighQuality
recaída	I-Premise	HighQuality
en	I-Premise	HighQuality
2	I-Premise	HighQuality
pacientes	I-Premise	HighQuality
(	I-Premise	HighQuality
13	I-Premise	HighQuality
%	I-Premise	HighQuality
)	I-Premise	HighQuality
;	I-Premise	HighQuality
con	I-Premise	HighQuality
dosis	I-Premise	HighQuality
más	I-Premise	HighQuality
altas	I-Premise	HighQuality
fue	I-Premise	HighQuality
de	I-Premise	HighQuality
516	I-Premise	HighQuality
días	I-Premise	HighQuality
.	I-Premise	HighQuality

Los	B-Premise	HighQuality
siguientes	I-Premise	HighQuality
efectos	I-Premise	HighQuality
adversos	I-Premise	HighQuality
relacionados	I-Premise	HighQuality
con	I-Premise	HighQuality
el	I-Premise	HighQuality
fármaco	I-Premise	HighQuality
fueron	I-Premise	HighQuality
reversibles	I-Premise	HighQuality
y	I-Premise	HighQuality
tratables:	I-Premise	HighQuality
hipertrigliceridemia	I-Premise	HighQuality
(	I-Premise	HighQuality
46	I-Premise	HighQuality
pacientes	I-Premise	HighQuality
[	I-Premise	HighQuality
79	I-Premise	HighQuality
%	I-Premise	HighQuality
]	I-Premise	HighQuality
)	I-Premise	HighQuality
,	I-Premise	HighQuality
hipercolesterolemia	I-Premise	HighQuality
(	I-Premise	HighQuality
28	I-Premise	HighQuality
pacientes	I-Premise	HighQuality
[	I-Premise	HighQuality
48	I-Premise	HighQuality
%	I-Premise	HighQuality
]	I-Premise	HighQuality
)	I-Premise	HighQuality
,	I-Premise	HighQuality
cefalea	I-Premise	HighQuality
(	I-Premise	HighQuality
27	I-Premise	HighQuality
pacientes	I-Premise	HighQuality
[	I-Premise	HighQuality
47	I-Premise	HighQuality
%	I-Premise	HighQuality
]	I-Premise	HighQuality
)	I-Premise	HighQuality
,	I-Premise	HighQuality
hipotiroidismo	I-Premise	HighQuality
central	I-Premise	HighQuality
(	I-Premise	HighQuality
23	I-Premise	HighQuality
pacientes	I-Premise	HighQuality
[	I-Premise	HighQuality
40	I-Premise	HighQuality
%	I-Premise	HighQuality
]	I-Premise	HighQuality
)	I-Premise	HighQuality
,	I-Premise	HighQuality
astenia	I-Premise	HighQuality
(	I-Premise	HighQuality
21	I-Premise	HighQuality
pacientes	I-Premise	HighQuality
[	I-Premise	HighQuality
36	I-Premise	HighQuality
%	I-Premise	HighQuality
]	I-Premise	HighQuality
)	I-Premise	HighQuality
y	I-Premise	HighQuality
leucopenia	I-Premise	HighQuality
(	I-Premise	HighQuality
16	I-Premise	HighQuality
pacientes	I-Premise	HighQuality
[	I-Premise	HighQuality
28	I-Premise	HighQuality
%	I-Premise	HighQuality
]	I-Premise	HighQuality
)	I-Premise	HighQuality
.	I-Premise	HighQuality

No	B-Premise	HighQuality
se	I-Premise	HighQuality
produjeron	I-Premise	HighQuality
casos	I-Premise	HighQuality
de	I-Premise	HighQuality
fiebre	I-Premise	HighQuality
neutropénica,	I-Premise	HighQuality
sepsis	I-Premise	HighQuality
o	I-Premise	HighQuality
muerte	I-Premise	HighQuality
relacionados	I-Premise	HighQuality
con	I-Premise	HighQuality
el	I-Premise	HighQuality
fármaco.	I-Premise	HighQuality

Se	B-Premise	HighQuality
produjo	I-Premise	HighQuality
pancreatitis	I-Premise	HighQuality
en	I-Premise	HighQuality
3	I-Premise	HighQuality
pacientes	I-Premise	HighQuality
con	I-Premise	HighQuality
niveles	I-Premise	HighQuality
de	I-Premise	HighQuality
triglicéridos	I-Premise	HighQuality
superiores	I-Premise	HighQuality
a	I-Premise	HighQuality
14,69	I-Premise	HighQuality
mmol/L	I-Premise	HighQuality
(	I-Premise	HighQuality
1300	I-Premise	HighQuality
mg/dL	I-Premise	HighQuality
)	I-Premise	HighQuality
,	I-Premise	HighQuality
todos	I-Premise	HighQuality
los	I-Premise	HighQuality
cuales	I-Premise	HighQuality
tomaban	I-Premise	HighQuality
300	I-Premise	HighQuality
mg/m	I-Premise	HighQuality
(	I-Premise	HighQuality
2	I-Premise	HighQuality
)	I-Premise	HighQuality
o	I-Premise	HighQuality
más	I-Premise	HighQuality
de	I-Premise	HighQuality
bexaroteno	I-Premise	HighQuality
oral	I-Premise	HighQuality
al	I-Premise	HighQuality
día	I-Premise	HighQuality
.	I-Premise	HighQuality

Bexaroteno	B-Claim	HighQuality
(	I-Claim	HighQuality
Targretin	I-Claim	HighQuality
cápsulas	I-Claim	HighQuality
)	I-Claim	HighQuality
(	I-Claim	HighQuality
el	I-Claim	HighQuality
primer	I-Claim	HighQuality
rexinoide	I-Claim	HighQuality
selectivo	I-Claim	HighQuality
del	I-Claim	HighQuality
receptor	I-Claim	HighQuality
X	I-Claim	HighQuality
retinoide	I-Claim	HighQuality
)	I-Claim	HighQuality
fue	I-Claim	HighQuality
bien	I-Claim	HighQuality
tolerado	I-Claim	HighQuality
y	I-Claim	HighQuality
eficaz	I-Claim	HighQuality
como	I-Claim	HighQuality
tratamiento	I-Claim	HighQuality
oral	I-Claim	HighQuality
para	I-Claim	HighQuality
15	I-Claim	HighQuality
(	I-Claim	HighQuality
54	I-Claim	HighQuality
%	I-Claim	HighQuality
)	I-Claim	HighQuality
de	I-Claim	HighQuality
28	I-Claim	HighQuality
pacientes	I-Claim	HighQuality
con	I-Claim	HighQuality
linfoma	I-Claim	HighQuality
cutáneo	I-Claim	HighQuality
de	I-Claim	HighQuality
células	I-Claim	HighQuality
T	I-Claim	HighQuality
refractario	I-Claim	HighQuality
o	I-Claim	HighQuality
persistente	I-Claim	HighQuality
en	I-Claim	HighQuality
fase	I-Claim	HighQuality
inicial	I-Claim	HighQuality
a	I-Claim	HighQuality
dosis	I-Claim	HighQuality
de	I-Claim	HighQuality
300	I-Claim	HighQuality
mg/m	I-Claim	HighQuality
(	I-Claim	HighQuality
2	I-Claim	HighQuality
)	I-Claim	HighQuality
al	I-Claim	HighQuality
día	I-Claim	HighQuality
.	I-Claim	HighQuality

La	B-Claim	HighQuality
hipertrigliceridemia	I-Claim	HighQuality
y	I-Claim	HighQuality
el	I-Claim	HighQuality
hipotiroidismo	I-Claim	HighQuality
requieren	I-Claim	HighQuality
vigilancia,	I-Claim	HighQuality
pero	I-Claim	HighQuality
son	I-Claim	HighQuality
reversibles	I-Claim	HighQuality
y	I-Claim	HighQuality
manejables	I-Claim	HighQuality
con	I-Claim	HighQuality
medicación	I-Claim	HighQuality
concomitante	I-Claim	HighQuality
.	I-Claim	HighQuality

Existen	O	-
pocos	O	-
ensayos	O	-
clínicos	O	-
controlados	O	-
que	O	-
apoyen	O	-
el	O	-
tratamiento	O	-
combinado	O	-
oral	O	-
en	O	-
la	O	-
hipertensión	O	-
arterial	O	-
pulmonar	O	-
(	O	-
HAP	O	-
)	O	-
.	O	-

Los	O	-
pacientes	O	-
con	O	-
HAP	O	-
(	O	-
idiopática	O	-
[	O	-
IPAH	O	-
]	O	-
o	O	-
asociada	O	-
a	O	-
enfermedad	O	-
del	O	-
tejido	O	-
conectivo	O	-
[	O	-
APAH-CTD	O	-
]	O	-
)	O	-
que	O	-
tomaban	O	-
bosentán	O	-
(	O	-
62,5	O	-
o	O	-
125	O	-
mg	O	-
dos	O	-
veces	O	-
al	O	-
día	O	-
a	O	-
una	O	-
dosis	O	-
estable	O	-
durante	O	-
≥3	O	-
meses	O	-
)	O	-
fueron	O	-
aleatorizados	O	-
(	O	-
1:1	O	-
)	O	-
a	O	-
sildenafilo	O	-
(	O	-
20	O	-
mg	O	-
,	O	-
3	O	-
veces	O	-
al	O	-
día	O	-
;	O	-
n	O	-
=	O	-
50	O	-
)	O	-
o	O	-
placebo	O	-
(	O	-
n	O	-
=	O	-
53	O	-
)	O	-
.	O	-

El	O	-
criterio	O	-
de	O	-
valoración	O	-
primario	O	-
fue	O	-
el	O	-
cambio	O	-
respecto	O	-
a	O	-
la	O	-
línea	O	-
de	O	-
base	O	-
en	O	-
la	O	-
distancia	O	-
de	O	-
marcha	O	-
de	O	-
6	O	-
minutos	O	-
(	O	-
6MWD	O	-
)	O	-
en	O	-
la	O	-
semana	O	-
12	O	-
,	O	-
evaluado	O	-
mediante	O	-
un	O	-
análisis	O	-
de	O	-
covarianza	O	-
.	O	-

Los	O	-
pacientes	O	-
podrían	O	-
continuar	O	-
en	O	-
un	O	-
estudio	O	-
de	O	-
extensión	O	-
de	O	-
52	O	-
semanas	O	-
.	O	-

Se	O	-
utilizó	O	-
un	O	-
modelo	O	-
de	O	-
análisis	O	-
de	O	-
covarianza	O	-
de	O	-
efectos	O	-
principales,	O	-
que	O	-
incluía	O	-
términos	O	-
categóricos	O	-
para	O	-
el	O	-
tratamiento,	O	-
la	O	-
DM6	O	-
basal	O	-
(	O	-
<	O	-
325	O	-
m	O	-
;	O	-
≥325	O	-
m	O	-
)	O	-
y	O	-
la	O	-
etiología	O	-
basal;	O	-
posteriormente	O	-
se	O	-
realizaron	O	-
análisis	O	-
de	O	-
sensibilidad.	O	-

En	B-Premise	HighQuality
los	I-Premise	HighQuality
brazos	I-Premise	HighQuality
de	I-Premise	HighQuality
sildenafilo	I-Premise	HighQuality
frente	I-Premise	HighQuality
a	I-Premise	HighQuality
los	I-Premise	HighQuality
de	I-Premise	HighQuality
placebo,	I-Premise	HighQuality
los	I-Premise	HighQuality
aumentos	I-Premise	HighQuality
de	I-Premise	HighQuality
la	I-Premise	HighQuality
6MWD	I-Premise	HighQuality
en	I-Premise	HighQuality
la	I-Premise	HighQuality
semana	I-Premise	HighQuality
12	I-Premise	HighQuality
fueron	I-Premise	HighQuality
similares	I-Premise	HighQuality
(	I-Premise	HighQuality
diferencia	I-Premise	HighQuality
media	I-Premise	HighQuality
de	I-Premise	HighQuality
mínimos	I-Premise	HighQuality
cuadrados	I-Premise	HighQuality
[	I-Premise	HighQuality
sildenafilo-placebo	I-Premise	HighQuality
]	I-Premise	HighQuality
,	I-Premise	HighQuality
-2,4	I-Premise	HighQuality
m	I-Premise	HighQuality
[	I-Premise	HighQuality
IC	I-Premise	HighQuality
del	I-Premise	HighQuality
90	I-Premise	HighQuality
%	I-Premise	HighQuality
:	I-Premise	HighQuality
-21,8	I-Premise	HighQuality
a	I-Premise	HighQuality
17,1	I-Premise	HighQuality
m	I-Premise	HighQuality
]	I-Premise	HighQuality
;	I-Premise	HighQuality
p	I-Premise	HighQuality
=	I-Premise	HighQuality
0,6	I-Premise	HighQuality
)	I-Premise	HighQuality
;	I-Premise	HighQuality
los	I-Premise	HighQuality
cambios	I-Premise	HighQuality
medios	I-Premise	HighQuality
±	I-Premise	HighQuality
SD	I-Premise	HighQuality
desde	I-Premise	HighQuality
el	I-Premise	HighQuality
inicio	I-Premise	HighQuality
fueron	I-Premise	HighQuality
de	I-Premise	HighQuality
26,4	I-Premise	HighQuality
±	I-Premise	HighQuality
45,7	I-Premise	HighQuality
frente	I-Premise	HighQuality
a	I-Premise	HighQuality
11,8	I-Premise	HighQuality
±	I-Premise	HighQuality
57,4	I-Premise	HighQuality
m	I-Premise	HighQuality
,	I-Premise	HighQuality
respectivamente	I-Premise	HighQuality
,	I-Premise	HighQuality
en	I-Premise	HighQuality
la	I-Premise	HighQuality
HIPP	I-Premise	HighQuality
(	I-Premise	HighQuality
65	I-Premise	HighQuality
%	I-Premise	HighQuality
de	I-Premise	HighQuality
la	I-Premise	HighQuality
población	I-Premise	HighQuality
)	I-Premise	HighQuality
y	I-Premise	HighQuality
de	I-Premise	HighQuality
-18,3	I-Premise	HighQuality
±	I-Premise	HighQuality
82,0	I-Premise	HighQuality
frente	I-Premise	HighQuality
a	I-Premise	HighQuality
17,5	I-Premise	HighQuality
±	I-Premise	HighQuality
59,1	I-Premise	HighQuality
m	I-Premise	HighQuality
en	I-Premise	HighQuality
la	I-Premise	HighQuality
HAP-CTD	I-Premise	HighQuality
(	I-Premise	HighQuality
35	I-Premise	HighQuality
%	I-Premise	HighQuality
de	I-Premise	HighQuality
la	I-Premise	HighQuality
población	I-Premise	HighQuality
)	I-Premise	HighQuality
.	I-Premise	HighQuality

La	O	-
supervivencia	O	-
a	O	-
un	O	-
año	O	-
fue	O	-
del	O	-
96%;	O	-
los	O	-
pacientes	O	-
mantuvieron	O	-
modestas	O	-
mejoras	O	-
en	O	-
la	O	-
6MWD	O	-
.	O	-

Los	B-Premise	HighQuality
cambios	I-Premise	HighQuality
en	I-Premise	HighQuality
la	I-Premise	HighQuality
clase	I-Premise	HighQuality
funcional	I-Premise	HighQuality
de	I-Premise	HighQuality
la	I-Premise	HighQuality
OMS	I-Premise	HighQuality
y	I-Premise	HighQuality
la	I-Premise	HighQuality
puntuación	I-Premise	HighQuality
de	I-Premise	HighQuality
disnea	I-Premise	HighQuality
de	I-Premise	HighQuality
Borg	I-Premise	HighQuality
y	I-Premise	HighQuality
la	I-Premise	HighQuality
incidencia	I-Premise	HighQuality
de	I-Premise	HighQuality
empeoramiento	I-Premise	HighQuality
clínico	I-Premise	HighQuality
no	I-Premise	HighQuality
difirieron	I-Premise	HighQuality
.	I-Premise	HighQuality

El	B-Premise	HighQuality
dolor	I-Premise	HighQuality
de	I-Premise	HighQuality
cabeza,	I-Premise	HighQuality
la	I-Premise	HighQuality
diarrea	I-Premise	HighQuality
y	I-Premise	HighQuality
el	I-Premise	HighQuality
rubor	I-Premise	HighQuality
fueron	I-Premise	HighQuality
más	I-Premise	HighQuality
frecuentes	I-Premise	HighQuality
con	I-Premise	HighQuality
el	I-Premise	HighQuality
sildenafilo.	I-Premise	HighQuality

El	B-Claim	HighQuality
sildenafilo,	I-Claim	HighQuality
además	I-Claim	HighQuality
del	I-Claim	HighQuality
tratamiento	I-Claim	HighQuality
estable	I-Claim	HighQuality
(	I-Claim	HighQuality
≥3	I-Claim	HighQuality
meses)	I-Claim	HighQuality
con	I-Claim	HighQuality
bosentán,	I-Claim	HighQuality
no	I-Claim	HighQuality
tuvo	I-Claim	HighQuality
ningún	I-Claim	HighQuality
beneficio	I-Claim	HighQuality
sobre	I-Claim	HighQuality
el	I-Claim	HighQuality
placebo	I-Claim	HighQuality
para	I-Claim	HighQuality
el	I-Claim	HighQuality
cambio	I-Claim	HighQuality
de	I-Claim	HighQuality
12	I-Claim	HighQuality
semanas	I-Claim	HighQuality
desde	I-Claim	HighQuality
el	I-Claim	HighQuality
inicio	I-Claim	HighQuality
en	I-Claim	HighQuality
la	I-Claim	HighQuality
6MWD	I-Claim	HighQuality
.	I-Claim	HighQuality

La	O	-
influencia	O	-
de	O	-
la	O	-
etiología	O	-
de	O	-
la	O	-
HAP	O	-
justifica	O	-
futuros	O	-
estudios.	O	-

El	O	-
linfoma	O	-
natural	O	-
killer	O	-
extraganglionar	O	-
de	O	-
células	O	-
T,	O	-
tipo	O	-
nasal	O	-
(	O	-
ENKTL	O	-
)	O	-
es	O	-
un	O	-
subtipo	O	-
raro	O	-
de	O	-
linfoma	O	-
que	O	-
suele	O	-
estar	O	-
asociado	O	-
a	O	-
un	O	-
mal	O	-
pronóstico	O	-
clínico	O	-
.	O	-

Varios	O	-
estudios	O	-
han	O	-
demostrado	O	-
que	O	-
la	O	-
infección	O	-
por	O	-
el	O	-
virus	O	-
de	O	-
la	O	-
hepatitis	O	-
B	O	-
(	O	-
VHB	O	-
)	O	-
puede	O	-
estar	O	-
asociada	O	-
a	O	-
un	O	-
mayor	O	-
riesgo	O	-
de	O	-
linfoma	O	-
no	O	-
Hodgkin	O	-
de	O	-
células	O	-
B	O	-
;	O	-
sin	O	-
embargo	O	-
,	O	-
debido	O	-
a	O	-
la	O	-
rareza	O	-
del	O	-
ENKTL	O	-
,	O	-
se	O	-
sabe	O	-
poco	O	-
sobre	O	-
su	O	-
asociación	O	-
con	O	-
el	O	-
VHB	O	-
.	O	-

Nuestro	O	-
estudio	O	-
tenía	O	-
como	O	-
objetivo	O	-
evaluar	O	-
si	O	-
la	O	-
infección	O	-
por	O	-
el	O	-
VHB	O	-
se	O	-
asociaba	O	-
a	O	-
un	O	-
aumento	O	-
de	O	-
las	O	-
probabilidades	O	-
de	O	-
ENKTL	O	-
.	O	-

Se	O	-
realizó	O	-
un	O	-
estudio	O	-
hospitalario	O	-
de	O	-
casos	O	-
y	O	-
controles	O	-
que	O	-
incluyó	O	-
417	O	-
casos	O	-
de	O	-
ENKTL	O	-
y	O	-
488	O	-
sujetos	O	-
emparejados	O	-
por	O	-
edad	O	-
y	O	-
sexo	O	-
con	O	-
enfermedades	O	-
no	O	-
malignas	O	-
no	O	-
relacionadas	O	-
con	O	-
la	O	-
infección	O	-
por	O	-
el	O	-
VHB	O	-
.	O	-

Se	O	-
realizaron	O	-
análisis	O	-
de	O	-
regresión	O	-
logística	O	-
incondicional	O	-
multivariable	O	-
para	O	-
estimar	O	-
las	O	-
odds	O	-
ratio	O	-
ajustadas	O	-
[	O	-
AOR	O	-
]	O	-
y	O	-
sus	O	-
correspondientes	O	-
intervalos	O	-
de	O	-
confianza	O	-
(	O	-
IC	O	-
)	O	-
del	O	-
95	O	-
%.	O	-

Los	B-Premise	HighQuality
resultados	I-Premise	HighQuality
del	I-Premise	HighQuality
análisis	I-Premise	HighQuality
multivariable	I-Premise	HighQuality
mostraron	I-Premise	HighQuality
que,	I-Premise	HighQuality
tras	I-Premise	HighQuality
el	I-Premise	HighQuality
ajuste	I-Premise	HighQuality
por	I-Premise	HighQuality
un	I-Premise	HighQuality
conjunto	I-Premise	HighQuality
de	I-Premise	HighQuality
factores	I-Premise	HighQuality
de	I-Premise	HighQuality
riesgo	I-Premise	HighQuality
conocidos,	I-Premise	HighQuality
los	I-Premise	HighQuality
pacientes	I-Premise	HighQuality
previamente	I-Premise	HighQuality
infectados	I-Premise	HighQuality
por	I-Premise	HighQuality
el	I-Premise	HighQuality
VHB	I-Premise	HighQuality
(	I-Premise	HighQuality
HBsAg-seronegativo/anti-HBc-seropositivo	I-Premise	HighQuality
)	I-Premise	HighQuality
y	I-Premise	HighQuality
naturalmente	I-Premise	HighQuality
inmunes	I-Premise	HighQuality
al	I-Premise	HighQuality
VHB	I-Premise	HighQuality
(	I-Premise	HighQuality
anti-HBs-seropositivo/anti-HBc-seropositivo	I-Premise	HighQuality
)	I-Premise	HighQuality
tenían	I-Premise	HighQuality
una	I-Premise	HighQuality
probabilidad	I-Premise	HighQuality
significativamente	I-Premise	HighQuality
mayor	I-Premise	HighQuality
de	I-Premise	HighQuality
ser	I-Premise	HighQuality
diagnosticados	I-Premise	HighQuality
de	I-Premise	HighQuality
ENKTL	I-Premise	HighQuality
(	I-Premise	HighQuality
AOR	I-Premise	HighQuality
,	I-Premise	HighQuality
1.497	I-Premise	HighQuality
;	I-Premise	HighQuality
95	I-Premise	HighQuality
%	I-Premise	HighQuality
CI	I-Premise	HighQuality
1.098-2.042	I-Premise	HighQuality
,	I-Premise	HighQuality
P=0.033	I-Premise	HighQuality
y	I-Premise	HighQuality
AOR	I-Premise	HighQuality
,	I-Premise	HighQuality
1.871	I-Premise	HighQuality
;	I-Premise	HighQuality
95	I-Premise	HighQuality
%	I-Premise	HighQuality
CI	I-Premise	HighQuality
1.302-2.689	I-Premise	HighQuality
,	I-Premise	HighQuality
P=0.001	I-Premise	HighQuality
,	I-Premise	HighQuality
respectivamente	I-Premise	HighQuality
)	I-Premise	HighQuality
.	I-Premise	HighQuality

Tras	B-Premise	HighQuality
ajustar	I-Premise	HighQuality
por	I-Premise	HighQuality
otros	I-Premise	HighQuality
factores,	I-Premise	HighQuality
se	I-Premise	HighQuality
observaron	I-Premise	HighQuality
probabilidades	I-Premise	HighQuality
significativamente	I-Premise	HighQuality
mayores	I-Premise	HighQuality
de	I-Premise	HighQuality
ser	I-Premise	HighQuality
diagnosticado	I-Premise	HighQuality
de	I-Premise	HighQuality
ENKTL	I-Premise	HighQuality
entre	I-Premise	HighQuality
los	I-Premise	HighQuality
casos	I-Premise	HighQuality
que	I-Premise	HighQuality
declararon	I-Premise	HighQuality
haber	I-Premise	HighQuality
bebido	I-Premise	HighQuality
alguna	I-Premise	HighQuality
vez	I-Premise	HighQuality
alcohol	I-Premise	HighQuality
(	I-Premise	HighQuality
AOR	I-Premise	HighQuality
,	I-Premise	HighQuality
1,675	I-Premise	HighQuality
;	I-Premise	HighQuality
IC	I-Premise	HighQuality
del	I-Premise	HighQuality
95	I-Premise	HighQuality
%:	I-Premise	HighQuality
1,054-2,660	I-Premise	HighQuality
,	I-Premise	HighQuality
P=0,029	I-Premise	HighQuality
)	I-Premise	HighQuality
.	I-Premise	HighQuality

Las	B-Premise	HighQuality
probabilidades	I-Premise	HighQuality
de	I-Premise	HighQuality
diagnóstico	I-Premise	HighQuality
de	I-Premise	HighQuality
ENKTL	I-Premise	HighQuality
no	I-Premise	HighQuality
se	I-Premise	HighQuality
asociaron	I-Premise	HighQuality
significativamente	I-Premise	HighQuality
con	I-Premise	HighQuality
el	I-Premise	HighQuality
grupo	I-Premise	HighQuality
sanguíneo	I-Premise	HighQuality
ABO,	I-Premise	HighQuality
el	I-Premise	HighQuality
hábito	I-Premise	HighQuality
de	I-Premise	HighQuality
fumar	I-Premise	HighQuality
o	I-Premise	HighQuality
los	I-Premise	HighQuality
antecedentes	I-Premise	HighQuality
familiares	I-Premise	HighQuality
de	I-Premise	HighQuality
cáncer.	I-Premise	HighQuality

Los	B-Claim	HighQuality
resultados	I-Claim	HighQuality
de	I-Claim	HighQuality
nuestro	I-Claim	HighQuality
estudio	I-Claim	HighQuality
sugieren	I-Claim	HighQuality
que	I-Claim	HighQuality
los	I-Claim	HighQuality
pacientes	I-Claim	HighQuality
previamente	I-Claim	HighQuality
infectados	I-Claim	HighQuality
por	I-Claim	HighQuality
el	I-Claim	HighQuality
VHB	I-Claim	HighQuality
y	I-Claim	HighQuality
naturalmente	I-Claim	HighQuality
inmunes	I-Claim	HighQuality
al	I-Claim	HighQuality
VHB	I-Claim	HighQuality
tenían	I-Claim	HighQuality
mayores	I-Claim	HighQuality
probabilidades	I-Claim	HighQuality
de	I-Claim	HighQuality
ser	I-Claim	HighQuality
diagnosticados	I-Claim	HighQuality
con	I-Claim	HighQuality
ENKTL	I-Claim	HighQuality
.	I-Claim	HighQuality

Se	O	-
evaluó	O	-
la	O	-
morfología	O	-
de	O	-
la	O	-
ampolla	O	-
y	O	-
el	O	-
efecto	O	-
de	O	-
reducción	O	-
de	O	-
la	O	-
presión	O	-
intraocular	O	-
(PIO)	O	-
de	O	-
la	O	-
trabeculectomía	O	-
con	O	-
ológeno	O	-
en	O	-
comparación	O	-
con	O	-
la	O	-
mitomicina	O	-
C	O	-
(MMC)	O	-
en	O	-
el	O	-
glaucoma	O	-
de	O	-
ángulo	O	-
abierto	O	-
juvenil	O	-
(GAAA).	O	-
Se	O	-
trata	O	-
de	O	-
un	O	-
estudio	O	-
comparativo	O	-
prospectivo	O	-
de	O	-
intervención	O	-
realizado	O	-
en	O	-
40	O	-
ojos	O	-
(20	O	-
pacientes)	O	-
con	O	-
GAAA	O	-
no	O	-
controlado	O	-
médicamente,	O	-
operando	O	-
aleatoriamente	O	-
un	O	-
ojo	O	-
para	O	-
trabeculectomía	O	-
con	O	-
ológeno	O	-
(grupo	O	-
A:	O	-
20	O	-
ojos)	O	-
y	O	-
el	O	-
otro	O	-
con	O	-
MMC	O	-
(grupo	O	-
B:	O	-
20	O	-
ojos).	O	-

La	O	-
medición	O	-
de	O	-
la	O	-
PIO	O	-
,	O	-
la	O	-
perimetría	O	-
estándar	O	-
SITA	O	-
,	O	-
y	O	-
la	O	-
tomografía	O	-
de	O	-
coherencia	O	-
óptica	O	-
(	O	-
OCT	O	-
)	O	-
de	O	-
dominio	O	-
espectral	O	-
para	O	-
el	O	-
espesor	O	-
de	O	-
la	O	-
capa	O	-
de	O	-
fibras	O	-
nerviosas	O	-
de	O	-
la	O	-
retina	O	-
(	O	-
RNFL	O	-
)	O	-
se	O	-
realizaron	O	-
antes	O	-
y	O	-
después	O	-
de	O	-
la	O	-
operación	O	-
.	O	-

Las	O	-
hemorragias	O	-
postoperatorias	O	-
se	O	-
evaluaron	O	-
clínicamente	O	-
mediante	O	-
el	O	-
sistema	O	-
de	O	-
clasificación	O	-
de	O	-
hemorragias	O	-
de	O	-
Moorfields	O	-
(	O	-
MBGS	O	-
)	O	-
y	O	-
la	O	-
OCT	O	-
del	O	-
segmento	O	-
anterior	O	-
(	O	-
AS-OCT	O	-
)	O	-
.	O	-

Todos	O	-
los	O	-
pacientes	O	-
fueron	O	-
examinados	O	-
hasta	O	-
un	O	-
año	O	-
después	O	-
de	O	-
la	O	-
operación.	O	-

La	B-Premise	HighQuality
media	I-Premise	HighQuality
de	I-Premise	HighQuality
la	I-Premise	HighQuality
PIO	I-Premise	HighQuality
postoperatoria	I-Premise	HighQuality
fue	I-Premise	HighQuality
significativamente	I-Premise	HighQuality
inferior	I-Premise	HighQuality
a	I-Premise	HighQuality
la	I-Premise	HighQuality
media	I-Premise	HighQuality
de	I-Premise	HighQuality
la	I-Premise	HighQuality
PIO	I-Premise	HighQuality
preoperatoria	I-Premise	HighQuality
en	I-Premise	HighQuality
cada	I-Premise	HighQuality
seguimiento	I-Premise	HighQuality
en	I-Premise	HighQuality
cada	I-Premise	HighQuality
grupo.	I-Premise	HighQuality

Al	B-Premise	HighQuality
año,	I-Premise	HighQuality
la	I-Premise	HighQuality
PIO	I-Premise	HighQuality
media	I-Premise	HighQuality
postoperatoria	I-Premise	HighQuality
era	I-Premise	HighQuality
significativamente	I-Premise	HighQuality
menor	I-Premise	HighQuality
en	I-Premise	HighQuality
el	I-Premise	HighQuality
grupo	I-Premise	HighQuality
A.	I-Premise	HighQuality

Según	B-Premise	HighQuality
el	I-Premise	HighQuality
MBGS	I-Premise	HighQuality
,	I-Premise	HighQuality
las	I-Premise	HighQuality
ampollas	I-Premise	HighQuality
con	I-Premise	HighQuality
un	I-Premise	HighQuality
implante	I-Premise	HighQuality
de	I-Premise	HighQuality
óxido	I-Premise	HighQuality
mostraron	I-Premise	HighQuality
una	I-Premise	HighQuality
puntuación	I-Premise	HighQuality
significativamente	I-Premise	HighQuality
mejor	I-Premise	HighQuality
que	I-Premise	HighQuality
las	I-Premise	HighQuality
de	I-Premise	HighQuality
MMC	I-Premise	HighQuality
.	I-Premise	HighQuality

La	B-Premise	HighQuality
AS-OCT	I-Premise	HighQuality
demostró	I-Premise	HighQuality
que	I-Premise	HighQuality
las	I-Premise	HighQuality
hemorragias	I-Premise	HighQuality
inducidas	I-Premise	HighQuality
por	I-Premise	HighQuality
el	I-Premise	HighQuality
ógeno	I-Premise	HighQuality
tenían	I-Premise	HighQuality
significativamente	I-Premise	HighQuality
más	I-Premise	HighQuality
espacios	I-Premise	HighQuality
llenos	I-Premise	HighQuality
de	I-Premise	HighQuality
líquido,	I-Premise	HighQuality
planos	I-Premise	HighQuality
de	I-Premise	HighQuality
hendidura	I-Premise	HighQuality
y	I-Premise	HighQuality
menos	I-Premise	HighQuality
fibrosis.	I-Premise	HighQuality

Ologen	B-Claim	HighQuality
dio	I-Claim	HighQuality
lugar	I-Claim	HighQuality
a	I-Claim	HighQuality
una	I-Claim	HighQuality
menor	I-Claim	HighQuality
PIO	I-Claim	HighQuality
postoperatoria	I-Claim	HighQuality
a	I-Claim	HighQuality
largo	I-Claim	HighQuality
plazo,	I-Claim	HighQuality
una	I-Claim	HighQuality
mejor	I-Claim	HighQuality
morfología	I-Claim	HighQuality
de	I-Claim	HighQuality
la	I-Claim	HighQuality
ampolla	I-Claim	HighQuality
y	I-Claim	HighQuality
menos	I-Claim	HighQuality
complicaciones.	I-Claim	HighQuality

Nuestros	B-Claim	HighQuality
resultados	I-Claim	HighQuality
sugieren	I-Claim	HighQuality
que	I-Claim	HighQuality
el	I-Claim	HighQuality
ologen	I-Claim	HighQuality
puede	I-Claim	HighQuality
ser	I-Claim	HighQuality
una	I-Claim	HighQuality
alternativa	I-Claim	HighQuality
útil	I-Claim	HighQuality
a	I-Claim	HighQuality
la	I-Claim	HighQuality
MMC	I-Claim	HighQuality
en	I-Claim	HighQuality
el	I-Claim	HighQuality
JOAG	I-Claim	HighQuality
.	I-Claim	HighQuality

El	B-Claim	HighQuality
KAMUT	I-Claim	HighQuality
khorasan	I-Claim	HighQuality
es	I-Claim	HighQuality
un	I-Claim	HighQuality
grano	I-Claim	HighQuality
ancestral	I-Claim	HighQuality
con	I-Claim	HighQuality
beneficios	I-Claim	HighQuality
para	I-Claim	HighQuality
la	I-Claim	HighQuality
salud	I-Claim	HighQuality
ampliamente	I-Claim	HighQuality
reconocidos.	I-Claim	HighQuality

El	O	-
objetivo	O	-
de	O	-
este	O	-
estudio	O	-
era	O	-
investigar	O	-
los	O	-
efectos	O	-
de	O	-
una	O	-
dieta	O	-
de	O	-
sustitución	O	-
con	O	-
productos	O	-
de	O	-
trigo	O	-
khorasan	O	-
antiguo	O	-
en	O	-
pacientes	O	-
con	O	-
NAFLD	O	-
,	O	-
en	O	-
comparación	O	-
con	O	-
una	O	-
dieta	O	-
de	O	-
sustitución	O	-
similar	O	-
con	O	-
productos	O	-
de	O	-
control	O	-
elaborados	O	-
con	O	-
trigo	O	-
moderno	O	-
semiintegral	O	-
orgánico	O	-
.	O	-

Se	O	-
incluyeron	O	-
40	O	-
pacientes	O	-
con	O	-
HGNA	O	-
(	O	-
12	O	-
M/28	O	-
F	O	-
;	O	-
edad	O	-
55,2	O	-
±	O	-
10,4	O	-
años	O	-
)	O	-
con	O	-
esteatosis	O	-
hepática	O	-
de	O	-
leve	O	-
a	O	-
moderada.	O	-

El	O	-
diseño	O	-
experimental	O	-
fue	O	-
un	O	-
estudio	O	-
aleatorio,	O	-
doble	O	-
ciego	O	-
y	O	-
de	O	-
brazos	O	-
paralelos	O	-
con	O	-
20	O	-
participantes	O	-
asignados	O	-
a	O	-
consumir	O	-
KAMUT	O	-
khorasan	O	-
o	O	-
productos	O	-
de	O	-
trigo	O	-
de	O	-
control	O	-
(	O	-
pasta,	O	-
pan,	O	-
galletas	O	-
saladas,	O	-
galletas	O	-
)	O	-
durante	O	-
un	O	-
período	O	-
de	O	-
3	O	-
meses	O	-
.	O	-

Se	O	-
realizaron	O	-
mediciones	O	-
antropométricas,	O	-
análisis	O	-
de	O	-
sangre	O	-
y	O	-
ecografías	O	-
al	O	-
principio	O	-
y	O	-
al	O	-
final	O	-
de	O	-
cada	O	-
intervención	O	-
dietética.	O	-

Tras	B-Premise	HighQuality
la	I-Premise	HighQuality
aplicación	I-Premise	HighQuality
de	I-Premise	HighQuality
un	I-Premise	HighQuality
modelo	I-Premise	HighQuality
lineal	I-Premise	HighQuality
general	I-Premise	HighQuality
de	I-Premise	HighQuality
medidas	I-Premise	HighQuality
repetidas	I-Premise	HighQuality
ajustado	I-Premise	HighQuality
a	I-Premise	HighQuality
los	I-Premise	HighQuality
datos	I-Premise	HighQuality
demográficos	I-Premise	HighQuality
de	I-Premise	HighQuality
referencia,	I-Premise	HighQuality
los	I-Premise	HighQuality
factores	I-Premise	HighQuality
de	I-Premise	HighQuality
riesgo	I-Premise	HighQuality
y	I-Premise	HighQuality
la	I-Premise	HighQuality
medicación,	I-Premise	HighQuality
la	I-Premise	HighQuality
alanina	I-Premise	HighQuality
aminotransferasa	I-Premise	HighQuality
(	I-Premise	HighQuality
ALT	I-Premise	HighQuality
)	I-Premise	HighQuality
se	I-Premise	HighQuality
redujo	I-Premise	HighQuality
significativamente	I-Premise	HighQuality
en	I-Premise	HighQuality
un	I-Premise	HighQuality
12	I-Premise	HighQuality
%,	I-Premise	HighQuality
la	I-Premise	HighQuality
aspartato	I-Premise	HighQuality
aminotransferasa	I-Premise	HighQuality
(	I-Premise	HighQuality
AST	I-Premise	HighQuality
)	I-Premise	HighQuality
en	I-Premise	HighQuality
un	I-Premise	HighQuality
14	I-Premise	HighQuality
%,	I-Premise	HighQuality
la	I-Premise	HighQuality
fosfatasa	I-Premise	HighQuality
alcalina	I-Premise	HighQuality
(	I-Premise	HighQuality
ALP	I-Premise	HighQuality
)	I-Premise	HighQuality
en	I-Premise	HighQuality
un	I-Premise	HighQuality
8	I-Premise	HighQuality
%	I-Premise	HighQuality
y	I-Premise	HighQuality
el	I-Premise	HighQuality
colesterol	I-Premise	HighQuality
en	I-Premise	HighQuality
un	I-Premise	HighQuality
6	I-Premise	HighQuality
%	I-Premise	HighQuality
sólo	I-Premise	HighQuality
en	I-Premise	HighQuality
el	I-Premise	HighQuality
grupo	I-Premise	HighQuality
de	I-Premise	HighQuality
khorasan	I-Premise	HighQuality
(	I-Premise	HighQuality
p	I-Premise	HighQuality
<	I-Premise	HighQuality
0,05	I-Premise	HighQuality
para	I-Premise	HighQuality
todos	I-Premise	HighQuality
)	I-Premise	HighQuality
.	I-Premise	HighQuality

Del	O	-
mismo	O	-
modo,	O	-
las	O	-
reducciones	O	-
significativas	O	-
del	O	-
factor	O	-
de	O	-
necrosis	O	-
tumoral	O	-
alfa	O	-
proinflamatorio	O	-
circulante	O	-
en	O	-
un	O	-
50	O	-
%,	O	-
del	O	-
antagonista	O	-
del	O	-
receptor	O	-
de	O	-
interleucina	O	-
l	O	-
alfa	O	-
en	O	-
un	O	-
37	O	-
%,	O	-
de	O	-
la	O	-
interleucina	O	-
8	O	-
en	O	-
un	O	-
24	O	-
%	O	-
y	O	-
del	O	-
interferón	O	-
gamma	O	-
en	O	-
un	O	-
24	O	-
%	O	-
fueron	O	-
evidentes	O	-
sólo	O	-
en	O	-
los	O	-
participantes	O	-
que	O	-
consumieron	O	-
los	O	-
productos	O	-
de	O	-
khorasan	O	-
(	O	-
p	O	-
<	O	-
0,05	O	-
para	O	-
todos	O	-
)	O	-
.	O	-

Por	O	-
último,	O	-
se	O	-
observaron	O	-
mejoras	O	-
significativas	O	-
en	O	-
la	O	-
clasificación	O	-
de	O	-
la	O	-
esteatosis	O	-
hepática,	O	-
los	O	-
valores	O	-
del	O	-
índice	O	-
de	O	-
perfusión	O	-
Doppler	O	-
y	O	-
la	O	-
producción	O	-
de	O	-
especies	O	-
reactivas	O	-
del	O	-
oxígeno	O	-
(ROS)	O	-
tras	O	-
el	O	-
consumo	O	-
de	O	-
los	O	-
productos	O	-
de	O	-
khorasan	O	-
y	O	-
de	O	-
control.	O	-

Este	B-Claim	HighQuality
estudio	I-Claim	HighQuality
sugiere	I-Claim	HighQuality
que	I-Claim	HighQuality
una	I-Claim	HighQuality
dieta	I-Claim	HighQuality
de	I-Claim	HighQuality
sustitución	I-Claim	HighQuality
a	I-Claim	HighQuality
corto	I-Claim	HighQuality
plazo	I-Claim	HighQuality
con	I-Claim	HighQuality
productos	I-Claim	HighQuality
antiguos	I-Claim	HighQuality
de	I-Claim	HighQuality
KAMUT	I-Claim	HighQuality
khorasan	I-Claim	HighQuality
es	I-Claim	HighQuality
más	I-Claim	HighQuality
eficaz	I-Claim	HighQuality
para	I-Claim	HighQuality
reducir	I-Claim	HighQuality
los	I-Claim	HighQuality
factores	I-Claim	HighQuality
de	I-Claim	HighQuality
riesgo	I-Claim	HighQuality
metabólico	I-Claim	HighQuality
y	I-Claim	HighQuality
mejorar	I-Claim	HighQuality
el	I-Claim	HighQuality
perfil	I-Claim	HighQuality
hepático	I-Claim	HighQuality
en	I-Claim	HighQuality
pacientes	I-Claim	HighQuality
con	I-Claim	HighQuality
NAFLD	I-Claim	HighQuality
.	I-Claim	HighQuality

El	O	-
papel	O	-
de	O	-
la	O	-
microbiota	O	-
intestinal	O	-
en	O	-
la	O	-
gestión	O	-
de	O	-
la	O	-
diabetes	O	-
se	O	-
muestra	O	-
.	O	-

En	O	-
este	O	-
ensayo	O	-
clínico	O	-
aleatorio	O	-
se	O	-
evaluaron	O	-
los	O	-
efectos	O	-
de	O	-
la	O	-
suplementación	O	-
con	O	-
sinbióticos	O	-
sobre	O	-
la	O	-
insulina	O	-
,	O	-
el	O	-
perfil	O	-
lipídico	O	-
y	O	-
el	O	-
estado	O	-
antioxidante	O	-
entre	O	-
las	O	-
mujeres	O	-
con	O	-
diabetes	O	-
mellitus	O	-
gestacional	O	-
(	O	-
DMG	O	-
)	O	-
.	O	-

Noventa	O	-
mujeres	O	-
embarazadas	O	-
con	O	-
DMG	O	-
fueron	O	-
asignadas	O	-
aleatoriamente	O	-
en	O	-
dos	O	-
grupos	O	-
para	O	-
recibir	O	-
una	O	-
cápsula	O	-
diaria	O	-
de	O	-
sinbióticos	O	-
-	O	-
consistente	O	-
en	O	-
L.	O	-
acidophilus	O	-
,	O	-
L.	O	-
plantarum	O	-
,	O	-
L.	O	-
fermentum	O	-
,	O	-
L.	O	-
gasseri	O	-
(	O	-
1,5-7,0	O	-
×	O	-
109-10	O	-
UFC/g	O	-
)	O	-
-	O	-
con	O	-
fructooligosacáridos	O	-
(	O	-
38,5	O	-
mg	O	-
)	O	-
,	O	-
o	O	-
un	O	-
placebo	O	-
durante	O	-
6	O	-
semanas	O	-
.	O	-

Se	O	-
evaluaron	O	-
la	O	-
glucosa	O	-
plasmática	O	-
en	O	-
ayunas	O	-
(	O	-
FPG	O	-
)	O	-
,	O	-
la	O	-
insulina	O	-
,	O	-
la	O	-
evaluación	O	-
del	O	-
modelo	O	-
de	O	-
homeostasis-resistencia	O	-
a	O	-
la	O	-
insulina	O	-
(	O	-
HOMA-IR	O	-
)	O	-
,	O	-
el	O	-
índice	O	-
cuantitativo	O	-
de	O	-
comprobación	O	-
de	O	-
la	O	-
sensibilidad	O	-
a	O	-
la	O	-
insulina	O	-
(	O	-
QUICKI	O	-
)	O	-
,	O	-
el	O	-
colesterol	O	-
de	O	-
lipoproteínas	O	-
de	O	-
alta	O	-
y	O	-
baja	O	-
densidad	O	-
(	O	-
HDL-C	O	-
,	O	-
LDL-C	O	-
)	O	-
,	O	-
el	O	-
colesterol	O	-
total	O	-
(	O	-
TC	O	-
)	O	-
,	O	-
los	O	-
triglicéridos	O	-
(	O	-
TG	O	-
)	O	-
,	O	-
la	O	-
capacidad	O	-
antioxidante	O	-
total	O	-
(	O	-
TAC	O	-
)	O	-
y	O	-
la	O	-
presión	O	-
arterial	O	-
sistólica	O	-
y	O	-
diastólica	O	-
(	O	-
PAS	O	-
,	O	-
DSP	O	-
)	O	-
antes	O	-
y	O	-
después	O	-
de	O	-
la	O	-
intervención	O	-
.	O	-

No	B-Premise	HighQuality
se	I-Premise	HighQuality
observaron	I-Premise	HighQuality
cambios	I-Premise	HighQuality
significativos	I-Premise	HighQuality
en	I-Premise	HighQuality
los	I-Premise	HighQuality
índices	I-Premise	HighQuality
de	I-Premise	HighQuality
FPG	I-Premise	HighQuality
,	I-Premise	HighQuality
resistencia/sensibilidad	I-Premise	HighQuality
a	I-Premise	HighQuality
la	I-Premise	HighQuality
insulina	I-Premise	HighQuality
,	I-Premise	HighQuality
perfil	I-Premise	HighQuality
lipídico	I-Premise	HighQuality
y	I-Premise	HighQuality
TAC	I-Premise	HighQuality
en	I-Premise	HighQuality
el	I-Premise	HighQuality
grupo	I-Premise	HighQuality
de	I-Premise	HighQuality
sinbióticos	I-Premise	HighQuality
en	I-Premise	HighQuality
comparación	I-Premise	HighQuality
con	I-Premise	HighQuality
el	I-Premise	HighQuality
de	I-Premise	HighQuality
placebo	I-Premise	HighQuality
(	I-Premise	HighQuality
p	I-Premise	HighQuality
>	I-Premise	HighQuality
0,05	I-Premise	HighQuality
)	I-Premise	HighQuality
.	I-Premise	HighQuality

Se	B-Premise	HighQuality
observaron	I-Premise	HighQuality
aumentos	I-Premise	HighQuality
significativos	I-Premise	HighQuality
dentro	I-Premise	HighQuality
del	I-Premise	HighQuality
grupo	I-Premise	HighQuality
para	I-Premise	HighQuality
los	I-Premise	HighQuality
niveles	I-Premise	HighQuality
de	I-Premise	HighQuality
HDL-C	I-Premise	HighQuality
y	I-Premise	HighQuality
TAC	I-Premise	HighQuality
en	I-Premise	HighQuality
el	I-Premise	HighQuality
grupo	I-Premise	HighQuality
de	I-Premise	HighQuality
sinbióticos	I-Premise	HighQuality
(	I-Premise	HighQuality
p	I-Premise	HighQuality
<	I-Premise	HighQuality
0,05	I-Premise	HighQuality
)	I-Premise	HighQuality
.	I-Premise	HighQuality

El	B-Premise	HighQuality
LDL-C	I-Premise	HighQuality
mostró	I-Premise	HighQuality
un	I-Premise	HighQuality
incremento	I-Premise	HighQuality
significativo	I-Premise	HighQuality
en	I-Premise	HighQuality
el	I-Premise	HighQuality
grupo	I-Premise	HighQuality
de	I-Premise	HighQuality
placebo	I-Premise	HighQuality
en	I-Premise	HighQuality
comparación	I-Premise	HighQuality
con	I-Premise	HighQuality
el	I-Premise	HighQuality
inicio	I-Premise	HighQuality
del	I-Premise	HighQuality
estudio	I-Premise	HighQuality
(	I-Premise	HighQuality
6,9	I-Premise	HighQuality
mg/dL	I-Premise	HighQuality
,	I-Premise	HighQuality
p	I-Premise	HighQuality
<	I-Premise	HighQuality
0,05	I-Premise	HighQuality
)	I-Premise	HighQuality
.	I-Premise	HighQuality

La	B-Premise	HighQuality
comparación	I-Premise	HighQuality
entre	I-Premise	HighQuality
grupos	I-Premise	HighQuality
mostró	I-Premise	HighQuality
una	I-Premise	HighQuality
disminución	I-Premise	HighQuality
significativa	I-Premise	HighQuality
de	I-Premise	HighQuality
la	I-Premise	HighQuality
PAS	I-Premise	HighQuality
y	I-Premise	HighQuality
la	I-Premise	HighQuality
PAD	I-Premise	HighQuality
en	I-Premise	HighQuality
el	I-Premise	HighQuality
grupo	I-Premise	HighQuality
de	I-Premise	HighQuality
sinbióticos	I-Premise	HighQuality
en	I-Premise	HighQuality
comparación	I-Premise	HighQuality
con	I-Premise	HighQuality
el	I-Premise	HighQuality
placebo	I-Premise	HighQuality
(	I-Premise	HighQuality
-2,5	I-Premise	HighQuality
frente	I-Premise	HighQuality
a	I-Premise	HighQuality
8,6	I-Premise	HighQuality
mmHg	I-Premise	HighQuality
,	I-Premise	HighQuality
y	I-Premise	HighQuality
-1,8	I-Premise	HighQuality
frente	I-Premise	HighQuality
a	I-Premise	HighQuality
2,1	I-Premise	HighQuality
mmHg	I-Premise	HighQuality
,	I-Premise	HighQuality
p	I-Premise	HighQuality
<	I-Premise	HighQuality
0,05	I-Premise	HighQuality
)	I-Premise	HighQuality
.	I-Premise	HighQuality

Los	B-Claim	HighQuality
resultados	I-Claim	HighQuality
mostraron	I-Claim	HighQuality
que,	I-Claim	HighQuality
en	I-Claim	HighQuality
las	I-Claim	HighQuality
mujeres	I-Claim	HighQuality
con	I-Claim	HighQuality
DMG,	I-Claim	HighQuality
la	I-Claim	HighQuality
suplementación	I-Claim	HighQuality
con	I-Claim	HighQuality
sinbióticos	I-Claim	HighQuality
no	I-Claim	HighQuality
tuvo	I-Claim	HighQuality
ningún	I-Claim	HighQuality
efecto	I-Claim	HighQuality
sobre	I-Claim	HighQuality
los	I-Claim	HighQuality
índices	I-Claim	HighQuality
de	I-Claim	HighQuality
FPG	I-Claim	HighQuality
y	I-Claim	HighQuality
de	I-Claim	HighQuality
resistencia/sensibilidad	I-Claim	HighQuality
a	I-Claim	HighQuality
la	I-Claim	HighQuality
insulina.	I-Claim	HighQuality

El	B-Claim	HighQuality
perfil	I-Claim	HighQuality
lipídico	I-Claim	HighQuality
y	I-Claim	HighQuality
el	I-Claim	HighQuality
estado	I-Claim	HighQuality
del	I-Claim	HighQuality
TAC	I-Claim	HighQuality
pueden	I-Claim	HighQuality
verse	I-Claim	HighQuality
afectados	I-Claim	HighQuality
por	I-Claim	HighQuality
la	I-Claim	HighQuality
suplementación	I-Claim	HighQuality
con	I-Claim	HighQuality
sinbióticos.	I-Claim	HighQuality

Los	B-Claim	HighQuality
simbióticos	I-Claim	HighQuality
son	I-Claim	HighQuality
eficaces	I-Claim	HighQuality
para	I-Claim	HighQuality
reducir	I-Claim	HighQuality
la	I-Claim	HighQuality
presión	I-Claim	HighQuality
arterial	I-Claim	HighQuality
en	I-Claim	HighQuality
las	I-Claim	HighQuality
mujeres	I-Claim	HighQuality
con	I-Claim	HighQuality
diabetes	I-Claim	HighQuality
gestacional.	I-Claim	HighQuality

La	O	-
hepatotoxicidad	O	-
asociada	O	-
a	O	-
la	O	-
terapia	O	-
preventiva	O	-
con	O	-
isoniazida	O	-
(	O	-
IPT	O	-
)	O	-
y	O	-
a	O	-
la	O	-
terapia	O	-
antirretroviral	O	-
(	O	-
ART	O	-
)	O	-
no	O	-
ha	O	-
sido	O	-
bien	O	-
estudiada	O	-
en	O	-
personas	O	-
gravemente	O	-
inmunodeprimidas	O	-
con	O	-
VIH	O	-
.	O	-

Nuestro	O	-
objetivo	O	-
fue	O	-
determinar	O	-
los	O	-
factores	O	-
de	O	-
riesgo	O	-
de	O	-
hepatotoxicidad	O	-
en	O	-
individuos	O	-
severamente	O	-
inmunosuprimidos	O	-
que	O	-
toman	O	-
IPT	O	-
y	O	-
ART	O	-
.	O	-

Estudio	O	-
multicéntrico	O	-
en	O	-
entornos	O	-
de	O	-
recursos	O	-
limitados	O	-
con	O	-
alta	O	-
carga	O	-
de	O	-
tuberculosis	O	-
.	O	-

Se	O	-
realizó	O	-
un	O	-
análisis	O	-
secundario	O	-
de	O	-
los	O	-
datos	O	-
de	O	-
un	O	-
brazo	O	-
aleatorizado	O	-
del	O	-
ensayo	O	-
REMEMBER.	O	-

El	O	-
análisis	O	-
incluye	O	-
a	O	-
los	O	-
participantes	O	-
con	O	-
recuentos	O	-
de	O	-
células	O	-
CD4	O	-
previos	O	-
a	O	-
la	O	-
TARGA	O	-
de	O	-
<	O	-
50	O	-
células/μL	O	-
que	O	-
reciben	O	-
TPI	O	-
y	O	-
TARGA	O	-
durante	O	-
24	O	-
semanas	O	-
.	O	-

La	O	-
hepatotoxicidad	O	-
se	O	-
definió	O	-
como	O	-
la	O	-
elevación	O	-
de	O	-
la	O	-
aspartato	O	-
aminotransferasa	O	-
(	O	-
AST	O	-
)	O	-
o	O	-
de	O	-
la	O	-
alanina	O	-
aminotransferasa	O	-
(	O	-
ALT	O	-
)	O	-
>	O	-
5	O	-
×	O	-
límite	O	-
superior	O	-
de	O	-
la	O	-
normalidad	O	-
o	O	-
la	O	-
hepatitis	O	-
sintomática	O	-
durante	O	-
el	O	-
TPI	O	-
y	O	-
el	O	-
TAR	O	-
.	O	-

Se	O	-
utilizó	O	-
la	O	-
regresión	O	-
logística	O	-
para	O	-
identificar	O	-
los	O	-
factores	O	-
de	O	-
riesgo	O	-
de	O	-
base	O	-
para	O	-
la	O	-
hepatotoxicidad	O	-
.	O	-

El	O	-
tiempo	O	-
hasta	O	-
la	O	-
aparición	O	-
de	O	-
la	O	-
hepatotoxicidad	O	-
se	O	-
estimó	O	-
mediante	O	-
el	O	-
método	O	-
de	O	-
Kaplan-Meier.	O	-

De	B-Premise	HighQuality
los	I-Premise	HighQuality
426	I-Premise	HighQuality
participantes	I-Premise	HighQuality
(53%	I-Premise	HighQuality
hombres,	I-Premise	HighQuality
mediana	I-Premise	HighQuality
de	I-Premise	HighQuality
edad	I-Premise	HighQuality
de	I-Premise	HighQuality
35	I-Premise	HighQuality
años,	I-Premise	HighQuality
mediana	I-Premise	HighQuality
de	I-Premise	HighQuality
recuento	I-Premise	HighQuality
de	I-Premise	HighQuality
CD4	I-Premise	HighQuality
de	I-Premise	HighQuality
19	I-Premise	HighQuality
células/µl),	I-Premise	HighQuality
31	I-Premise	HighQuality
desarrollaron	I-Premise	HighQuality
hepatotoxicidad	I-Premise	HighQuality
(7,3%).	I-Premise	HighQuality

El	B-Premise	HighQuality
aumento	I-Premise	HighQuality
de	I-Premise	HighQuality
la	I-Premise	HighQuality
AST/ALT	I-Premise	HighQuality
antes	I-Premise	HighQuality
del	I-Premise	HighQuality
tratamiento	I-Premise	HighQuality
(	I-Premise	HighQuality
odds	I-Premise	HighQuality
ratio	I-Premise	HighQuality
[	I-Premise	HighQuality
OR	I-Premise	HighQuality
]	I-Premise	HighQuality
3,6	I-Premise	HighQuality
,	I-Premise	HighQuality
intervalo	I-Premise	HighQuality
de	I-Premise	HighQuality
confianza	I-Premise	HighQuality
del	I-Premise	HighQuality
95	I-Premise	HighQuality
%	I-Premise	HighQuality
[	I-Premise	HighQuality
CI	I-Premise	HighQuality
]	I-Premise	HighQuality
:	I-Premise	HighQuality
1,7	I-Premise	HighQuality
a	I-Premise	HighQuality
7,7	I-Premise	HighQuality
)	I-Premise	HighQuality
y	I-Premise	HighQuality
la	I-Premise	HighQuality
seropositividad	I-Premise	HighQuality
al	I-Premise	HighQuality
antígeno	I-Premise	HighQuality
de	I-Premise	HighQuality
superficie	I-Premise	HighQuality
de	I-Premise	HighQuality
la	I-Premise	HighQuality
hepatitis	I-Premise	HighQuality
B	I-Premise	HighQuality
(	I-Premise	HighQuality
HBsAg	I-Premise	HighQuality
)	I-Premise	HighQuality
al	I-Premise	HighQuality
inicio	I-Premise	HighQuality
del	I-Premise	HighQuality
tratamiento	I-Premise	HighQuality
(	I-Premise	HighQuality
OR	I-Premise	HighQuality
4,7	I-Premise	HighQuality
,	I-Premise	HighQuality
IC	I-Premise	HighQuality
del	I-Premise	HighQuality
95	I-Premise	HighQuality
%	I-Premise	HighQuality
:	I-Premise	HighQuality
1,7	I-Premise	HighQuality
a	I-Premise	HighQuality
12,9	I-Premise	HighQuality
)	I-Premise	HighQuality
se	I-Premise	HighQuality
asociaron	I-Premise	HighQuality
significativamente	I-Premise	HighQuality
con	I-Premise	HighQuality
un	I-Premise	HighQuality
mayor	I-Premise	HighQuality
riesgo	I-Premise	HighQuality
de	I-Premise	HighQuality
desarrollar	I-Premise	HighQuality
hepatotoxicidad	I-Premise	HighQuality
.	I-Premise	HighQuality

Los	B-Premise	HighQuality
participantes	I-Premise	HighQuality
con	I-Premise	HighQuality
AST/ALT	I-Premise	HighQuality
elevada	I-Premise	HighQuality
y	I-Premise	HighQuality
HBsAg	I-Premise	HighQuality
positivo	I-Premise	HighQuality
tenían	I-Premise	HighQuality
un	I-Premise	HighQuality
riesgo	I-Premise	HighQuality
mayor	I-Premise	HighQuality
(	I-Premise	HighQuality
OR	I-Premise	HighQuality
19,9	I-Premise	HighQuality
,	I-Premise	HighQuality
IC	I-Premise	HighQuality
95	I-Premise	HighQuality
%	I-Premise	HighQuality
:	I-Premise	HighQuality
5,3	I-Premise	HighQuality
a	I-Premise	HighQuality
74,3	I-Premise	HighQuality
)	I-Premise	HighQuality
y	I-Premise	HighQuality
una	I-Premise	HighQuality
aparición	I-Premise	HighQuality
más	I-Premise	HighQuality
temprana	I-Premise	HighQuality
de	I-Premise	HighQuality
la	I-Premise	HighQuality
hepatotoxicidad	I-Premise	HighQuality
que	I-Premise	HighQuality
los	I-Premise	HighQuality
participantes	I-Premise	HighQuality
que	I-Premise	HighQuality
no	I-Premise	HighQuality
tenían	I-Premise	HighQuality
estas	I-Premise	HighQuality
condiciones	I-Premise	HighQuality
al	I-Premise	HighQuality
inicio	I-Premise	HighQuality
del	I-Premise	HighQuality
estudio	I-Premise	HighQuality
.	I-Premise	HighQuality

La	B-Claim	HighQuality
incidencia	I-Claim	HighQuality
de	I-Claim	HighQuality
hepatotoxicidad	I-Claim	HighQuality
durante	I-Claim	HighQuality
el	I-Claim	HighQuality
TPI	I-Claim	HighQuality
y	I-Claim	HighQuality
el	I-Claim	HighQuality
TAR	I-Claim	HighQuality
fue	I-Claim	HighQuality
elevada.	I-Claim	HighQuality

Los	B-Claim	HighQuality
individuos	I-Claim	HighQuality
gravemente	I-Claim	HighQuality
inmunodeprimidos	I-Claim	HighQuality
con	I-Claim	HighQuality
una	I-Claim	HighQuality
AST/ALT	I-Claim	HighQuality
elevada	I-Claim	HighQuality
antes	I-Claim	HighQuality
del	I-Claim	HighQuality
tratamiento	I-Claim	HighQuality
o	I-Claim	HighQuality
con	I-Claim	HighQuality
seropositividad	I-Claim	HighQuality
al	I-Claim	HighQuality
HBsAg	I-Claim	HighQuality
necesitan	I-Claim	HighQuality
una	I-Claim	HighQuality
vigilancia	I-Claim	HighQuality
más	I-Claim	HighQuality
estrecha	I-Claim	HighQuality
para	I-Claim	HighQuality
detectar	I-Claim	HighQuality
la	I-Claim	HighQuality
hepatotoxicidad.	I-Claim	HighQuality

Determinar	O	-
los	O	-
predictores	O	-
de	O	-
eventos	O	-
adversos	O	-
graves	O	-
(	O	-
SAE	O	-
)	O	-
que	O	-
implican	O	-
síncope	O	-
,	O	-
hipotensión	O	-
y	O	-
caídas	O	-
,	O	-
con	O	-
especial	O	-
atención	O	-
a	O	-
la	O	-
edad	O	-
,	O	-
en	O	-
el	O	-
ensayo	O	-
de	O	-
intervención	O	-
sobre	O	-
la	O	-
presión	O	-
arterial	O	-
sistólica	O	-
.	O	-

Consultas	O	-
académicas	O	-
y	O	-
privadas	O	-
de	O	-
todo	O	-
Estados	O	-
Unidos	O	-
(	O	-
N	O	-
=	O	-
102	O	-
)	O	-
.	O	-

Adultos	O	-
de	O	-
50	O	-
años	O	-
o	O	-
más	O	-
con	O	-
una	O	-
presión	O	-
arterial	O	-
sistólica	O	-
(	O	-
PAS	O	-
)	O	-
de	O	-
130	O	-
a	O	-
180	O	-
mmHg	O	-
con	O	-
alto	O	-
riesgo	O	-
de	O	-
eventos	O	-
de	O	-
enfermedades	O	-
cardiovasculares	O	-
,	O	-
pero	O	-
sin	O	-
diabetes	O	-
,	O	-
antecedentes	O	-
de	O	-
accidente	O	-
cerebrovascular	O	-
,	O	-
insuficiencia	O	-
cardíaca	O	-
sintomática	O	-
o	O	-
fracción	O	-
de	O	-
eyección	O	-
inferior	O	-
al	O	-
35%	O	-
,	O	-
demencia	O	-
,	O	-
o	O	-
PAS	O	-
de	O	-
pie	O	-
inferior	O	-
a	O	-
110	O	-
mmHg	O	-
(	O	-
N	O	-
=	O	-
9.361	O	-
)	O	-
.	O	-

Tratamiento	O	-
de	O	-
la	O	-
PAS	O	-
hasta	O	-
un	O	-
objetivo	O	-
inferior	O	-
a	O	-
120	O	-
mmHg	O	-
o	O	-
140	O	-
mmHg	O	-
.	O	-

Los	O	-
resultados	O	-
fueron	O	-
los	O	-
EAE	O	-
relacionados	O	-
con	O	-
el	O	-
síncope,	O	-
la	O	-
hipotensión	O	-
y	O	-
las	O	-
caídas.	O	-

Los	O	-
predictores	O	-
fueron	O	-
la	O	-
asignación	O	-
del	O	-
tratamiento,	O	-
las	O	-
características	O	-
demográficas,	O	-
las	O	-
comorbilidades,	O	-
las	O	-
mediciones	O	-
iniciales	O	-
y	O	-
el	O	-
uso	O	-
inicial	O	-
de	O	-
medicamentos	O	-
cardiovasculares.	O	-

Ciento	O	-
setenta	O	-
y	O	-
dos	O	-
(	O	-
1,8	O	-
%	O	-
)	O	-
participantes	O	-
tuvieron	O	-
EAS	O	-
relacionadas	O	-
con	O	-
síncopes,	O	-
155	O	-
(	O	-
1,6	O	-
%	O	-
)	O	-
con	O	-
hipotensión	O	-
y	O	-
203	O	-
(	O	-
2,2	O	-
%	O	-
)	O	-
con	O	-
caídas.	O	-

La	B-Premise	HighQuality
aleatorización	I-Premise	HighQuality
para	I-Premise	HighQuality
el	I-Premise	HighQuality
control	I-Premise	HighQuality
intensivo	I-Premise	HighQuality
de	I-Premise	HighQuality
la	I-Premise	HighQuality
PAS	I-Premise	HighQuality
se	I-Premise	HighQuality
asoció	I-Premise	HighQuality
con	I-Premise	HighQuality
un	I-Premise	HighQuality
mayor	I-Premise	HighQuality
riesgo	I-Premise	HighQuality
de	I-Premise	HighQuality
un	I-Premise	HighQuality
EAS	I-Premise	HighQuality
que	I-Premise	HighQuality
incluyera	I-Premise	HighQuality
hipotensión	I-Premise	HighQuality
(	I-Premise	HighQuality
cociente	I-Premise	HighQuality
de	I-Premise	HighQuality
riesgos	I-Premise	HighQuality
instantáneos	I-Premise	HighQuality
(	I-Premise	HighQuality
CRI	I-Premise	HighQuality
)	I-Premise	HighQuality
=	I-Premise	HighQuality
1,67	I-Premise	HighQuality
,	I-Premise	HighQuality
intervalo	I-Premise	HighQuality
de	I-Premise	HighQuality
confianza	I-Premise	HighQuality
(	I-Premise	HighQuality
IC	I-Premise	HighQuality
)	I-Premise	HighQuality
del	I-Premise	HighQuality
95	I-Premise	HighQuality
%	I-Premise	HighQuality
=	I-Premise	HighQuality
1,21-2,32	I-Premise	HighQuality
,	I-Premise	HighQuality
p	I-Premise	HighQuality
=	I-Premise	HighQuality
0,002	I-Premise	HighQuality
)	I-Premise	HighQuality
,	I-Premise	HighQuality
y	I-Premise	HighQuality
posiblemente	I-Premise	HighQuality
síncope	I-Premise	HighQuality
(	I-Premise	HighQuality
CRI	I-Premise	HighQuality
=	I-Premise	HighQuality
1,32	I-Premise	HighQuality
,	I-Premise	HighQuality
IC	I-Premise	HighQuality
del	I-Premise	HighQuality
95	I-Premise	HighQuality
%	I-Premise	HighQuality
=	I-Premise	HighQuality
0,98-1,79	I-Premise	HighQuality
,	I-Premise	HighQuality
p	I-Premise	HighQuality
=	I-Premise	HighQuality
0,07	I-Premise	HighQuality
)	I-Premise	HighQuality
,	I-Premise	HighQuality
pero	I-Premise	HighQuality
no	I-Premise	HighQuality
caídas	I-Premise	HighQuality
(	I-Premise	HighQuality
CRI	I-Premise	HighQuality
=	I-Premise	HighQuality
0,98	I-Premise	HighQuality
,	I-Premise	HighQuality
IC	I-Premise	HighQuality
del	I-Premise	HighQuality
95	I-Premise	HighQuality
%	I-Premise	HighQuality
=	I-Premise	HighQuality
0,75-1,29	I-Premise	HighQuality
,	I-Premise	HighQuality
p	I-Premise	HighQuality
=	I-Premise	HighQuality
0,90	I-Premise	HighQuality
)	I-Premise	HighQuality
.	I-Premise	HighQuality

El	B-Premise	HighQuality
riesgo	I-Premise	HighQuality
de	I-Premise	HighQuality
los	I-Premise	HighQuality
tres	I-Premise	HighQuality
resultados	I-Premise	HighQuality
fue	I-Premise	HighQuality
mayor	I-Premise	HighQuality
para	I-Premise	HighQuality
los	I-Premise	HighQuality
participantes	I-Premise	HighQuality
con	I-Premise	HighQuality
enfermedad	I-Premise	HighQuality
renal	I-Premise	HighQuality
crónica	I-Premise	HighQuality
o	I-Premise	HighQuality
fragilidad	I-Premise	HighQuality
.	I-Premise	HighQuality

La	B-Premise	HighQuality
edad	I-Premise	HighQuality
avanzada	I-Premise	HighQuality
también	I-Premise	HighQuality
se	I-Premise	HighQuality
asoció	I-Premise	HighQuality
con	I-Premise	HighQuality
un	I-Premise	HighQuality
mayor	I-Premise	HighQuality
riesgo	I-Premise	HighQuality
de	I-Premise	HighQuality
síncope,	I-Premise	HighQuality
hipotensión	I-Premise	HighQuality
y	I-Premise	HighQuality
caídas,	I-Premise	HighQuality
pero	I-Premise	HighQuality
no	I-Premise	HighQuality
hubo	I-Premise	HighQuality
interacción	I-Premise	HighQuality
entre	I-Premise	HighQuality
la	I-Premise	HighQuality
edad	I-Premise	HighQuality
y	I-Premise	HighQuality
el	I-Premise	HighQuality
tratamiento	I-Premise	HighQuality
para	I-Premise	HighQuality
ninguno	I-Premise	HighQuality
de	I-Premise	HighQuality
los	I-Premise	HighQuality
resultados	I-Premise	HighQuality
de	I-Premise	HighQuality
los	I-Premise	HighQuality
EAE.	I-Premise	HighQuality

Los	B-Claim	HighQuality
participantes	I-Claim	HighQuality
asignados	I-Claim	HighQuality
al	I-Claim	HighQuality
azar	I-Claim	HighQuality
al	I-Claim	HighQuality
control	I-Claim	HighQuality
intensivo	I-Claim	HighQuality
de	I-Claim	HighQuality
la	I-Claim	HighQuality
PAS	I-Claim	HighQuality
tuvieron	I-Claim	HighQuality
mayor	I-Claim	HighQuality
riesgo	I-Claim	HighQuality
de	I-Claim	HighQuality
hipotensión	I-Claim	HighQuality
y	I-Claim	HighQuality
posiblemente	I-Claim	HighQuality
de	I-Claim	HighQuality
síncope	I-Claim	HighQuality
,	I-Claim	HighQuality
pero	I-Claim	HighQuality
no	I-Claim	HighQuality
de	I-Claim	HighQuality
caídas	I-Claim	HighQuality
.	I-Claim	HighQuality

El	O	-
mayor	O	-
riesgo	O	-
de	O	-
desarrollar	O	-
estos	O	-
eventos	O	-
asociado	O	-
al	O	-
tratamiento	O	-
intensivo	O	-
no	O	-
varió	O	-
según	O	-
la	O	-
edad	O	-
.	O	-

La	B-Claim	HighQuality
resección	I-Claim	HighQuality
anterior	I-Claim	HighQuality
baja	I-Claim	HighQuality
con	I-Claim	HighQuality
anastomosis	I-Claim	HighQuality
coloanal	I-Claim	HighQuality
evita	I-Claim	HighQuality
un	I-Claim	HighQuality
estoma	I-Claim	HighQuality
definitivo	I-Claim	HighQuality
en	I-Claim	HighQuality
pacientes	I-Claim	HighQuality
con	I-Claim	HighQuality
cáncer	I-Claim	HighQuality
rectal	I-Claim	HighQuality
distal	I-Claim	HighQuality
.	I-Claim	HighQuality

Sin	B-Premise	HighQuality
embargo,	I-Premise	HighQuality
en	I-Premise	HighQuality
el	I-Premise	HighQuality
postoperatorio	I-Premise	HighQuality
se	I-Premise	HighQuality
observan	I-Premise	HighQuality
con	I-Premise	HighQuality
frecuencia	I-Premise	HighQuality
la	I-Premise	HighQuality
necesidad	I-Premise	HighQuality
imperiosa	I-Premise	HighQuality
de	I-Premise	HighQuality
defecar,	I-Premise	HighQuality
la	I-Premise	HighQuality
fragmentación	I-Premise	HighQuality
de	I-Premise	HighQuality
las	I-Premise	HighQuality
heces,	I-Premise	HighQuality
la	I-Premise	HighQuality
prolongación	I-Premise	HighQuality
de	I-Premise	HighQuality
las	I-Premise	HighQuality
sesiones	I-Premise	HighQuality
de	I-Premise	HighQuality
defecación	I-Premise	HighQuality
y	I-Premise	HighQuality
pequeños	I-Premise	HighQuality
problemas	I-Premise	HighQuality
de	I-Premise	HighQuality
incontinencia	I-Premise	HighQuality
que	I-Premise	HighQuality
afectan	I-Premise	HighQuality
negativamente	I-Premise	HighQuality
a	I-Premise	HighQuality
la	I-Premise	HighQuality
calidad	I-Premise	HighQuality
de	I-Premise	HighQuality
vida.	I-Premise	HighQuality

Por	O	-
lo	O	-
tanto,	O	-
la	O	-
bolsa	O	-
en	O	-
J	O	-
del	O	-
colon	O	-
se	O	-
construyó	O	-
originalmente	O	-
para	O	-
crear	O	-
un	O	-
depósito	O	-
de	O	-
heces.	O	-

En	O	-
un	O	-
estudio	O	-
aleatorio	O	-
y	O	-
prospectivo,	O	-
se	O	-
probó	O	-
la	O	-
función	O	-
y	O	-
la	O	-
continencia	O	-
de	O	-
la	O	-
bolsa	O	-
colónica	O	-
corta	O	-
(5	O	-
cm)	O	-
frente	O	-
a	O	-
la	O	-
anastomosis	O	-
coloanal	O	-
recta.	O	-

Durante	O	-
un	O	-
período	O	-
de	O	-
30	O	-
meses,	O	-
se	O	-
incluyeron	O	-
74	O	-
pacientes	O	-
consecutivos	O	-
(55	O	-
hombres)	O	-
con	O	-
cáncer	O	-
de	O	-
recto	O	-
en	O	-
el	O	-
tercio	O	-
inferior	O	-
y	O	-
medio	O	-
del	O	-
recto	O	-
y	O	-
se	O	-
distribuyeron	O	-
aleatoriamente	O	-
en	O	-
dos	O	-
grupos.	O	-

La	O	-
anastomosis	O	-
se	O	-
realizó	O	-
como	O	-
una	O	-
anastomosis	O	-
coloanal	O	-
o	O	-
como	O	-
una	O	-
anastomosis	O	-
colon-bolsa-anal.	O	-

El	O	-
procedimiento	O	-
quirúrgico	O	-
estandarizado	O	-
incluyó	O	-
la	O	-
movilización	O	-
del	O	-
hemicolon	O	-
izquierdo	O	-
,	O	-
la	O	-
ligadura	O	-
central	O	-
de	O	-
la	O	-
arteria	O	-
y	O	-
vena	O	-
mesentérica	O	-
inferior	O	-
,	O	-
la	O	-
disección	O	-
de	O	-
los	O	-
ganglios	O	-
linfáticos	O	-
preaórticos	O	-
,	O	-
la	O	-
preservación	O	-
del	O	-
nervio	O	-
autónomo	O	-
y	O	-
la	O	-
escisión	O	-
mesorrectal	O	-
total	O	-
.	O	-

La	O	-
anastomosis	O	-
se	O	-
realizó	O	-
en	O	-
el	O	-
canal	O	-
anal	O	-
superior	O	-
o	O	-
a	O	-
nivel	O	-
interesfinteriano.	O	-

Todos	O	-
los	O	-
pacientes	O	-
fueron	O	-
evaluados	O	-
en	O	-
el	O	-
preoperatorio	O	-
y	O	-
en	O	-
el	O	-
postoperatorio	O	-
de	O	-
seis	O	-
meses	O	-
para	O	-
la	O	-
continencia	O	-
fecal	O	-
,	O	-
incluyendo	O	-
la	O	-
manometría	O	-
del	O	-
esfínter	O	-
y	O	-
los	O	-
hábitos	O	-
de	O	-
defecación.	O	-

Además,	O	-
la	O	-
calidad	O	-
de	O	-
vida	O	-
se	O	-
determinó	O	-
mediante	O	-
el	O	-
uso	O	-
de	O	-
un	O	-
cuestionario	O	-
estandarizado	O	-
(	O	-
Organización	O	-
Europea	O	-
para	O	-
la	O	-
Investigación	O	-
y	O	-
el	O	-
Tratamiento	O	-
del	O	-
Cáncer	O	-
,	O	-
EORTC-QLQ-C30	O	-
)	O	-
.	O	-

Treinta	O	-
y	O	-
siete	O	-
pacientes	O	-
fueron	O	-
asignados	O	-
al	O	-
azar	O	-
a	O	-
cada	O	-
grupo.	O	-

En	O	-
general,	O	-
los	O	-
problemas	O	-
de	O	-
continencia	O	-
para	O	-
líquidos	O	-
o	O	-
gases	O	-
se	O	-
produjeron	O	-
con	O	-
menos	O	-
frecuencia	O	-
en	O	-
el	O	-
grupo	O	-
de	O	-
la	O	-
bolsa	O	-
J	O	-
colónica	O	-
6	O	-
meses	O	-
después	O	-
de	O	-
la	O	-
cirugía.	O	-

La	B-Premise	HighQuality
frecuencia	I-Premise	HighQuality
de	I-Premise	HighQuality
las	I-Premise	HighQuality
deposiciones	I-Premise	HighQuality
fue	I-Premise	HighQuality
menor	I-Premise	HighQuality
en	I-Premise	HighQuality
el	I-Premise	HighQuality
grupo	I-Premise	HighQuality
de	I-Premise	HighQuality
la	I-Premise	HighQuality
bolsa	I-Premise	HighQuality
J	I-Premise	HighQuality
(	I-Premise	HighQuality
2,5	I-Premise	HighQuality
al	I-Premise	HighQuality
día	I-Premise	HighQuality
)	I-Premise	HighQuality
que	I-Premise	HighQuality
en	I-Premise	HighQuality
el	I-Premise	HighQuality
grupo	I-Premise	HighQuality
coloanal	I-Premise	HighQuality
(	I-Premise	HighQuality
4,7	I-Premise	HighQuality
al	I-Premise	HighQuality
día	I-Premise	HighQuality
)	I-Premise	HighQuality
.	I-Premise	HighQuality

Es	O	-
importante	O	-
destacar	O	-
que,	O	-
en	O	-
un	O	-
estudio	O	-
manométrico	O	-
en	O	-
el	O	-
mismo	O	-
punto	O	-
postoperatorio,	O	-
la	O	-
capacidad	O	-
neorrectal	O	-
disminuyó	O	-
en	O	-
un	O	-
grado	O	-
similar	O	-
en	O	-
ambos	O	-
grupos	O	-
en	O	-
comparación	O	-
con	O	-
el	O	-
volumen	O	-
rectal	O	-
preoperatorio.	O	-

Por	O	-
lo	O	-
tanto,	O	-
el	B-Premise	HighQuality
efecto	I-Premise	HighQuality
de	I-Premise	HighQuality
reserva	I-Premise	HighQuality
esperado	I-Premise	HighQuality
y	I-Premise	HighQuality
postulado	I-Premise	HighQuality
no	I-Premise	HighQuality
se	I-Premise	HighQuality
pudo	I-Premise	HighQuality
lograr	I-Premise	HighQuality
mediante	I-Premise	HighQuality
la	I-Premise	HighQuality
formación	I-Premise	HighQuality
de	I-Premise	HighQuality
una	I-Premise	HighQuality
bolsa	I-Premise	HighQuality
J	I-Premise	HighQuality
colónica	I-Premise	HighQuality
de	I-Premise	HighQuality
5	I-Premise	HighQuality
cm.	I-Premise	HighQuality

La	B-Claim	HighQuality
bolsa	I-Claim	HighQuality
colónica	I-Claim	HighQuality
en	I-Claim	HighQuality
J	I-Claim	HighQuality
fue	I-Claim	HighQuality
superior	I-Claim	HighQuality
en	I-Claim	HighQuality
cuanto	I-Claim	HighQuality
a	I-Claim	HighQuality
la	I-Claim	HighQuality
continencia	I-Claim	HighQuality
de	I-Claim	HighQuality
gases	I-Claim	HighQuality
y	I-Claim	HighQuality
líquidos	I-Claim	HighQuality
en	I-Claim	HighQuality
comparación	I-Claim	HighQuality
con	I-Claim	HighQuality
una	I-Claim	HighQuality
anastomosis	I-Claim	HighQuality
coloanal	I-Claim	HighQuality
recta.	I-Claim	HighQuality

Además,	O	-
la	B-Claim	HighQuality
frecuencia	I-Claim	HighQuality
de	I-Claim	HighQuality
las	I-Claim	HighQuality
deposiciones	I-Claim	HighQuality
fue	I-Claim	HighQuality
significativamente	I-Claim	HighQuality
menor	I-Claim	HighQuality
en	I-Claim	HighQuality
el	I-Claim	HighQuality
grupo	I-Claim	HighQuality
de	I-Claim	HighQuality
la	I-Claim	HighQuality
bolsa	I-Claim	HighQuality
en	I-Claim	HighQuality
J	I-Claim	HighQuality
que	I-Claim	HighQuality
en	I-Claim	HighQuality
el	I-Claim	HighQuality
grupo	I-Claim	HighQuality
de	I-Claim	HighQuality
la	I-Claim	HighQuality
reconstrucción	I-Claim	HighQuality
coloanal.	I-Claim	HighQuality

Sin	O	-
embargo,	O	-
debido	B-Claim	HighQuality
a	I-Claim	HighQuality
que	I-Claim	HighQuality
la	I-Claim	HighQuality
capacidad	I-Claim	HighQuality
neorrectal	I-Claim	HighQuality
disminuyó	I-Claim	HighQuality
por	I-Claim	HighQuality
igual	I-Claim	HighQuality
en	I-Claim	HighQuality
ambos	I-Claim	HighQuality
grupos,	I-Claim	HighQuality
especulamos	O	-
que	O	-
la	O	-
ventaja	O	-
de	O	-
la	O	-
bolsa	O	-
J	O	-
colónica	O	-
no	O	-
está	O	-
en	O	-
la	O	-
creación	O	-
de	O	-
un	O	-
reservorio	O	-
neorrectal	O	-
más	O	-
grande,	O	-
sino	O	-
que	O	-
puede	O	-
estar	O	-
relacionada	O	-
con	O	-
la	O	-
disminución	O	-
de	O	-
la	O	-
motilidad.	O	-

Observar	O	-
el	O	-
efecto	O	-
de	O	-
la	O	-
administración	O	-
combinada	O	-
de	O	-
entecavir	O	-
y	O	-
adefovir	O	-
dipivoxil	O	-
para	O	-
mejorar	O	-
la	O	-
fibrosis	O	-
hepática	O	-
en	O	-
pacientes	O	-
de	O	-
hepatitis	O	-
B	O	-
con	O	-
resistencia	O	-
al	O	-
interferón	O	-
.	O	-

Este	O	-
estudio	O	-
incluyó	O	-
90	O	-
pacientes	O	-
de	O	-
hepatitis	O	-
B	O	-
con	O	-
fibrosis	O	-
hepática	O	-
y	O	-
resistencia	O	-
al	O	-
interferón	O	-
(	O	-
IFN	O	-
)	O	-
que	O	-
fueron	O	-
admitidos	O	-
en	O	-
el	O	-
departamento	O	-
de	O	-
enfermedades	O	-
infecciosas	O	-
del	O	-
hospital	O	-
para	O	-
el	O	-
diagnóstico	O	-
y	O	-
el	O	-
tratamiento	O	-
entre	O	-
enero	O	-
de	O	-
2013	O	-
y	O	-
septiembre	O	-
de	O	-
2015	O	-
.	O	-

Se	O	-
dividieron	O	-
aleatoriamente	O	-
en	O	-
dos	O	-
grupos	O	-
de	O	-
acuerdo	O	-
con	O	-
la	O	-
tabla	O	-
de	O	-
números	O	-
aleatorios:	O	-
el	O	-
grupo	O	-
de	O	-
tratamiento	O	-
combinado	O	-
(	O	-
N.=45	O	-
)	O	-
y	O	-
el	O	-
grupo	O	-
de	O	-
entecavir	O	-
(	O	-
N.=45	O	-
)	O	-
.	O	-

Se	O	-
observaron	O	-
las	O	-
variaciones	O	-
en	O	-
los	O	-
índices	O	-
de	O	-
función	O	-
hepática	O	-
y	O	-
fibrosis	O	-
,	O	-
así	O	-
como	O	-
las	O	-
puntuaciones	O	-
del	O	-
Modelo	O	-
de	O	-
Enfermedad	O	-
Hepática	O	-
Terminal	O	-
(	O	-
MELD	O	-
)	O	-
,	O	-
antes	O	-
y	O	-
después	O	-
del	O	-
tratamiento	O	-
.	O	-

Después	B-Premise	HighQuality
del	I-Premise	HighQuality
tratamiento	I-Premise	HighQuality
,	I-Premise	HighQuality
los	I-Premise	HighQuality
niveles	I-Premise	HighQuality
de	I-Premise	HighQuality
los	I-Premise	HighQuality
índices	I-Premise	HighQuality
en	I-Premise	HighQuality
ambos	I-Premise	HighQuality
grupos	I-Premise	HighQuality
(	I-Premise	HighQuality
el	I-Premise	HighQuality
grupo	I-Premise	HighQuality
de	I-Premise	HighQuality
tratamiento	I-Premise	HighQuality
combinado	I-Premise	HighQuality
vs.	I-Premise	HighQuality
el	I-Premise	HighQuality
grupo	I-Premise	HighQuality
de	I-Premise	HighQuality
entecavir	I-Premise	HighQuality
)	I-Premise	HighQuality
fueron	I-Premise	HighQuality
los	I-Premise	HighQuality
siguientes	I-Premise	HighQuality
:	I-Premise	HighQuality
bilirrubina	I-Premise	HighQuality
(	I-Premise	HighQuality
67,5±7,7	I-Premise	HighQuality
vs.	I-Premise	HighQuality
82,4±13.5	I-Premise	HighQuality
μmol/L	I-Premise	HighQuality
)	I-Premise	HighQuality
;	I-Premise	HighQuality
Relación	I-Premise	HighQuality
Internacional	I-Premise	HighQuality
Normalizada	I-Premise	HighQuality
(	I-Premise	HighQuality
INR	I-Premise	HighQuality
)	I-Premise	HighQuality
(	I-Premise	HighQuality
1,21±0,8	I-Premise	HighQuality
vs.	I-Premise	HighQuality
1,14±0,7	I-Premise	HighQuality
)	I-Premise	HighQuality
;	I-Premise	HighQuality
creatinina	I-Premise	HighQuality
(	I-Premise	HighQuality
147,3±12,4	I-Premise	HighQuality
vs.	I-Premise	HighQuality
287,4±21,6	I-Premise	HighQuality
mg/dL	I-Premise	HighQuality
)	I-Premise	HighQuality
;	I-Premise	HighQuality
GGT	I-Premise	HighQuality
(	I-Premise	HighQuality
67,4±23,2	I-Premise	HighQuality
vs.	I-Premise	HighQuality
88,4±23,7	I-Premise	HighQuality
U/L	I-Premise	HighQuality
)	I-Premise	HighQuality
;	I-Premise	HighQuality
y	I-Premise	HighQuality
ALT	I-Premise	HighQuality
(	I-Premise	HighQuality
63,4±40,8	I-Premise	HighQuality
vs.	I-Premise	HighQuality
96,5±23,5	I-Premise	HighQuality
U/L	I-Premise	HighQuality
)	I-Premise	HighQuality
.	I-Premise	HighQuality

En	B-Premise	HighQuality
la	I-Premise	HighQuality
comparación	I-Premise	HighQuality
de	I-Premise	HighQuality
los	I-Premise	HighQuality
índices	I-Premise	HighQuality
de	I-Premise	HighQuality
fibrosis	I-Premise	HighQuality
hepática	I-Premise	HighQuality
entre	I-Premise	HighQuality
los	I-Premise	HighQuality
dos	I-Premise	HighQuality
grupos	I-Premise	HighQuality
,	I-Premise	HighQuality
encontramos	I-Premise	HighQuality
las	I-Premise	HighQuality
siguientes	I-Premise	HighQuality
diferencias	I-Premise	HighQuality
:	I-Premise	HighQuality
PCIII	I-Premise	HighQuality
(	I-Premise	HighQuality
67,5±7,7	I-Premise	HighQuality
vs	I-Premise	HighQuality
82,4±13,5	I-Premise	HighQuality
μg/L	I-Premise	HighQuality
)	I-Premise	HighQuality
;	I-Premise	HighQuality
IV-C	I-Premise	HighQuality
(	I-Premise	HighQuality
61,3±18,7	I-Premise	HighQuality
vs	I-Premise	HighQuality
74,5±17,9	I-Premise	HighQuality
μg/L	I-Premise	HighQuality
)	I-Premise	HighQuality
;	I-Premise	HighQuality
HA	I-Premise	HighQuality
(	I-Premise	HighQuality
147,3±12,4	I-Premise	HighQuality
vs	I-Premise	HighQuality
87,4±31,6	I-Premise	HighQuality
μg/L	I-Premise	HighQuality
)	I-Premise	HighQuality
;	I-Premise	HighQuality
y	I-Premise	HighQuality
LN	I-Premise	HighQuality
(	I-Premise	HighQuality
88,7±13,2	I-Premise	HighQuality
vs	I-Premise	HighQuality
102,5±23,4	I-Premise	HighQuality
μg/L	I-Premise	HighQuality
)	I-Premise	HighQuality
.	I-Premise	HighQuality

Los	B-Premise	HighQuality
resultados	I-Premise	HighQuality
mostraron	I-Premise	HighQuality
que	I-Premise	HighQuality
las	I-Premise	HighQuality
diferencias	I-Premise	HighQuality
en	I-Premise	HighQuality
la	I-Premise	HighQuality
comparación	I-Premise	HighQuality
de	I-Premise	HighQuality
los	I-Premise	HighQuality
índices	I-Premise	HighQuality
antes	I-Premise	HighQuality
y	I-Premise	HighQuality
después	I-Premise	HighQuality
del	I-Premise	HighQuality
tratamiento	I-Premise	HighQuality
eran	I-Premise	HighQuality
estadísticamente	I-Premise	HighQuality
significativas	I-Premise	HighQuality
(	I-Premise	HighQuality
P	I-Premise	HighQuality
<	I-Premise	HighQuality
0,05	I-Premise	HighQuality
)	I-Premise	HighQuality
.	I-Premise	HighQuality

Tras	B-Premise	HighQuality
el	I-Premise	HighQuality
tratamiento,	I-Premise	HighQuality
la	I-Premise	HighQuality
puntuación	I-Premise	HighQuality
MELD	I-Premise	HighQuality
de	I-Premise	HighQuality
los	I-Premise	HighQuality
pacientes	I-Premise	HighQuality
del	I-Premise	HighQuality
grupo	I-Premise	HighQuality
de	I-Premise	HighQuality
tratamiento	I-Premise	HighQuality
combinado	I-Premise	HighQuality
fue	I-Premise	HighQuality
significativamente	I-Premise	HighQuality
menor	I-Premise	HighQuality
que	I-Premise	HighQuality
la	I-Premise	HighQuality
del	I-Premise	HighQuality
grupo	I-Premise	HighQuality
de	I-Premise	HighQuality
entecavir	I-Premise	HighQuality
(	I-Premise	HighQuality
18,7±3,2	I-Premise	HighQuality
frente	I-Premise	HighQuality
a	I-Premise	HighQuality
22,5±3,4	I-Premise	HighQuality
)	I-Premise	HighQuality
,	I-Premise	HighQuality
con	I-Premise	HighQuality
una	I-Premise	HighQuality
diferencia	I-Premise	HighQuality
estadísticamente	I-Premise	HighQuality
significativa	I-Premise	HighQuality
(	I-Premise	HighQuality
P	I-Premise	HighQuality
<	I-Premise	HighQuality
0,05	I-Premise	HighQuality
)	I-Premise	HighQuality
.	I-Premise	HighQuality

En	B-Claim	HighQuality
los	I-Claim	HighQuality
pacientes	I-Claim	HighQuality
de	I-Claim	HighQuality
hepatitis	I-Claim	HighQuality
B	I-Claim	HighQuality
crónica	I-Claim	HighQuality
con	I-Claim	HighQuality
resistencia	I-Claim	HighQuality
al	I-Claim	HighQuality
interferón,	I-Claim	HighQuality
la	I-Claim	HighQuality
administración	I-Claim	HighQuality
combinada	I-Claim	HighQuality
de	I-Claim	HighQuality
entecavir	I-Claim	HighQuality
y	I-Claim	HighQuality
adefovir	I-Claim	HighQuality
dipivoxil	I-Claim	HighQuality
puede	I-Claim	HighQuality
mejorar	I-Claim	HighQuality
significativamente	I-Claim	HighQuality
la	I-Claim	HighQuality
función	I-Claim	HighQuality
hepática,	I-Claim	HighQuality
la	I-Claim	HighQuality
fibrosis	I-Claim	HighQuality
hepática	I-Claim	HighQuality
y	I-Claim	HighQuality
las	I-Claim	HighQuality
puntuaciones	I-Claim	HighQuality
MELD.	I-Claim	HighQuality

Los	B-Claim	HighQuality
resultados	I-Claim	HighQuality
ponen	I-Claim	HighQuality
de	I-Claim	HighQuality
manifiesto	I-Claim	HighQuality
la	I-Claim	HighQuality
necesidad	I-Claim	HighQuality
de	I-Claim	HighQuality
promover	I-Claim	HighQuality
los	I-Claim	HighQuality
beneficios	I-Claim	HighQuality
de	I-Claim	HighQuality
esta	I-Claim	HighQuality
combinación	I-Claim	HighQuality
de	I-Claim	HighQuality
fármacos	I-Claim	HighQuality
para	I-Claim	HighQuality
ayudar	I-Claim	HighQuality
a	I-Claim	HighQuality
los	I-Claim	HighQuality
pacientes	I-Claim	HighQuality
con	I-Claim	HighQuality
hepatitis	I-Claim	HighQuality
B	I-Claim	HighQuality
crónica	I-Claim	HighQuality
resistentes	I-Claim	HighQuality
al	I-Claim	HighQuality
interferón	I-Claim	HighQuality
,	I-Claim	HighQuality
y	I-Claim	HighQuality
de	I-Claim	HighQuality
promover	I-Claim	HighQuality
su	I-Claim	HighQuality
aplicación	I-Claim	HighQuality
en	I-Claim	HighQuality
las	I-Claim	HighQuality
prácticas	I-Claim	HighQuality
clínicas	I-Claim	HighQuality
.	I-Claim	HighQuality

En	O	-
China,	O	-
el	O	-
manejo	O	-
clínico	O	-
de	O	-
la	O	-
hepatitis	O	-
B	O	-
crónica	O	-
(	O	-
CHB	O	-
)	O	-
se	O	-
complica	O	-
por	O	-
el	O	-
uso	O	-
de	O	-
varios	O	-
regímenes	O	-
de	O	-
análogos	O	-
de	O	-
nucleos	O	-
(	O	-
t	O	-
)	O	-
ide	O	-
(	O	-
NUC	O	-
)	O	-
en	O	-
pacientes	O	-
sin	O	-
tratamiento	O	-
,	O	-
incluyendo	O	-
NUCs	O	-
con	O	-
bajas	O	-
barreras	O	-
genéticas	O	-
a	O	-
la	O	-
resistencia	O	-
,	O	-
con/sin	O	-
terapia	O	-
adicional	O	-
y	O	-
combinaciones	O	-
de	O	-
NUC	O	-
de	O	-
novo	O	-
.	O	-

Por	O	-
lo	O	-
tanto,	O	-
este	O	-
estudio	O	-
observacional	O	-
longitudinal	O	-
investigó	O	-
el	O	-
manejo	O	-
clínico	O	-
en	O	-
el	O	-
mundo	O	-
real	O	-
y	O	-
la	O	-
eficacia	O	-
de	O	-
la	O	-
terapia	O	-
NUC	O	-
en	O	-
pacientes	O	-
con	O	-
CHB	O	-
no	O	-
tratados	O	-
en	O	-
China.	O	-

Los	O	-
pacientes	O	-
de	O	-
CHB	O	-
sin	O	-
tratamiento	O	-
iniciados	O	-
en	O	-
la	O	-
terapia	O	-
NUC	O	-
fueron	O	-
reclutados	O	-
en	O	-
63	O	-
hospitales	O	-
de	O	-
ciudades	O	-
chinas	O	-
de	O	-
nivel	O	-
2.	O	-

Se	O	-
recogieron	O	-
datos	O	-
demográficos	O	-
y	O	-
específicos	O	-
del	O	-
tratamiento,	O	-
con	O	-
el	O	-
objetivo	O	-
de	O	-
informar	O	-
sobre	O	-
los	O	-
patrones	O	-
de	O	-
tratamiento	O	-
en	O	-
el	O	-
mundo	O	-
real	O	-
y	O	-
comparar	O	-
la	O	-
eficacia	O	-
del	O	-
tratamiento	O	-
con	O	-
entecavir	O	-
(	O	-
ETV	O	-
)	O	-
y	O	-
el	O	-
tratamiento	O	-
basado	O	-
en	O	-
lamivudina	O	-
(	O	-
LAM	O	-
)	O	-
.	O	-

A	O	-
continuación	O	-
presentamos	O	-
los	O	-
datos	O	-
del	O	-
primer	O	-
año.	O	-

Se	O	-
incluyeron	O	-
3.408	O	-
pacientes	O	-
no	O	-
tratados	O	-
con	O	-
NUCs	O	-
(	O	-
53%	O	-
ETV	O	-
,	O	-
18%	O	-
basados	O	-
en	O	-
LAM	O	-
,	O	-
29%	O	-
otros	O	-
)	O	-
.	O	-

En	B-Premise	HighQuality
general,	I-Premise	HighQuality
el	I-Premise	HighQuality
6,6%	I-Premise	HighQuality
de	I-Premise	HighQuality
los	I-Premise	HighQuality
pacientes	I-Premise	HighQuality
modificaron	I-Premise	HighQuality
su	I-Premise	HighQuality
tratamiento	I-Premise	HighQuality
inicial,	I-Premise	HighQuality
siendo	I-Premise	HighQuality
la	I-Premise	HighQuality
ETV	I-Premise	HighQuality
la	I-Premise	HighQuality
que	I-Premise	HighQuality
presentó	I-Premise	HighQuality
menores	I-Premise	HighQuality
tasas	I-Premise	HighQuality
de	I-Premise	HighQuality
modificación	I-Premise	HighQuality
del	I-Premise	HighQuality
tratamiento	I-Premise	HighQuality
que	I-Premise	HighQuality
otros	I-Premise	HighQuality
NUCs	I-Premise	HighQuality
principales	I-Premise	HighQuality
(	I-Premise	HighQuality
P	I-Premise	HighQuality
<	I-Premise	HighQuality
0,05	I-Premise	HighQuality
)	I-Premise	HighQuality
.	I-Premise	HighQuality

En	B-Premise	HighQuality
la	I-Premise	HighQuality
semana	I-Premise	HighQuality
52	I-Premise	HighQuality
,	I-Premise	HighQuality
la	I-Premise	HighQuality
tasa	I-Premise	HighQuality
de	I-Premise	HighQuality
respuesta	I-Premise	HighQuality
virológica	I-Premise	HighQuality
fue	I-Premise	HighQuality
mayor	I-Premise	HighQuality
con	I-Premise	HighQuality
ETV	I-Premise	HighQuality
que	I-Premise	HighQuality
con	I-Premise	HighQuality
el	I-Premise	HighQuality
tratamiento	I-Premise	HighQuality
basado	I-Premise	HighQuality
en	I-Premise	HighQuality
LAM	I-Premise	HighQuality
(	I-Premise	HighQuality
77,0	I-Premise	HighQuality
%	I-Premise	HighQuality
frente	I-Premise	HighQuality
a	I-Premise	HighQuality
61,4	I-Premise	HighQuality
%	I-Premise	HighQuality
,	I-Premise	HighQuality
P	I-Premise	HighQuality
<	I-Premise	HighQuality
0,0001	I-Premise	HighQuality
)	I-Premise	HighQuality
.	I-Premise	HighQuality

El	B-Premise	HighQuality
tratamiento	I-Premise	HighQuality
basado	I-Premise	HighQuality
en	I-Premise	HighQuality
LAM	I-Premise	HighQuality
se	I-Premise	HighQuality
asoció	I-Premise	HighQuality
con	I-Premise	HighQuality
una	I-Premise	HighQuality
mayor	I-Premise	HighQuality
probabilidad	I-Premise	HighQuality
de	I-Premise	HighQuality
ruptura	I-Premise	HighQuality
virológica	I-Premise	HighQuality
y	I-Premise	HighQuality
resistencia	I-Premise	HighQuality
genotípica	I-Premise	HighQuality
(	I-Premise	HighQuality
21,4%	I-Premise	HighQuality
y	I-Premise	HighQuality
19,6%	I-Premise	HighQuality
,	I-Premise	HighQuality
respectivamente	I-Premise	HighQuality
)	I-Premise	HighQuality
que	I-Premise	HighQuality
el	I-Premise	HighQuality
ETV	I-Premise	HighQuality
(	I-Premise	HighQuality
1,6%	I-Premise	HighQuality
y	I-Premise	HighQuality
0,1%	I-Premise	HighQuality
,	I-Premise	HighQuality
respectivamente	I-Premise	HighQuality
)	I-Premise	HighQuality
(	I-Premise	HighQuality
P	I-Premise	HighQuality
<	I-Premise	HighQuality
0,0001	I-Premise	HighQuality
)	I-Premise	HighQuality
.	I-Premise	HighQuality

Los	B-Premise	HighQuality
efectos	I-Premise	HighQuality
adversos	I-Premise	HighQuality
relacionados	I-Premise	HighQuality
con	I-Premise	HighQuality
el	I-Premise	HighQuality
tratamiento	I-Premise	HighQuality
o	I-Premise	HighQuality
los	I-Premise	HighQuality
efectos	I-Premise	HighQuality
adversos	I-Premise	HighQuality
graves	I-Premise	HighQuality
fueron	I-Premise	HighQuality
poco	I-Premise	HighQuality
frecuentes.	I-Premise	HighQuality

En	O	-
este	O	-
estudio	O	-
observacional	O	-
a	O	-
nivel	O	-
nacional,	O	-
más	O	-
del	O	-
50%	O	-
de	O	-
los	O	-
pacientes	O	-
con	O	-
CHB	O	-
en	O	-
hospitales	O	-
de	O	-
ciudades	O	-
de	O	-
nivel	O	-
2	O	-
en	O	-
China	O	-
recibieron	O	-
inicialmente	O	-
terapia	O	-
ETV.	O	-

En	B-Claim	HighQuality
consonancia	I-Claim	HighQuality
con	I-Claim	HighQuality
los	I-Claim	HighQuality
resultados	I-Claim	HighQuality
de	I-Claim	HighQuality
los	I-Claim	HighQuality
ensayos	I-Claim	HighQuality
clínicos,	I-Claim	HighQuality
la	I-Claim	HighQuality
ETV	I-Claim	HighQuality
fue	I-Claim	HighQuality
más	I-Claim	HighQuality
eficaz	I-Claim	HighQuality
que	I-Claim	HighQuality
los	I-Claim	HighQuality
tratamientos	I-Claim	HighQuality
basados	I-Claim	HighQuality
en	I-Claim	HighQuality
el	I-Claim	HighQuality
MELA	I-Claim	HighQuality
en	I-Claim	HighQuality
un	I-Claim	HighQuality
entorno	I-Claim	HighQuality
real,	I-Claim	HighQuality
siendo	I-Claim	HighQuality
la	I-Claim	HighQuality
modificación	I-Claim	HighQuality
del	I-Claim	HighQuality
tratamiento	I-Claim	HighQuality
relativamente	I-Claim	HighQuality
baja	I-Claim	HighQuality
en	I-Claim	HighQuality
los	I-Claim	HighQuality
pacientes	I-Claim	HighQuality
tratados	I-Claim	HighQuality
con	I-Claim	HighQuality
ETV.	I-Claim	HighQuality

Comparar	O	-
la	O	-
presión	O	-
intraocular	O	-
(	O	-
PIO	O	-
)	O	-
postoperatoria	O	-
y	O	-
la	O	-
incidencia	O	-
de	O	-
complicaciones	O	-
tempranas	O	-
tras	O	-
la	O	-
trabeculectomía	O	-
con	O	-
sutura	O	-
liberable	O	-
con	O	-
la	O	-
trabeculectomía	O	-
estándar	O	-
en	O	-
pacientes	O	-
chinos	O	-
con	O	-
glaucoma	O	-
primario	O	-
de	O	-
ángulo	O	-
cerrado	O	-
.	O	-

Ciento	O	-
setenta	O	-
y	O	-
cinco	O	-
pacientes	O	-
diagnosticados	O	-
de	O	-
glaucoma	O	-
primario	O	-
de	O	-
ángulo	O	-
cerrado	O	-
con	O	-
6	O	-
horas	O	-
de	O	-
reloj	O	-
o	O	-
más	O	-
de	O	-
sinequia	O	-
anterior	O	-
periférica	O	-
fueron	O	-
asignados	O	-
aleatoriamente	O	-
a	O	-
2	O	-
grupos	O	-
de	O	-
tratamiento:	O	-
87	O	-
fueron	O	-
sometidos	O	-
a	O	-
trabeculectomía	O	-
estándar	O	-
(grupo	O	-
S:	O	-
2	O	-
suturas	O	-
permanentes	O	-
interrumpidas	O	-
en	O	-
el	O	-
colgajo	O	-
escleral)	O	-
y	O	-
88	O	-
recibieron	O	-
trabeculectomía	O	-
con	O	-
2	O	-
suturas	O	-
permanentes	O	-
y	O	-
2	O	-
liberables	O	-
(grupo	O	-
R).	O	-

Se	O	-
comparó	O	-
la	O	-
PIO	O	-
postoperatoria	O	-
y	O	-
las	O	-
complicaciones	O	-
durante	O	-
los	O	-
tres	O	-
primeros	O	-
meses	O	-
después	O	-
de	O	-
la	O	-
cirugía.	O	-

Ciento	O	-
setenta	O	-
y	O	-
un	O	-
pacientes	O	-
(	O	-
97,7%	O	-
)	O	-
acudieron	O	-
a	O	-
la	O	-
visita	O	-
de	O	-
los	O	-
3	O	-
meses	O	-
.	O	-

